HUE033245T2 - Bispecifikus ellenanyag molekula - Google Patents

Description

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16128 <2006 01> C07K 16130 <2006 01> 15.03.2017 Bulletin 2017/11 C07K 16146<200601> (21) Application number: 12798623.0 (86) International application number: PCT/EP2012/072364 (22) Date of filing: 12.11.2012 (87) International publication number: WO 2013/092001 (27.06.2013 Gazette 2013/26)

(54) BISPECIFIC ANTIBODY MOLECULE

BISPEZIFISCHES ANTIKORPERMOLEKLIL MOLECULE D’ANTICORPS BISPECIFIQUE (84) Designated Contracting States: WO-A2-2007/109254 WO-A2-2011/025964

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO · LU D ET AL: "Fab-scFvfusion protein: an efficient PL PT RO RS SE SI SK SM TR approach to production of bispecific antibody

fragments", JOURNAL OF IMMUNOLOGICAL

(30) Priority: 19.12.2011 US 201161577327 P METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 267, no. 2, 15 (43) Date of publication of application: September 2002 (2002-09-15), pages 213-226, 29.10.2014 Bulletin 2014/44 XP004375842, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(02)00148-5 (73) Proprietor: Synimmune GmbH · SEIFERT Ο ET AL: "The IgM CH2 domain as 72076 TUbingen (DE) covalently linked homodimerization module for the generation of fusion proteins with dual

(72) Inventors: specificity", PROTEIN ENGINEERING, DESIGN • JUNG, Gundram AND SELECTION, OXFORD JOURNAL, LONDON, 72108 Rottenburg-Wendelsheim (DE) GB, vol. 25, no. 10, 17 September 2012 • DURBEN, Michael (2012-09-17),pages603-612,XP002689666,ISSN: 72076 Tuebingen (DE) 1741-0126, DOI: 10.1093/PROTEIN/GZS059 • GROSSE-HOVEST, Ludger [retrieved on 2012-09-17] 72070 Tuebingen (DE) · BAUDINO LUCIE ETAL: "Impact of a three amino acid deletion in the CH2 domain of murine lgG1

(74) Representative: Schiweck, Weinzierl &amp; Koch on Fc-associated effector functions", THE

Patentanwalte Partnerschaft mbB JOURNAL OF IMMUNOLOGY, THE AMERICAN

European Patent Attorneys ASSOCIATION OF IMMUNOLOGISTS, US, vol.

Landsberger StraRe 98 181,no.6,15September2008(2008-09-15),pages 80339 MUnchen (DE) 4107-4112, XP002590015, ISSN: 0022-1767 • BAUDINO LUCIE ET AL: "Crucial role of aspartic (56) References cited: acid at position 265 in the CH2 domain for murine WO-A1-2009/018386 WO-A1-2011/047180 lgG2a and lgG2b Fc-associated effector WO-A2-2006/031994 WO-A2-2006/116260 functions", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 181, no. 9,1 November 2008 (2008-11-01), pages 6664-6669, XP002590016, ISSN: 0022-1767

Description

FIELD OF THE INVENTION

[0001] The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.

BACKGROUND

[0002] Monoclonal antibodies against the antigen-specific T cell receptor (TCR)/CD3-complex are able to efficiently activate T cells. This activation, however, requires the antibody to be - via its Fc portion - multimerized on the surface of Fc receptor expressing cells, which often also provide accessory signals for T cell activation (Davis, L., Vida, R. and Lipsky, P.E., Regulation of human T lymphocyte mitogenesis by antibodies to CD3, J. Immunol. [1986] 137: 3758-3767).

[0003] Bispecific antibodies, which recognize both an antigen on target cells (e.g. FLT3 or CD19 on leukemia cells, the CSPG4-antigen on melanoma cells or EGFR on glioblastoma cells) and the antigen specific T cell receptor (TCR)/CD3-complex, are likewise able to activate T cells (Jung.G., Ledbetter,J .A., and Muller-Eberhard.H.J., Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates, Proc.Natl.Acad.Sci.U.S.A [1987] 84: 4611-4615; Jung.G., &amp; Eberhard.FI.J., An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immunol.Today [1988] 9: 257-260; Jung.G., Brandi,M., Eisner,W., Fraunberger.P., Reifenberger.G., Schlegel.U., Wiestler.O.D., Reulen.H.J., Wilmanns.W. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ T-cell activation and therapeutic efficacy, Int J Cancer. [2001] 91: 225-30), and in addition to focus the activated cells on the target cell (Staerz.U.D., Kanagawa.O., and Bevan.M.J., Hybrid antibodies can target sites for attack by T cells, Nature [1985] 314: 628-631; Perez,P., Hoffman,R.W., Shaw.S., Bluestone.J.A., and Segal,D.M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody, Nature [1985] 316: 354-356; Jung.G., Honsik.C.J., Reisfeld.R.A. and Muller-Eberhard.H.J. Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates, Proc.Natl.Acad.Sci.U.S.A, 83: 4479-4483, 1986). As a result T cell mediated lysis of tumour cells occurs. Agonistic antibodies to T-cell costimulatory molecule such as CD28, enhance anti-CD3 mediated T-cell activation. Such costimulatory antibodies are particularly effective if they are also provided in a bispecific format (Grosse-Hovest.L., Hartlapp,!., Marwan.W., Brem.G., Rammensee.H.G., and Jung.G., A recombinant bispecific singlechain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing, Eur.J.Immunol. [2003] 33: 1334-1340). In any case, we regard it as an absolute requirement for therapeutic applications of bispecific antibodies having CD3 specificity that binding to Fc receptors can be excluded (Jung, G., and Eberhard, H.J., An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immunol.Today [1988] 9: 257-260; Jung.G., Freimann.U., Von Marshall,Z., Reisfeld.R.A., and Wilmanns.W., Target cell-induced T cell activation with bi- and trispecific antibody fragments, Eur.J.Immunol. [1991] 21: 2431-2435). Such binding to Fc receptors would result in T cell activation in vivo, which occurs, regardless of the binding to a target antigen, at any location where Fc receptor expressing cells can be found, for instance within the entire hematopoietic, lymphatic and reticulo-endothelial system. According to experience such T cell activation results in systemic activation of T cells, accompanied by a cytokine release syndrome, a dreaded adverse reaction during therapeutic use of T cell activating cytokines or antibodies (Rosenberg, S.A., Lotze, M.T., Yang.J.C., Aebersold.P.M., Linehan.W.M., Seipp.C.A., and White.D.E., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann.Surg. [1989] 210: 474-484; Tibben.J.G., Boerman.O.C., Massuger.L.F., Schijf.C.P., Claessens.R.A., and Corstens.F.H., Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab’)2 in ovarian carcinoma patients, Int.J.Cancer [1996] 66: 477-483; Kroesen.B.J., Buter.J., Sleijfer.D.T., Janssen,R.A., van der Graaf.W.T., The.T.H., de, L.L. and Mulder,N.H., Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2, Br.J.Cancer [1994] 70: 652-661). Hence, the aim in formatting bispecific CD3 antibodies needs to be avoiding an Fc mediated systemic activation of T cells, and thereby allowing target cell restricted activation, which is exclusively dependent on binding of the target portion of the bispecific antibody to the corresponding target antigen (Jung.G., &amp; Eberhard,H.J., An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immunol. Today [1988] 9: 257-260; Jung.G., Freimann.U., Von Marshall,Z., Reisfeld.R.A., and Wilmanns, W. Target cell-induced T cell activation with bi- and trispecific antibody fragments, Eur. J. Immunol. [1991] 21: 2431-2435). From the above said it emerges that when selecting the target antigen, expression as restricted to malign cells as possible has to be taken care of. In this way activation by non-malign cells and an accompanying release of cytokines can be kept as low as possible.

[0004] Similar considerations apply if bispecific antibodies are constructed that contain agonistic effector antibodies binding to triggering receptors on immune cells other than T cells, such as CD16 expressed on NK cells. In any case, Fc-mediated binding of the antibodies to Fc receptors should be avoided according to the reasoning outlined above for T cells.

[0005] The bispecific antibody which has proceeded furthest in clinical development today is Blinatumomab (Micromet, Inc., Rockville, MD), a bispecific single chain antibody with CD19xCD3 specificity and a remarkable therapeutic activity against lymphoma and leukemia cells (Bargou, R., et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science [2008] 321: 974-977; Topp, M.S., et al., Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J.Clin.Oncol. [2011] 29: 2493-2498).

[0006] Since the single chain format does not contain any domain of the Fc part, this antibody is target cell restricted within the above explained meaning, i.e. it only activates T cells in the presence of CD19 expressing target cells (Br-ischwein.K., et al., Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class, J.lmmunother. [2007] 30: 798-807).

[0007] CD19 is, however, also expressed on normal B cells so that, despite target cell restriction, following therapeutic application, a systemic release of cytokines occurs, causing significant cytotoxicity already at daily doses around 100 μg (Bargou,R., et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science [2008] 321: 974-977; Topp, M.S., et al., Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J.Clin.Oncol. [2011] 29: 2493-2498).

[0008] In addition the single chain format has the following disadvantages: (i) the molecular weight of about 50 kDa is relatively low und is associated with a short serum half life, (ii) antibodies of this format easily aggregate and (iii) are difficult to produce in conventional fermenting processes (Grosse-Hovest.L., Hartlapp,!., Marwan.W., Brem.G., Ram-mensee.H.G., and Jung,G., A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing, Eur.J.Immunol. [2003] 33:1334-1340; Grosse-Hovest.L., etal., Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing, Proc.Natl.Acad.Sci.U.S.A [2004] 101: 6858-6863).

[0009] WO 2011/047180 discloses bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. WO 2009/018386 discloses multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. WO 2007/109254 discloses stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. WO 2011/025964 discloses DLL4 binding proteins, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. WO 2006/031994 discloses design and production of immunoglobulin Fc domains including variants to stabilise their monomeric forms. Lu et al., 2002, Journal of Immunological Methods, 267(2): 213-226 discloses Fab-scFv fusion proteins.

[0010] It is therefore an object of the present invention to provide a bispecific antibody molecule that overcomes at least some of the above difficulties and that can be generally used in therapy, amongst others for strictly target cell restricted activation of immune cells as described above.

SUMMARY OF THE INVENTION

[0011] In a first aspect the present invention provides a recombinant bispecific antibody molecule consisting of a Fab fragment comprising a first binding site for a first antigen, a single chain Fv fragment comprising a second binding site for a second antigen and an immunoglobulin CFI2 domain, wherein the Fab fragment further comprises the hinge region, wherein the Fab fragment and the single chain Fv fragment are linked via the CFI2 domain, wherein at least one amino acid residue of the CH2 domain that is able to mediate binding to Fc receptors is lacking or mutated, and wherein further the amino acid residues of sequence positions 226 and 229 (numbering of sequence positions according to the EU-index), are lacking or mutated, wherein the at least one amino acid residue of the hinge region or the CH2 domain that is able to mediate binding to Fc receptors is lacking or mutated, is selected from the group consisting of sequence position 228, 230, 231,232, 233, 234, 235, 236, 237, 238, 265, 297, 327, and 330 (numbering of sequence positions according to the EU-index).

[0012] The disclosure provides a tetrameric antibody molecule. The tetrameric antibody molecule includes a dimer of the antibody molecule according to the first aspect. The dimer is generally defined by a bond between cysteine residues of two antibody molecules of the first aspect, namely between cysteins in the hinge region. Such cysteine residues are typically preserved amino acids (C226 and C229 in human IgG- immunoglobulins).

[0013] The disclosure provides a recombinant bispecific antibody molecule. The recombinant bispecific antibody molecule includes a Fab fragment that includes a first binding site for a first antigen, a single chain Fv fragment that includes a second binding site for a second antigen, an immunoglobuline CFI2 domain, and an immunoglobuline CFI3 domain. The Fab fragment and the single chain Fv fragment are linked via the CFI2 domain/CH3 domain. At least one amino acid residue of the CFI2 domain that is able to mediate binding to Fc-receptors is lacking or mutated. Typically at least one of the cystein residues forming inter-chain disulfide bonds (C226 and C229 in human IgG-antibodies) is exchanged. Some of such molecules may contain additional modifications in the CH3 region that prevent dimerization with homotypic CH3 domains.

[0014] The disclosure provides a tetrameric antibody molecule. The tetrameric antibody molecule consists of a dimer of the recombinant bispecific antibody molecule according to the third aspect. The dimer is generally defined by a bond between preserved cysteins in the hinge region (C226 and C229 in human IgG-antibodies).

[0015] The disclosure provides a further recombinant bispecifc antibody molecule. This antibody molecule includes a Fab fragment including a first binding site for a first antigen, a single chain Fv fragment including a second binding site for a second antigen, an immunoglobulin CH2 domain, and an immunoglobulin CH3 domain. The Fab fragment and the single chain Fv fragment are linked to each other via the CH2 domain and the CH3 domain. At least one cysteine residue of this antibody molecule that is able to form a disulfide bridge for dimerisation is lacking or mutated.

[0016] The invention provides a nucleic acid molecule. The nucleic acid molecule encodes an antibody molecule according to the invention.

[0017] The invention provides a pharmaceutical composition. The pharmaceutical composition includes an antibody molecule according to the invention.

[0018] The disclosure provides a method of treating a disease. The method includes using an antibody molecule according to the disclosure. Generally the antibody molecule is administered to a patient in need thereof.

[0019] The invention provides a host cell that includes a nucleic acid molecule according to the invention.

[0020] The invention provides a method of producing an antibody molecule according to the invention. The method includes expressing a nucleic acid encoding the antibody molecule under conditions that allow expression of the nucleic acid molecule.

[0021] The invention will be more fully understood in view of the following description, drawings and non-limiting examples.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022]

Fig. 1 schematically depicts bispecific antibody molecules according to the invention and/or the disclosure.

Fig. 1A depicts a bivalent molecule with a Fab fragment, a CH2 domain and a single chain Fv fragment. The antibody molecule has a main chain in which the CH2 domain is coupled via its N-terminus to the heavy chain CH1 and VH domains of a Fab fragment and via its C-terminus to a single chain Fv fragment (bsFc-1/2-format).

Fig. 1B depicts a bivalent antibody molecule with a main chain in which the CH2 domain is linked to the light chain of a Fab fragment, i.e. in which the main chain includes a VL and a CL domain, a hinge region, a CH2 domain and a single chain Fv fragment.

Fig. 1C shows a bivalent antibody molecule in which the main chain includes a VL and a CH1 domain, a hinge region, a CH2 domain and a single chain Fv fragment. A second chain of lower weight includes a VH and a CL domain. In the antibody molecule of Fig. 1C the Fab fragment is thus not a "classical (naturally occurring)" Fab fragment in which the variable domain of the light and the heavy chain are fused to its respective constant domain (CL or CH1, respectively) but a "hybrid" Fab fragment in which the variable domain is fused to the constant domain of the "opposite chain, i.e. the VH domain is fused to the CL domain and the VL domain is fused to the CH1 domain.

Fig. 1D depicts a bivalent antibody molecule with a main chain in which the CH2 domain is linked to a CL and a VH domain. A second chain of lower weight includes a VL and a CH1 domain. The antibody molecule of Fig. 1D thus includes a "hybrid Fab fragment" (that includes the first binding site) as it is also present in the molecule of Fig.1C.

Fig. 1E depicts a bivalent antibody molecule with a build-up as in Fig. 1 A, in which amino acids in the CH2 domain and/or the hinge region have been modified (indicated by "X" as depicted in Fig. 10, bsFcko-1/2-format). Likewise, such modifications can be inserted into the molecules depicted in 1B-1D. In the molecules depicted in Figs. 1A-1E the cystein residues forming inter-chain disulfide bonds (C226 and C229 in human IgG-antibodies) are exchanged to prevent formation of dimers (·).

Fig. 1F depicts an illustrative tetravalent molecule being a dimer of the unit depicted in Fig. 1A. Such a molecule may also be constructed in the Fab-configurations depicted in Figs. 1B-1D with and without the Fc modifications depicted in Fig. 1E. These modifications are listed in Figure 1P.

Fig. 1G depicts an illustrative tetravalent molecule, being a dimer of a unit that includes a Fab fragment, a CH2 domain, a CH3 domain and a single chain Fv fragment. Amino acids in the CH2 domain and in the hinge region have been modified (X); summerized in Fig. 1P. The two main chains of the antibody include a VFI and a CH1 domain, a hinge region, a CFI2 domain, a CFI3 domain and a single chain Fv fragment (bsFcko-1-format). Similar molecules may also be constructed in the Fab-configurations depicted in Figs. 1A-1E. In all these molecules dimers are defined by means of preserved cysteins in the hinge region (C226 and C229 in human IgG-antibodies).

Fig. 1H depicts a tetravalent molecule, being a dimer of a unit that includes with a Fab fragment, a CH2 domain, a CFI3 domain and a single chain Fv fragment. Within the Fab fragment the two main chains of the antibody include a VFI and a CL domain.

Fig. 11 shows a tetravalent antibody with a general build-up as depicted in Fig. 1G. In contrast to the molecule of Fig. 1G only one of the two main chains of this antibody includes amino acids in the CFI2 domain and the hinge region that have been modified (indicated by "X").

Fig. 1J depicts a tetravalent molecule in which the two main chains include a VL and a CL domain, a hinge region, a CFI2 domain, a CFI3 domain and a single chain Fv fragment.

Fig. 1K depicts a tetravalent molecule with two structurally different Fab fragments. The first main chain of the antibody includes a VL and a CL domain, a hinge region, a CH2 domain, a CH3 domain and a single chain Fv fragment. The second main chain of the antibody includes a VH and a CH1 domain, a hinge region, a CFI2 domain, a CFI3 domain and a single chain Fv fragment.

Fig. 1 L depicts a tetravalent molecule, being a dimer of a unit that includes a Fab fragment, a CH2 domain, a CH3 domain and a single chain Fv fragment. Within the Fab fragment the two main chains of the antibody include a VL and a CFH1 domain.

Fig. 1M depicts a further tetravalent molecule with two structurally different Fab fragments. The first main chain of the antibody includes a VL and a CH1 domain, a hinge region, a CH2 domain, a CH3 domain and a single chain Fv fragment. The second main chain of the antibody includes a VH and a CL domain, a hinge region, a CH2 domain, a CH3 domain and a single chain Fv fragment.

Fig. 1 N depicts a bivalent molecule with a Fab fragment, a CH2 and CH3 domain and a single chain Fv fragment. The antibody molecule has a main chain in which the CH2 domain is coupled via its N-terminus to the heavy chain CH1 and VH domains of a Fab fragment and via its C-terminus to a CH3 domain which is coupled via its C-terminus to a single chain Fv-fragment. Such a molecule may also be constructed in the Fab-configurations depicted in Figs. 1A-1D and may contain Fc modifications in the hinge and CH2 region ("X") as depicted in Figs. 1E and 10. In addition they may contain modifications in the CH3 domain that prevent dimerization of this domain and may influence binding to the neonatal Fc receptor (FcRn). Examples of residues that are involved in the dimerization and thus may be modified by deletion or mutation include T366, L368, F405, Y407, and K409 (cf. Dall’Aqua et al. "Contribution of domain interface residues to the stability of antibody CH3 domain homodimers" Biochemistry (1998) Volume: 37, Issue: 26, Pages: 9266-9273. Other contact residues in the CH3 domain interface, that can be modified, include Q347, Y349, T350, L351, L368, K370, K392, T394, P395, V397, L398, D399, F405, Y407, and K409. See S.Miller Protein-Protein Recognition and the Association of Immunoglobulin Constant Domains. J.Mol.Biol. (1990) Volume 216 pp 965-973, and J. Deisenhofer Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry (1981) Volume 20 pp 2361-2370, and, as far as the binding of the neonatal Fc receptor is concerned, for example, the following amino acids residues of the CH2 domain: T250, M252, S254, T256, T307 H310 and of the CH3 domain: E380 M428, H433, N434, H435 (see the review of Roopenian &amp; Akilesh; FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology (2007) Volume 7 pp:715-725. In all these molecules the cystein residues forming inter-chain disulfide bonds (C226 and C229 in human IgG-antibodies) are exchanged to prevent formation of dimers (·)

Further illustrative molecules not depicted in Fig. 1A -1N include molecules where, relative to the depicted molecules, the C-terminal single chain Fv-part may be in a VL-VH- rather than the depicted VH-VL-orientation, meaning that the VL domain is fused to the respective constant domain.

Fig. 10 lists illustrative modifications that can be introduced into the bivalent antibody variants depicted in Figs.lA-D and Fig. 1N to obtain Fc deficient derivatives as exemplified in Fig. 1E. Modifications are identical to those shown in Fig. 1P with the exception of the preserved cysteins (C226 and C229 in human IgG-antibodies). The numbering of amino acids is in line with the Kabat numbering [EU-Index], wt = lgG1 humane wild type sequence; Δ1 = knockout; Glycan = Δ1-knock-out with deletion of saccharide moieties =297; Δ2-5 further knock-out variants in continuation of Δ1; - = the amino acid has been deleted.

Fig. 1P lists illustrative modifications that can be used to obtain a tetravalent molecule as depicted in Fig. 1 F-M. The numbering of amino acids is in line with the Kabat numbering [EU-Index], wt= lgG1 humane wild type sequence; Δ1 = knock-out; Glycan = Δ1-knock-out with deletion of saccharide moieties s297; Δ2-5 further knock-out variants in continuation of Δ1; - = the amino acid has been deleted.

Figs. 2Ato 2C depict a schematic representation of the cloning procedure for the generation of an optimized heavy chain (main chain) for the antibodies depicted in Fig. 1, either as bivalent or tetravalent bispecific antibodies with modified ADCC-attenuated Fc-parts. i) The original vector, based on the plasmid-backbone of pcDNA3 (Invitrogen; CMV promoter and bovine growth hormone termination signal are deleted), is depicted. This plasmid contains the human γ1 isotype Ig heavy chain with regulatory elements of the immunoglobulin heavy chain locus. ii) The exchange of a VDJ (variable domain of the heavy chain) or VJ (variable domain of the light chain) element via the restriction endonuclease site Aatll and Clal is indicated. iii) the simple exchange (via restriction sites Mlul and Spel) of the complete human γ1 isotype Ig heavy chain against the coding sequence for a scFv fragment, a CH3-deleted and hinge and CH2 modified DNA element resulting in a bivalent bispecific antibody heavy chain is shown. For certain antibody variants, e.g. those depicted in Fig. 1D, the CH1 domain may be replaced by a CL-domain. iv) Exchanging the modified CH1-H-CH2 fragment (via restriction sites Mlul and BspEI) against a hinge and CH2 modified CH1-H-CH2-CH3 element results in a tetravalent bispecific antibody heavy chain or as shown in v) . If, in addition, or only as such the cysteines at position C226 and C229 are exchanged the resulting molecules are bivalent bispecific antibody molecules as depicted in Fig. 1N. v) Exchanging the scFv fragment (via restriction sites BspEI and Spel) against a scFv-fragment of any other antigen specificity or of different VH and VL orientation. Substitutions iv) and v) can be combined.

In Fig. 2B and 2C) the regions adjacent to the inserted VDJ - CH1 and scFv-elements, respectively, are shown in detail.

Figs. 2D-F depicts a schematic representation of the cloning procedure for the generation of the light chain of human monospecific antibodies. i) The parental vector, based on the plasmid backbone of pCR-Script (Stratagene; lacZ promoter and termination signal are deleted) contains the VJ region and the C region of human κ-gene as well as regulatory elements of the immunoglobulin light chain locus. ii) Exchange of a VJ (variable domain of the light chain) element or VDJ (variable domain of the heavy chain) element via the restriction endonucleases Xhol and Spel. iii) Exchange of CL (constant light chain) element via the restriction endonucleases Pmll and BsmBI.

In Figs. 2E and 2F the regions adjacent to the inserted VJ and CL elements are shown in detail.

Boxes represent exons, circles enhancer elements and thin lines UT regions and intron sequences. L1 and L2, leader sequences encoded by two different exons (also shown in Figure 2B and 2E); V, variable regions; D, diversity region; J, joining regions; CH1, CH2, CH3, CL exons of constant heavy and light chains, respectively, H, hinge region, scFv single-chain Fv-fragment; X = amino acid modifications. Notl, Aatll, Clal, Mlul, BspEI, Spel, Xhol, Kpnl, Xhol, Spel, Pmll, BsmBI, Sail, restriction endonucleases used for cloning; AmpR and NeoR represent the coding regions for Ampicillin and Neomycin resistance respectively.

The cleavage sites for secretory signal peptides are indicated by |; and exon-intron boundaries by [, ].

Fig. 3A illustrates target cell restricted T cell activation (3H-thymidine incorporation) by two bispecific antibodies of different format according to the invention and/or disclosure, having FLT3 X CD3 specificity. The antibodies are used on cells that do not (empty symbols) and that do (filled symbols) include FLT3/CD19-positive REFI cells. O,·: bivalent antibody molecule as depicted in Fig. 1A with the sequence "Glycan" as depicted in Figs. 1E and Fig. 10 (bsFcko-1/2-format) Fab fragment with FLT3 binding site, scFv fragment with CD3 binding site. □, : tetravalent antibody molecule as depicted in Fig. 1G with the sequence Δ1 as depicted in Fig. 1P, (bsFcko-1-format). Fab2 fragment with FLT3 binding site, scFv fragment with CD3 binding site. *: intact monospecific anti-CD3 antibody without target cells. In the absence of target cells, intact monospecific CD3 antibodies effectively activate T cells in an Fc/FcR dependent manner whereas the bispecific antibodies are ineffective. This demonstrates that the bispecific format of the invention lack Fc/FcR binding as good as entirely. Fig. 3B illustrates target cell restricted T cell activation (TNF release) by different bivalent bispecific antibodies according to the invention and/or disclosure, used on cells that do not (empty symbols) and that do (filled symbols) include FLT3/CD19-positive REH cells. O,·: bivalent antibody molecule as depicted in Fig. 1A with the sequence "Glycan" as depicted in Fig. 1Eand Fig 10, Fab fragment with FLT3 binding site, scFv fragment with CD3 binding site; 0, ♦: bivalent antibody molecule as depicted in 1E with the sequence "Glycan" as depicted in Fig 10, Fab fragment with CD19 binding site, scFv fragment with TCR binding site; V,Y: bivalent antibody molecule as depicted in Fig. 1E with the sequence "Glycan" as depicted in Fig 10, Fab fragment with CSPG4 binding site, scFvfragment with CD3 binding site. The chondroitinsulfate proteoglycan CSPG4 is a target antigen of melanoma cells and is not expressed on REH cells.

Fig. 4 depicts the specific lysis of FLT3/CD19 expressing REH cells (A) and CSPG expressing SKMel63 cells (B), respectively, by means of bispecific antibodies according to the invention and/or disclosure and by activated CD8 positive T killer cells in a 4hr 51chromium release test. ·: FLT3 X CD3, bsFcko-1/2 format as depicted in Fig. 1 E; : FLT3 X CD3, bsFcko-1 format as depicted in Fig. 1 G; Y : CSPG4 X CD3, bsFcko-1/2 format as depicted in Fig. 1 E; ♦: CD19 X TCR, bsFcko-1/2 format as depicted in Fig. 1E.

Fig. 5 shows a comparison of FLT3 X CD3 antibodies of identical specificity in three different formats: bispecific single-chain format (bs-scFv), bsFcko-1/2 format as depicted in Fig. 1E, and bsFcko-1 format as depicted in Fig. 1G. A: determination of aggregation (values in percent) by means of gel filtration. Aggregates are migrating close to the void volume and are 43%, 0%, 2% for bs-scFv, bsFcko-1/2, bsFcko-1, respectively. It is concluded that formation of aggregates is considerably more pronounced if the antibody is expressed as bs-scFv rather than bsFcko-1/2 or bsFcko-1. B: production rate following transfection of antibody genes into production cells and purification via affinity chromatography. As can be seen, the formation of aggregates is significantly reduced for the two Fcko formats according to the invention and/or the disclosure, and production rates are substantially higher than with the bispecific single chain format (bs-scFv).

Fig. 6A shows the sequences of illustrative light chains that may be included in an antibody of the invention. The respective peptide chains correspond to the mature protein without the corresponding leader peptide sequence. The sequences contain an N-terminal variable domain represented in bold and a C-terminal constant domain depicted in italic. The complementarity determining regions (CDRs) of the variable domain are underlined.

Fig. 6B depicts the sequences of illustrative main chains, which can in the present case also be addressed as heavy chains that may be included in an antibody of the invention and/or disclosure. This particular main chain for the bsFc-1/2 format (Figs 1E) includes a VH domain, a CH1 domain, a hinge region, a modified CH2 domain, a VL domain and a VH domain of a scFv fragment. In sequence example 21) (SEQ ID NO: 26) the main chain contains a CH3 domain as depicted in the example Fig. 1G-M (bsFcko-1-format).

[0023] The VH domains are depicted in bold the CH1 domain in regular, and the hinge, CH2 and CH3 regions in regular, underlined text. The main chain further includes a VL domain, which is depicted in bold, italic text, and a VH domain (bold) of a scFvfragment. The VH and the VL domains are coupled to each othervia a linker, which is represented in italic, underlined text. The complementarity determining residues (CDRs) of the respective VL and VH regions are underlined. The CH2 domain and the scFv fragment are coupled to each othervia a small linker (GQPSG), which is represented in italic.

DETAILED DESCRIPTION

[0024] The present invention relates to a recombinant bispecific antibody molecule. This antibody molecule is composed of elements that are also found in native, i.e. naturally occurring, immunoglobulins, namely domains of heavy chains and light chains of immunoglobulins.

[0025] The term "antibody" generally refers to a proteinaceous binding molecule with immunoglobulin-like functions. Typical examples of an antibody are immunoglobulins, as well as derivatives or functional fragments thereof which still retain the binding specificity. Techniques for the production of antibodies are well known in the art. The term "antibody" also includes immunoglobulins (Ig’s) of different classes (i.e. IgA, IgG, IgM, IgD and IgE) and subclasses (such as lgG1, lgG2 etc.). Illustrative examples of an antibody are Fab fragments, F(ab’)2, Fv fragments, single-chain Fv fragments (scFv), diabodies or domain antibodies (Holt LJ et al., Trends Biotechnol. 21(11), 2003, 484-490). Domain antibodies may be single domain antibodies, single variable domain antibodies or immunoglobulin single variable domain having only one variable domain, which may be VFI orVL, that specifically bind an antigen or epitope independently of other V regions or domains. Such an immunoglobulin single variable domain may not only encompass an isolated antibody single variable domain polypeptide, but also a larger polypeptide that includes or consists of one or more monomers of an antibody single variable domain polypeptide sequence. The definition of the term "antibody" thus also includes embodiments such as chimeric, single chain and humanized antibodies.

[0026] An antibody molecule according to the invention may carry one or more domains that have a sequence with at least about 60 %, at least about 70 %, at least about 75 %, at least about 80 %, at least about 85 %, at least about 90 %, at least about 92 %, at least about 95 %, at least about 96 %, at least about 97 %, at least about 98 % or at least about 99 % sequence identity with a corresponding naturally occuring domain of an immunoglobulin M, an immunoglobulin G, an immunoglobulin A, an immunoglobulin D or an immunoglobulin E. It is noted in this regard, the term "about" or "approximately" as used herein means within a deviation of 20%, such as within a deviation of 10% or within 5% of a given value or range.

[0027] Accordingly, the main chain (longer polypeptide chain) of an antibody molecule of the invention may include, including consist of, domains with the above sequence identity with a corresponding domain of an immunoglobulin mu heavy chain, of an immunoglobulin gamma heavy chain, of an immunoglobulin alpha heavy chain, of an immunoglobulin delta heavy chain or of an immunoglobulin epsilon heavy chain. Further, an antibody molecule of the invention may include, including consist of, domains with the above sequence identity with a corresponding domain of an immunoglobulin lambda light chain or of an immunoglobulin kappa light chain. In some embodiments the entire heavy chain domains of an antibody molecule according to the invention have at least about 60 %, at least about 70 %, at least about 75 %, at least about 80 %, at least about 85 %, at least about 90 %, at least about 92 %, at least about 95 %, at least about 97 %, at least about 98 % or at least about 99 % sequence identity with the corresponding regions of an immunoglobulin mu heavy chain, of an immunoglobulin gamma heavy chain (such as gamma 1, gamma 2, gamma 3 or gamma 4 heavy chains), of an immunoglobulin alpha heavy chain (such as alpha 1 or alpha 2 heavy chains), of an immunoglobulin delta heavy chain or of an immunoglobulin epsilon heavy chain. In some embodiments all light chain domains present in an antibody molecule according to the invention have at least about 60 %, at least about 70 %, at least about 75 %, at least about 80 %, at least about 85 %, at least about 90 %, at least about 92 %, at least about 95 %, at least about 97 %, at least about 98 % or at least about 99 % sequence identity with the corresponding regions of an immunoglobulin lambda light chain (such as lambda 1, lambda 2, lambda 3 or lambda 4 light chains) or of an immunoglobulin kappa light chain.

[0028] " Percent (%) sequence identity" with respect to amino acid sequences disclosed herein is defined as the percentage of amino acid residues in a candidate sequence that are pair-wise identical with the amino acid residues in a reference sequence, i.e. an antibody molecule of the present disclosure, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publically available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared. The same is true for nucleotide sequences disclosed herein.

[0029] The term "variable" refers to the portions of the immunoglobulin domains that exhibit variability in their sequence and that are involved in determining the specificity and binding affinity of a particular antibody (i.e., the "variable do-main(s)"). Variability is not evenly distributed throughout the variable domains of antibodies; it is concentrated in sub-domains of each of the heavy and light chain variable regions. These sub-domains are called "hypervariable regions", "HVR," or "HV," or "complementarity determining regions" (CDRs). The more conserved (i.e., non-hypervariable) portions of the variable domains are called the "framework" regions (FR). The variable domains of naturally occurring heavy and light chains each include four FR regions, largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the β -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FR and, with the hypervariable regions from the other chain, contribute to the formation of the antigen- binding site (see Kabat et al., see below). Generally, naturally occurring immunoglobulins include six CDRs (see below); three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). In naturally occurring immunoglobulins, H3 and L3 display the most diversity of the six CDRs, and H3 in particular is believed to play a unique role in conferring fine specificity to immunoglobulins. The constant domains are not directly involved in antigen binding, but exhibit various effector functions, such as, for example, antibody-dependent, cell-mediated cyto- toxicity and complement activation.

[0030] The corresponding immunoglobulin mu heavy chain, gamma heavy chain, alpha heavy chain, delta heavy chain, epsilon heavy chain, lambda light chain or kappa light chain may be of any species, such as a mammalian species, including a rodent species, an amphibian, e.g. of the subclass Lissamphibia that includes e.g. frogs, toads, salamanders or newts or an invertebrate species. Examples of mammals include, but are not limited to, a rat, a mouse, a rabbit, a guinea pig, a squirrel, a hamster, a hedgehog, a platypus, an American pika, an armadillo, a dog, a lemur, a goat, a pig, a cow, an opossum, a horse, a bat, a woodchuck, an orang-utan, a rhesus monkey, a woolly monkey, a macaque, a chimpanzee, a tamarin (saguinus oedipus), a marmoset or a human.

[0031] The term "immunoglobulin" refers to a glycoprotein that includes at least two heavy (H) chains and two light (L) chains linked by disulfide bonds, or an antigen binding portion thereof. Each heavy chain has a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. In some embodiments the heavy chain constant region includes three domains, CH1, CH2 and CH3. Each light chain has a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region includes one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). The CDRs contain most of the residues responsible for specific interactions of the antibody with the antigen. Each VH and VL has three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an epitope of an antigen.

[0032] Each light chain of an immunoglobulin includes an N-terminal variable (V) domain (VL) and a constant (C) domain (CL). Each heavy chain includes an N-terminal V domain (VH), three or four C domains (CHs), and a hinge region. An antibody molecule according to the disclosure likewise contains these domains and regions (even though one binding site of the bispecific antibody molecule is only formed by a single chain Fv fragment).

[0033] An immunoglobulin when used herein, is typically a tetrameric glycosylated protein composed of two light (L) chains of approximately 25 kDa each and two heavy (H) chains of approximately 50 kDa each. Two types of light chain, termed lambda and kappa, may be found in immunoglobulins. Depending on the amino acid sequence of the constant domain of heavy chains, immunoglobulins can be assigned to five major classes: A, D, E, G, and M, and several of these may be further divided into subclasses (isotypes), e.g., lgG1, lgG2, lgG3, lgG4, lgA1, and lgA2. An IgM immunoglobulin consists of 5 of the basic heterotetramer unit along with an additional polypeptide called a J chain, and contains 10 antigen binding sites, while IgA immunoglobulins contain from 2-5 of the basic 4-chain units which can polymerize to form polyvalent assemblages in combination with the J chain. In the case of IgGs, the 4-chain unit is generally about 150,000 daltons.

[0034] The term "amino acid" or "amino acid residue" refers to an a- or β-amino carboxylic acid.

[0035] When used in connection with a protein or peptide, the term "amino acid" or "amino acid residue" typically refers to an α-amino carboxylic acid having its art recognized definition such as an amino acid selected from the group consisting of: L-alanine (Ala or A); L-arginine (Arg or R); L-asparagine (Asn or N); L-aspartic acid (Asp or D); L-cysteine (Cys or C); L-glutamine (Gin or Q); L-glutamic acid (Glu or E); glycine (Gly or G); L-histidine (His or H); L-isoleucine (ILE or I): L-leucine (Leu or L); L-lysine (Lys or K); L-methionine (Met or M); L-phenylalanine (Phe or F); L-proline (Pro or P); L-serine (Ser or S); L-threonine (Thror T); L-tryptophan (Trp or W); L-tyrosine (Tyror Y); and L-valine (Val orV), although modified, synthetic, or rare amino acids such as e.g. taurine, ornithine, selenocysteine, homocystine, hydroxyproline, thioproline, iodo-tyrosine, 3-nitro-tyrosine, ornithine, citrulline, canavanine, 5-hydroxytryptophane, carnosine, cycloleucine, 3,4-dihydroxy phenylalanine, N-acetylcysteine, prolinol, allylglycine or acetidine-2-carboxylic acid may be used as desired. Generally, amino acids can be grouped as having a nonpolar side chain (e.g., Ala, Cys, ILE, Leu, Met, Phe, Pro, Val); a negatively charged side chain (e.g., Asp, Glu); a positively charged sidechain (e.g., Arg, His, Lys); or an uncharged polar side chain (e.g., Asn, Cys, Gin, Gly, His, Met, Phe, Ser, Thr, Trp, and Tyr).

[0036] The term "epitope", also known as the "antigenic determinant", refers to the portion of an antigen to which an antibody or T-cell receptor specifically binds, thereby forming a complex. Thus, the term "epitope" includes any molecule or protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. The binding site(s) (paratope) of an antibody molecule described herein may specifically bind to/interact with conformational or continuous epitopes, which are unique for the target structure. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. In some embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, orsulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics. With regard to polypeptide antigens a conformational or discontinuous epitope is characterized by the presence of two or more discrete amino acid residues, separated in the primary sequence, but assembling to a consistent structure on the surface of the molecule when the polypeptide folds into the native protein/antigen (Sela, M., Science (1969) 166, 1365-1374; Laver, W.G., et al. Cell (1990) 61,553-556). The two or more discrete amino acid residues contributing to the epitope may be present on separate sections of one or more polypeptide chain(s). These residues come together on the surface of the molecule when the polypeptide chain(s) fold(s) into a three-dimensional structure to constitute the epitope. In contrast, a continuous or linear epitope consists of two or more discrete amino acid residues, which are present in a single linear segment of a polypeptide chain. As an illustrative example, a "context-dependent" CD3 epitope refers to the conformation of said epitope. Such a context-dependent epitope, localized on the epsilon chain of CD3, can only develop its correct conformation if it is embedded within the rest of the epsilon chain and held in the right position by heterodimerization of the epsilon chain with either CD3 gamma or delta chain. In contrast thereto, a context-independent CD3 epitope may be an N-terminal 1-27 amino acid residue polypeptide or a functional fragment thereof of CD3 epsilon. Generally, epitopes can be linear in nature or can be a discontinuous epitope. Thus, as used herein, the term "conformational epitope" refers to a discontinuous epitope formed by a spatial relationship between amino acids of an antigen other than an unbroken series of amino acids. The term "epitope" also includes an antigenic determinant of a hapten, which is known as a small molecule that can serve as an antigen by displaying one or more immunologically recognized epitopes upon binding to larger matter such as a larger molecule e.g. a protein.

[0037] An antibody or antibody molecule/fragment is said to specifically bind to an antigen when it recognizes its target antigen in a complex mixture of proteins and/or macromolecules. Antibodies are said to "bind to the same epitope" if the antibodies cross-corn pete so that only one antibody can bind to the epitope at a given point of time, i.e. one antibody prevents the binding or modulating effect of the other.

[0038] The term "specific" in this context, or "specifically recognizing", also used as "directed to", means in accordance with this invention that the antibody molecule is capable of specifically interacting with and/or binding to at least two, e.g. at least three or at least four amino acids of an epitope but does not essentially bind to another epitope or antigen. Such binding may be exemplified by the specificity of a "lock-and-key-principle". Specific binding is believed to be effected by specific motifs in the amino acid sequence of the binding region of the antibody, and the antibody and the epitope or the antigen bind to each other as a result of their primary, secondary or tertiary structure as well as the result of secondary modifications of said structure. The specific interaction of the epitope/antigen-interaction-site with its specific epitope/an-tigen may result as well in a simple binding of said site to the antigen. Moreover, the specific interaction of the antigen-interaction-site with its specific epitope/antigen may alternatively result in the initiation of a signal, such as for instance due to the induction of a change of the conformation of the antigen or an oligomerization of the antigen.

[0039] Typically, binding is considered specific when the binding affinity is higher than 10"6 M. In particular, binding is considered specific when binding affinity is about 10-8 to 10"11 M (KD), or of about 10"9 to 10"11 M or even higher. Thus, antibody molecules with an affinity of the first binding site and/or the second binding site in the picomolar range (with a KD of 10-12 M) are also encompassed in the present invention. If necessary, nonspecific binding of a binding site can be reduced without substantially affecting specific binding by varying the binding conditions.

[0040] In some embodiments an antigen to which an antibody according to the invention binds is an antigen that is included in the extracellular matrix or it is a cell surface antigen. In some embodiments an antigen to which an antibody according to the invention binds is a tumor associated antigen. It is understood that such a tumour associated antigen may be included in the extracellular matrix or be a cell surface antigen.

[0041] The term "extracellular matrix" refers to the tissue region of a multicellular animal, including a human that is found in the intercellular space, i.e. between the cells of the respective tissue. The extracellular matrix is largely a network of proteins such as fibrillar and non-fibrillar collagens or elastin, of glycoproteins such as laminin or fibronectin, of proteoglycans, such as chondroitin sulfate or keratan sulphate and of polysaccharides such as Hyaluronic acid. The extracellular matrix serves inter alia in segregating different tissues from each other or in regulating intercellular communication. In some embodiments a tumor associated antigen may be expressed partly or exclusively at the extracellular matrix of a tumor.

[0042] The term "cell surface antigen" as used herein refers to a molecule that is displayed on the surface of a cell. Typically such a molecule is located in or on the plasma membrane of the cell such that at least part of this molecule remains accessible from the ambience, i.e. from outside the cell. A respective molecule consists of or includes typically amino acid and/or saccharide moieties. An illustrative example of a cell surface molecule, which is located in the plasma membrane, is a transmembrane protein that, in its three-dimensional conformation, has regions of hydrophilicity and hydrophobicity. One or more hydrophobic region(s) allow(s) the cell surface molecule to be embedded, or inserted in the hydrophobic plasma membrane of the cell whereas hydrophilic regions of the protein extend on either side of the plasma membrane into the cytoplasm and extracellular space, respectively. Examples of a cell surface molecule located on the plasma membrane include, but are not limited to, a protein with a posttranslationally modified cysteine residue carrying a palmitoyl group, a protein modified at a C-terminal cysteine residue carrying a farnesyl group or a protein modified at the C-terminus carrying a glycosyl phosphatidyl inositol ("GPI") anchor. These groups allow covalent attachment of proteins to the outer surface of the plasma membrane, where they remain accessible for recognition by extracellular molecules such as antibodies. Examples of cell surface antigens include a cell surface receptor molecule such as a G protein coupled receptor (e.g. the β adrenergic receptor), a tyrosin kinase receptor (such as EGFR, EGFRvlll, Her2/neu, HER2/c-neu, PDGFRa, ILR-1, TNFR, CD30, CD33 or GMCSFR), a membrane receptor with associated tyrosin kinase activity (such as IL6R or LIFR) or a membrane receptor with Ser/Thr kinase activity (such as TGFpR), to name only a few examples.

[0043] Examples of a tumor associated antigen that is included in the extracellular matrix include, but are not limited to, a proteoglycan such as Melanoma-associated Chondroitin Sulfate Proteoglycan (CSPG4) or CD44v6, including a mucin such as Muc-1 ora membrane-bound enzyme such as Carbonic anhydrase IX(CAIX). Examples for such antigens are tenascin and the fibroblast activating protein (FAP).

[0044] The term "isolated antibody molecule" as used herein refers to an antibody molecule that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are matter that would interfere with diagnostic or therapeutic uses forthe anti body, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In some embodiments the antibody molecule is purified to greater than 95% by weight of antibody as determined by the Lowry method, such as more than 99% by weight. In some embodiments the antibody molecule is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator. In some embodiments the antibody is purified to homogeneity as judged by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. An isolated antibody molecule may in some embodiments be present within recombinant cells with one or more component(s) of the antibody’s natural environment not being present. Typically an isolated antibody is prepared by at least one purification step.

[0045] The terms "VH" and "VL" are used herein to refer to the heavy chain variable domain and light chain variable domain respectively of an immunoglobulin. An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions. Thus, the term "hypervariable region" refers to the amino acid residues of an antibody which are responsible for antigen binding. The hypervariable region includes amino acid residues from a "Complementarity Determining Region" or "CDR". There are three heavy chains and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDRs" as used herein refers to all three heavy chain CDRs (CDRH1, CDRH2 and CDRH3), or all three light chain CDRs (CDRL1, CDRL2 and CDRL3) or both all heavy and all light chain CDRs, if appropriate. Three CDRs make up the binding character of a light chain variable region and three make up the binding character of a heavy chain variable region. CDRs determine the antigen specificity of an immunoglobulin molecule and are separated by amino acid sequences that include scaffolding or framework regions. The exact definitional CDR boundaries and lengths are subject to different classification and numbering systems. The structure and protein folding of the antibody may mean that other residues are considered part of the antigen binding region and would be understood to be so by a skilled person. CDRs provide the majority of contact residues for the binding of the immunoglobulin to the antigen or epitope.

[0046] CDR3 is typically the greatest source of molecular diversity within the antibody-binding site. H3, for example, can be as short as two amino acid residues or greater than 26 amino acids. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known in the art. For a review of the antibody structure, see Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988. One of skill in the art will recognize that each subunit structure, e.g., a CH, VH, CL, VL, CDR, FR structure, includes active fragments, e.g., the portion of the VH, VL, or CDR subunit binds to the antigen, i.e., the antigen-binding fragment, or, e.g., the portion of the CH subunit that binds to and/or activates, e.g., an Fc receptor and/or complement. The CDRs typically refer to the Kabat CDRs, as described in Sequences of Proteins of immunological Interest, US Department of Health and Human Services (1991), eds. Kabat et al. Another standard for characterizing the antigen binding site is to refer to the hypervariable loops as described by Chothia. See, e.g., Chothia, et al. (1992; J. Mol. Biol. 227:799-817; and Tomlinson et al. (1995) EMBO J. 14:4628-4638. Still another standard is the AbM definition used by Oxford Molecular’s AbM antibody modelling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Embodiments described with respect to Kabat CDRs can alternatively be implemented using similar described relationships with respect to Chothia hypervariable loops or to the AbM-defined loops.

[0047] "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. Thus, a "human framework region" is a framework region that is substantially identical (about 85% or more, usually 90-95% or more) to the framework region of a naturally occurring human immunoglobulin. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDR’s. The CDR’s are primarily responsible for binding to an epitope of an antigen.

[0048] The terms "Fab", "Fab region", "Fab portion" or "Fab fragment" are understood to define a polypeptide that includes a VH, a CH1, a VL, and a CL immunoglobulin domain. Fab may refer to this region in isolation, or this region in the context of an antibody molecule according to the invention, as well as a full length immunoglobulin or immunoglobulin fragment. Typically a Fab region contains an entire light chain of an antibody. A Fab region can be taken to define "an arm" of an immunoglobulin molecule. It contains the epitope-binding portion of that Ig. The Fab region of a naturally occurring immunoglobulin can be obtained as a proteolytic fragment by a papain-digestion. A "F(ab’)2 portion" is the proteolytic fragment of a pepsin-digested immunoglobulin. A "Fab’ portion" is the product resulting from reducing the disulfide bonds of an F(ab’)2 portion. As used herein the terms "Fab", "Fab region", "Fab portion" or "Fab fragment" may further include a hinge region that defines the C-terminal end of the antibody arm (cf. above). This hinge region corresponds to the hinge region found C-terminally of the CH1 domain within a full length immunoglobulin at which the arms of the antibody molecule can be taken to define a Y. The term hinge region is used in the art because an immunoglobulin has some flexibility at this region.

[0049] An "Fv" or "Fv fragment" consists of only the VL and VH domains of a "single arm" of an immunoglobulin. Thus an "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and binding site. A "two-chain" Fv fragment consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. A single-chain Fv species (scFv) includes a VH and a VL domain of an immunoglobulin, with these domains being present in a single polypeptide chain in which they are covalently linked to each other by a flexible peptide linker. Typically, in a scFv fragment the variable domains of the light and heavy chain associate in a dimeric structure analogous to that in a two-chain Fv species. In single chain Fv fragments, it is possible to either have the variable domain of the light chain arranged at the N-terminus of the single polypeptide chain, followed by the linker and the variable domain of the heavy chain arranged at the C-terminus of the polypeptide chain or vice versa, having the variable domain of the heavy chain arranged on the N-terminus and the variable domain of the light chain at the C-terminus with the peptide linker arranged inbetween. The peptide linker can be any flexible linker known in the art, for example, made from glycine and serine residues. It is also possible to additionally stabilize the domain association between the VH and the VL domain by introducing disulfide bonds into conserved framework regions (see Reiter et al. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions, Biochemistry 1994, 33, 6551-5459). Such scFv fragments are also known as disulfide-stabilized scFv fragments (ds-scFv).

[0050] The term "Fc region" or "Fc fragment" is used herein to define a C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. The Fc part mediates the effector function of antibodies, e.g. the activation of the complement system and of Fc-receptor bearing immune effector cells, such as NK cells. In human IgG molecules, the Fc region is generated by papain cleavage N-terminal to Cys226. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during production or purification of the antibody molecule, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody antibody molecule. Accordingly, a composition of intact antibodies may include antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue. Suitable native-sequence Fc regions for use in the antibodies of the disclosure include mammalian, e.g. human or murine, lgG1, lgG2 (lgG2A, lgG2B), lgG3 and lgG4. The Fc region contains two or three constant domains, depending on the class of the antibody. In embodiments where the immunoglobulin is an IgG the Fc region has a CH2 and a CH3 domain.

[0051] An antibody molecule according to the invention has two chains, a shorter chain, which may in some embodiments be a light chain, and a main chain, which may in some embodiments also be addressed as the heavy chain. The antibody molecule is usually a dimer of these two chains. On the basis of the domains included in an antibody molecule of the invention the antibody molecule can be taken to have a Fab fragment, which generally includes a hinge region, a Ch2 domain and a single chain Fv fragment. In some molecules of the disclosure the antibody molecule also has a Ch3 domain, generally arranged C-terminally of the CH2 domain. In some molecules the arrangement of the domains of an antibody of the disclosure corresponds to the arrangement of domains in an immunoglobulin. As two examples, the shorter chain of an antibody molecule of the invention may have a VL domain at the N-terminus and a CL domain at the C-terminus of the shorter chain, and the main chain may have a VH domain at the N-terminus and a CH1 domain C-terminally thereto. In some embodiments the shorter chain may have a VL domain at the N-terminus and a CH1 domain at the C-terminus of the shorter chain. In some embodiments the shorter chain may have a VH domain at the N-terminus and a CH1 domain at the C-terminus of the shorter chain. In some embodiments the shorter chain may have a VH domain at the N-terminus and a CL domain at the C-terminus of the shorter chain. In some embodiments the main chain may have a VL domain at the N-terminus and a CH1 domain C-terminally thereto. In some embodiments the main chain may have a VH domain at the N-terminus and a CL domain C-terminally thereto. In some embodiments the main chain may have a VL domain at the N-terminus and a CL domain C-terminally thereto.

[0052] The shorter chain of the antibody may be linked to the main chain of the antibody by means of one or more, including two or three, disulphide bonds. A respective disulphide bond may define a bridge between a C-terminal cysteine residue of the smaller chain and a cysteine residue within the hinge region of the main chain of the antibody.

[0053] In an antibody molecule according to the invention the C-terminal region of the main chain may be defined by a single chain Fv fragment. The C-terminus of the main chain may in some embodiments be defined by the VH domain of the scFv fragment. In some embodiments the C-terminus of the main chain may be defined by the VL domain of the scFv fragment. Accordingly, the scFv fragment may in some embodiments be coupled to the CH2 domain, of the main chain via the VH domain, e.g. the N-terminal end of the VH domain. In some embodiments the scFv fragment may be coupled to the CH2 domain, of the main chain via the VL domain, e.g. the N-terminal end of the VL domain. In some embodiments the CH2 domain of the antibody molecule, is linked to the scFv fragment via the variable domain of the light chain (VL domain) of the scFv fragment. In some embodiments the CFI2 domain is linked to the scFv fragment via the variable domain of the heavy chain (VFI domain) of the scFv fragment.

[0054] The Fab fragment of an antibody molecule according to the invention is in some embodiments linked to the CH2 domain via a heavy chain domain of the Fab fragment. Accordingly, the main chain of the antibody may have a heavy chain domain such as a CH1 domain (supra), which is coupled to the CFI2 domain. As explained above, a respective CH 1 domain may be coupled to the CFI2 domain via a hinge region. The respective heavy chain domain of the Fab fragment may in some embodiments be arranged at the N-terminus of the polypeptide chain of the main chain of the antibody. In some embodiments the Fab fragment of an antibody molecule according to the invention is linked to the CH2 domain via a light chain domain of the Fab fragment. Accordingly, the main chain of the antibody molecule may have a light chain domain such as a CL domain, which is coupled to the CH2 domain. Again, a respective CL domain may be coupled to the CFI2 domain via a hinge region. The respective light chain domain of the Fab fragment may in some embodiments be arranged at the N-terminus of the polypeptide chain of the main chain of the antibody molecule. To prevent dimerization of the molecules in bivalent embodiments (Fig. 1A-E and 1 N) the cysteine residues in the hinge region providing inter-chain disulfide bonds may be exchanged. In tetravalent embodiments (Figs. 1 F-M) these cysteine residues are preserved. In these embodiments the antibody molecule can accordingly be taken to define a dimer of a bivalent, dimeric antibody molecule as described above and each main chain and each shorter chain can be individually selected. As an example, the first of the shorter chains may have a VH domain at the N-terminus and a CL domain at the C-terminus. The first main chain may have a VL domain at the N-terminus and a CH1 domain C-terminally thereto. Further, the first main chain may have a CH2 and a CH3 domain, as well as a C-terminal scFv fragment. The scFv fragment may be coupled to the CH3 domain via the VL domain. The second of the shorter chains may have a VH domain at the N-terminus and a CH1 domain at the C-terminus. The second main chain may have a VL domain at the N-terminus and a CL domain C-terminally thereto. The second main chain may also have a CH2 and a CH3 domain, as well as a C-terminal scFv fragment. The scFv fragment may be coupled to the CH3 domain via the VL domain.

[0055] A respective tetrameric antibody molecule may be composed of two dimeric antibody molecules that are linked to each other via one or more, such as two, disulphide bonds. Such a disulphide bond may define a bridge between a cysteine residue of the main chain of a first dimeric antibody molecule and a cysteine residue of the main chain of a second dimeric antibody molecule. Typically, the respective cysteine residues are positioned within the hinge region of the corresponding main chain of each dimeric antibody molecule. In some antibody molecules one or both of the two main chains, i.e. the main chain of the first dimeric molecule and the main chain of the second dimeric molecule of a tetrameric antibody molecule, have a cysteine residue at sequence position 226 and/or at sequence position 229 of one of the respective hinge domain, in line with the Kabat numbering [EU-Index]. In one antibody molecule of the disclosure a disulphide bond between the hinge domain of the first main chain and a hinge domain of the second main chain is defined by at least one of a cysteine residue at sequence position 226 and a cysteine residue at sequence position 229 of one of the hinge domains, according to the Kabat numbering [EU-Index]. A tetrameric antibody molecule may have one or more disulphide bonds linking the hinge regions of the two main chains of the dimeric antibody molecules and a disulphide bond linking the hinge regions of the two main chains of the dimeric antibody molecules. In some antibody molecules of the disclosure two dimeric antibody molecules of a tetrameric antibody molecule according to the disclosure may be linked by means of a disulphide bond that is defined by a cysteine residue that is included in the CH2 domain of the main chain of a first dimeric antibody molecule and a cysteine residue that is included in the CH2 domain of the main chain of a second dimeric antibody molecule.

[0056] As a further example, the first of the shorter chains may have a VL domain at the N-terminus and a CH1 domain at the C-terminus. The first main chain may have a VH domain at the N-terminus and C-terminally linked thereto a CL domain. Further, the first main chain may have a CH2 and a CH3 domain, as well as a C-terminal scFv fragment. The scFv fragment may be coupled to the CH3 domain via the VH domain. The second of the shorter chains may have a VL domain at the N-terminus and a CL domain at the C-terminus. The second main chain may have a VH domain at the N-terminus and a CH1 domain C-terminally thereto. The second main chain may also have a CH2 and a CH3 domain, as well as a C-terminal scFv fragment. The scFv fragment may be coupled to the CH3 domain via the VH domain.

[0057] A "bispecific" or "bifunctional" antibody molecule is an antibody molecule that has two different epitope/antigen binding sites, and accordingly has binding specificities for two different target epitopes. These two epitopes may be epitopes of the same antigen or of different antigens. In contrast thereto a "bivalent antibody" may have binding sites of identical antigenic specificity.

[0058] A "bispecific antibody" may be an antibody molecule that binds one antigen or epitope on one of two or more binding arms, defined by a first pair of heavy and light chain or of main and shorter/smaller chain (supra), and binds a different antigen or epitope on a second arm, defined by a second pair of heavy and light chain or of main and smaller chain. Such an embodiment of a bispecific antibody has two distinct antigen binding arms, in both specificity and CDR sequences. Typically, a bispecific antibody is monovalent for each antigen it binds to. A bispecific antibody is a hybrid antibody molecule, which may have a first binding region that is defined by a first light chain variable region and a first heavy chain variable region, and a second binding region that is defined by a second light chain variable region and a second heavy chain variable region. In some embodiments one of these binding regions may be defined by a heavy/light chain pair. As explained above, in the context of the present invention the bispecific antibody molecule has a first binding site, defined by variable regions of a main chain and a smaller chain, and a second, different binding site defined by a variable region of a scFv fragment that is included in the main chain of the antibody molecule.

[0059] Methods of making a bispecific antibody molecule are known in the art, e.g. chemical conjugation of two different monoclonal antibodies or for example, also chemical conjugation of two antibody fragments, for example, of two Fab fragments. Alternatively, bispecific antibody molecules are made recombinantly. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin H chain-L chain pairs, where the two H chains have different binding specificities. Because of the random assortment of H and L chains, a potential mixture of ten different antibody structures are produced of which only one has the desired binding specificity. An alternative approach involves fusing the variable domains with the desired binding specificities to heavy chain constant region including at least part of the hinge region, CH2 and CH3 regions. In one embodiment the CH1 region containing the site necessary for light chain binding is present in at least one of the fusions. DNA encoding these fusions, and if desired the L chain are inserted into separate expression vectors and are then co-transfected into a suitable host organism. It is possible though to insert the coding sequences for two or all three chains into one expression vector.

[0060] The bispecific antibody molecule of the invention can act as a monoclonal antibody (MAb) with respect to each target. In some embodiments the antibody is chimeric, humanized or fully human.

[0061] A "dual-specific antibody", which may for instance be a full-length immunoglobulin or a construct with immunoglobulin like binding properties, is generally understood to have two binding arms, in particular arms defined by a pair of HC/LC, that can bind two different antigens or epitopes in each of its (see PCT publication WO 02/02773). Accordingly a dual-specific binding protein has two identical antigen binding arms, with identical specificity and identical CDR sequences, and is bivalent for each antigen it binds to.

[0062] TheT cell receptor (TCR) is a particular receptor that is present on the cell surface of T cells, i.e. T lymphocytes. In vivo the T cell receptor exists as a complex of several proteins. The T cell receptor generally has two separate peptide chains, typically T cell receptor alpha and beta (TCRa and TCRP) chains, on some T cells T cell receptor gamma and delta (TCRy and TCR6). The other proteins in the complex are the CD3 proteins: CD3sy and CD3s6 heterodimers and, most important, a Οϋ3ζ homodimer, which has a total of six ITAM motifs. The ITAM motifs on the Οϋ3ζ can be phos-phorylated by Lck and in turn recruit ZAP-70. Lck and/or ZAP-70 can also phosphorylate the tyrosines on many other molecules, not least CD28, LAT and SLP-76, which allows the aggregation of signalling complexes around these proteins.

[0063] An antibody molecule according to the invention includes a light chain with a VL domain and a CL domain. The antibody molecule further includes a main chain that includes a VH domain, a CH1 domain and a hinge region. The VH domain is arranged at the N-terminus of the main chain, and the VH domain is linked to the CH1 domain, either directly linked thereto or coupled via a linking peptide of typically 20 or less, including 10 or less amino acid residues. The hinge region is linked to the C-terminal end of the CH1 domain. Accordingly, the portion of the antibody molecule that is defined by the adjacent arrangement of the VL, the CL, the VH and the CH1 domain as well as the hinge region, can be taken to define a Fab fragment and is accordingly referred to also as such herein. As in a naturally occurring immunoglobulin the pairing of the VH and the VL domain together defines a single antigen-binding site. Hence, the Fab fragment of an antibody of the invention includes the binding site for a first antigen. In a respective antibody molecule the light chain is linked to the main chain by a disulfide bond. In some examples an antibody molecule according to the disclosure is a dimer that includes two main chains and two light chains as described above (cf. also below).

[0064] In some embodiments the sequence of a recombinant bispecific antibody molecule according to the invention can be compared against the sequence of IgG 1, since the sequence of the antibody molecule according to the invention has a certain degree of similarity with the sequence of IgG 1, as illustrated further below. In comparison to the amino acid sequence of IgG 1 according to Kabat et al. (1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda) a main chain of an antibody molecule according to the invention in some embodiments includes a VH domain at amino acid positions 1 to 117, a CH1 domain at positions 118 to 215, a hinge region at positions 216 to 230 and a CH2 domain at positions 231 to 340.

[0065] In accordance with the amino acid sequence of the main chain of an antibody of the invention the Fab fragment, consisting of the VH domain, the CH1 domain and the hinge region, in these embodiments typically spans amino acids 1 to 230. Within this Fab fragment the VH domain is typically defined by amino acids 1 to 118, the CH1 domain is defined by amino acids 119 to 216, and the hinge region is defined by amino acids 217 to 231, according to the Kabat numbering. The antibody chain with the sequence of SEQ ID NO: 6 may serve as an example of a respective embodiment. In some embodiments the antibody molecule according to the invention has, at the positions 342 et sqq of the main chain, a chimeric sequence composed of a VH domain and a VL domain. In some embodiments the VL domain is arranged to define the C-terminal domain of this chimeric sequence. In some examples the antibody according to the disclosure has, in comparison to the amino acid sequence of IgG 1 according to Kabat et al., a CH3 domain at positions 342 to 447, followed by a chimeric sequence composed of a VH domain and a C-terminal VL domain. In such examples where a Ch3 domain is included in the antibody according to the disclosure, this CH3 domain is defined by amino acids 342 to 448 in accordance with the amino acid sequence of the main chain of the antibody molecule. The chimeric sequence composed of a VH domain and a VL domain, which may be C-terminal (supra), is in these examples located at the positions 449 et sqq of the amino acid sequence of the main chain of the antibody molecule.

[0066] A bispecific antibody molecule according to the invention may have two binding sites of any desired specificity. In some embodiments one of the binding sites is capable of binding a tumour associated antigen. In some embodiments the binding site included in the Fab fragment is a binding site specific for a tumour associated surface antigen. In some embodiments the binding site included in the single chain Fv fragment is a binding site specific for a tumour associated antigen such as a tumour associated surface antigen.

[0067] The term "tumour associated surface antigen" as used herein refers to an antigen that is or can be presented on a surface that is located on or within tumour cells. These antigens can be presented on the cell surface with an extracellular part, which is often combined with a transmembrane and cytoplasmic part of the molecule. These antigens can in some embodiments be presented only by tumour cells and not by normal, i.e. non-tumour cells. Tumour antigens can be exclusively expressed on tumour cells or may represent a tumour specific mutation compared to non-tumour cells. In such an embodiment a respective antigen may be referred to as a tumour-specific antigen. Some antigens are presented by both tumour cells and non-tumour cells, which may be referred to as tumour-associated antigens. These tumour-associated antigens can be overexpressed on tumour cells when compared to non-tumour cells or are accessible for antibody binding in tumour cells due to the less compact structure of the tumour tissue compared to non-tumour tissue. In some embodiments the tumour associated surface antigen is located on the vasculature of a tumour.

[0068] Illustrative examples of a tumor associated surface antigen are CD10, CD19, CD20, CD22, CD33, Fms-like tyrosine kinase 3 (FLT-3, CD135), chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), Epidermal growth factor receptor (EGFR), Fler2neu, Fler3, IGFR.CD133, IL3R, fibroblast activating protein (FAP), CDCP1, Derlinl, Tenascin, frizzled 1-10, the vascular antigens VEGFR2 (KDR/FLK1), VEGFR3 (FLT4, CD309), PDGFR-α (CD140a), PDGFR-β (CD140b) Endoglin, CLEC14, Tem1-8, and Tie2. Further examples may include A33, CAMPATFI-1 (CDw52), Carcinoembryonic antigen (CEA), Carboanhydrase IX (MN/CA IX), CD21, CD25, CD30, CD34, CD37, CD44v6, CD45, CD133, de2-7 EGFR, EGFRvlll, EpCAM, Ep-CAM, Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135), c-Kit (CD117), CSF1R (CD115), HLA-DR, IGFR, IL-2 receptor, IL3R, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane), Muc-1, Prostate-specific membrane antigen (PSMA), Prostate stem cell antigen (PSCA), Prostate specific antigen (PSA), and TAG-72. Examples of antigens expressed on the extracellular matrix of tumors are tenascin and the fibroblast activating protein (FAP).

[0069] In some embodiments one of the binding sites of an antibody molecule according to the invention is able to bind a T-cell specific receptor molecule and/or a natural killer cell (NK cell) specific receptor molecule. A T-cell specific receptor is the so called "T-cell receptor" (TCRs), which allows a T cell to bind to and, if additional signals are present, to be activated by and respond to an epitope/antigen presented by another cell called the antigen-presenting cell or APC. The T cell receptor is known to resemble a Fab fragment of a naturally occurring immunoglobulin. It is generally monovalent, encompassing a- and β-chains, in some embodiments it encompasses γ-chains and δ-chains (supra). Accordingly, in some embodiments the TCR is TCR (alpha/beta) and in some embodiments it is TCR (gamma/delta). The T cell receptor forms a complex with the CD3 T-Cell co-receptor. CD3 is a protein complex and is composed of four distinct chains. In mammals, the complex contains a CD3y chain, a CD36 chain, and two CD3s chains. These chains associate with a molecule known as the T cell receptor (TCR) and the ζ-chain to generate an activation signal in T lymphocytes. Flence, in some embodiments a T-cell specific receptor is the CD3T-Cell co-receptor. In some embodiments a T-cell specific receptor is CD28, a protein that is also expressed on T cells. CD28 can provide co-stimulatory signals, which are required forT cell activation. CD28 plays important roles in T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Yet a further example of a T-cell specific receptor is CD134, also termed 0x40. CD134/0X40 is being expressed after 24 to 72 hours following activation and can be taken to define a secondary costimulatory molecule. Another example of a T-cell receptor is 4-1BB capable of binding to 4-1BB-Ligand on antigen presenting cells (APCs), whereby a costimulatory signal for the T cell is generated. Another example of a receptor predominantly found on T-cells is CD5, which is also found on B cells at low levels. A further example of a receptor modifying T cell functions is CD95, also known as the Fas receptor, which mediates apoptotic signaling by Fas-ligand expressed on the surface of other cells. CD95 has been reported to modulate TCR/CD3-driven signaling pathways in resting T lymphocytes.

[0070] An example of a NK cell specific receptor molecule is CD16, a low affinity Fc receptor and NKG2D. An example of a receptor molecule that is present on the surface of both T cells and natural killer (NK) cells is CD2 and further members of the CD2-superfamily. CD2 is able to act as a co-stimulatory molecule on T and NK cells.

[0071] In some embodiments the first binding site of the antibody molecule binds a tumour associated surface antigen and the second binding site binds a T cell specific receptor molecule and/or a natural killer (NK) cell specific receptor molecule. In some embodiments the first binding site of the antibody molecule binds one of A33, CAMPATFI-1 (CDw52),

Carcinoembryonic antigen (CEA), Carboanhydrase IX (MN/CA IX), CD10, CD19, CD20, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CD133, CDCP1, Her3, chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), CLEC14, Derlin 1, Epidermal growth factor receptor (EGFR), de2-7 EGFR, EGFRvlll, EpCAM, Endoglin, Ep-CAM, Fibroblast activation protein (FAP), Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135), c-Kit (CD117), CSF1 R(CD115), frizzled 1-10, Her2/neu, HLA-DR, IGFR, IL-2 receptor, IL3R, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane), Muc-1, Prostate-specific membrane antigen (PSMA), Prostate stem cell antigen (PSCA), Prostate specific antigen (PSA), TAG-72, Tenascin, Tem1-8, Tie2 and VEGFR2 (KDR/FLK1), VEGFR3 (FLT4, CD309), PDGFR-α (CD140a), PDGFR-β (CD140b), and the second binding site binds a T cell specific receptor molecule and/or a natural killer (NK) cell specific receptor molecule. In some embodiments the first binding site of the antibody molecule binds a tumour associated surface antigen and the second binding site binds one of CD3, the T cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1BB, CD2, CD5 and CD95.

[0072] In some embodiments the first binding site of the antibody molecule binds a T cell specific receptor molecule and/or a natural killer (NK) cell specific receptor molecule and the second binding site binds a tumour associated surface antigen. In some embodiments the first binding site of the antibody binds a T cell specific receptor molecule and/or a natural killer (NK) cell specific receptor molecule and the second binding site binds one of A33, CAMPATFI-1 (CDw52), Carcinoembryonic antigen (CEA), Carboanhydrase IX (MN/CA IX), CD10, CD19, CD20, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CD133, CDCP1, Her3, chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), CLEC14, Derlin 1, Epidermal growth factor receptor (EGFR), de2-7 EGFR, EGFRvlll, EpCAM, Endoglin, Ep-CAM, Fibroblast activation protein (FAP), Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135), frizzled 1-10, Fler2/neu, FI LA-DR, IGFR, IL-2 receptor, IL3R, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane), Muc-1, Prostate-specific membrane antigen (PSMA), Prostate specific antigen (PSA), TAG-72, Tenascin, Tern 1-8, Tie2 and VEGFR. In some embodiments the first binding site of the antibody binds one of CD3, theT cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1 BB, CD2, CD5 and CD95, and the second binding site binds a tumour associated surface antigen.

[0073] The term "glycosylation" means the attachment of oligosaccharides (carbohydrates containing two or more simple sugars linked together e.g. from two to about twelve simple sugars linked together) to a glycoprotein. The oligosaccharide side chains are typically linked to the backbone of the glycoprotein through either N- or O-linkages. The oligosaccharides of antibodies disclosed herein occur generally are attached to a CFI2 domain of an Fc region as N-linked oligosaccharides. "N-linked glycosylation" refers to the attachment of the carbohydrate moiety to an asparagine residue in a glycoprotein chain. The skilled artisan will recognize that, for example, each of murine lgG1, lgG2a, lgG2b and lgG3aswell as human lgG1, lgG2, lgG3, lgG4, IgA and IgD CFI2 domains have a single site for N-linked glycosylation at residue 297.

[0074] Sequences of domains or regions included in an antibody molecule according to the invention may be sequences of any desired species. Depending on the subsequent use of the antibody molecule it may, nevertheless, be desirable in some embodiments, to introduce alterations that prevent undesired side effects caused by the antibody. The use of intact non-human antibodies in the treatment of human diseases or disorders carries with it the potential for the now well established problems of immunogenicity, which means that the immune system of the patient may recognise the non-human intact antibody as non-self and mount a neutralising response. This is particularly evident upon multiple administration of the non-human antibody to a human patient. Various techniques have been developed over the years to overcome these problems and generally involve reducing the composition of non-human amino acid sequences in the intact antibody whilst retaining the relative ease in obtaining non-human antibodies from an immunised animal e.g. mouse, rat or rabbit. Broadly two approaches have been used to achieve this. The first are chimeric antibodies, which generally have a non-human (e.g. rodent such as mouse) variable domain fused to a human constant region. Because the antigen-binding site of an antibody is defined by residues within the variable domains the chimeric antibody retains its binding affinity for the antigen but acquires the effector functions of the human constant region and are therefore able to perform effector functions such as described supra. Chimeric antibodies are typically produced using recombinant DNA methods. DNA encoding the antibodies (e.g. cDNA) is isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are capable of binding specifically to genes encoding the H and L chains of the antibody of the invention. Hybridoma cells serve as a typical source of such DNA. Once isolated, the DNA is placed into expression vectors which are then transfected into host cells such as E. coli, COS cells, CHO cells or myeloma cells that do not otherwise produce immunoglobulin protein to obtain synthesis of the antibody. The DNA may be modified by substituting the coding sequence for human L and FI chains for the corresponding non-human, e.g. murine, FI and L constant regions (see e.g. Morrison; PNAS [1984] 81, 6851).

[0075] The second approach involves the generation of humanised antibodies wherein the non-human content of the antibody is reduced by humanizing the variable domains. Two techniques for humanisation have gained popularity. The first is humanisation by CDR grafting. CDRs define loops (supra) and antigen-binding specificity of an antibody is mainly defined by the topography and by the chemical characteristics of its CDR surface. These features are in turn determined by the conformation of the individual CDRs, by the relative disposition of the CDRs, and by the nature and disposition of the side chains of the residues including the CDRs. A large decrease in immunogenicity can be achieved by grafting only the CDRs of a non-human, e.g. murine, antibodies ("donor" antibodies) onto human framework ("acceptor framework") and constant regions (see Jones et al (1986) Nature 321,522-525 and Verhoeyen M et al (1988) Science 239, 1534-1536). However, CDR grafting per se may not result in the complete retention of antigen-binding properties and it is frequently found that some framework residues (sometimes referred to as "back mutations") of the donor antibody need to be preserved in the humanised molecule if significant antigen-binding affinity is to be recovered (see Queen C et al (1989) PNAS 86, 10,029-10,033, Co, M et al (1991) Nature 351,501-502). In this case, human variable domains showing the greatest sequence homology to the non-human donor antibody are chosen from a database in order to provide the human framework (FR). The selection of human FRs can be made eitherfrom human consensus or individual human antibodies. Where necessary key residues from the donor antibody are substituted into the human acceptor framework to preserve CDR conformations, computer modelling of the antibody may be used to help identify such structurally important residues. See W099/48523, for example.

[0076] Alternatively, humanisation maybe achieved by a process of "veneering". A statistical analysis of unique human and murine immunoglobulin heavy and light chain variable domains revealed that the precise patterns of exposed residues are different in human and murine antibodies, and most individual surface positions have a strong preference for a small number of different residues (see Padlan E. A. et al; (1991) Mol. Immunol. 28, 489-498 and Pedersen J. T. et al (1994) J. Mol. Biol. 235; 959-973). Therefore it is possible to reduce the immunogenicity of a non-human Fv by replacing exposed residues in its framework regions that differ from those usually found in human antibodies. Because protein antigenicity may be correlated with surface accessibility, replacement of the surface residues may be sufficient to render the mouse variable domain "invisible" to the human immune system (see also Mark G. E. et al (1994) in Handbook of Experimental Pharmacology vol. 113: The pharmacology of monoclonal Antibodies, Springer-Verlag, pp 105-134). This procedure of humanisation is referred to as "veneering" because only the surface of the antibody is altered, the supporting residues remain undisturbed.

[0077] An antibody molecule of the invention may be produced using any known and well-established expression system and recombinant cell culturing technology, for example, by expression in bacterial hosts (prokaryotic systems), or eukaryotic systems such as yeasts, fungi, insect cells or mammalian cells. An antibody molecule of the present invention may be produced in transgenic organisms such as a goat, a plant or a XENOMOUSE transgenic mouse, an engineered mouse strain that has large fragments of the human immunoglobulin loci and is deficient in mouse antibody production. An antibody may also be produced by chemical synthesis.

[0078] For recombinant production of an antibody molecule of the invention typically a polynucleotide encoding the antibody is isolated and inserted into a replicable vectorsuch as a plasmid for further cloning (amplification) or expression. An illustrative example of a suitable expression system is a glutamate synthetase system (such as sold by Lonza Biologies), with the host cell being for instance CHO or NS0. A polynucleotide encoding the antibody is readily isolated and sequenced using conventional procedures. Vectors that may be used include plasmid, virus, phage, transposons, minichromsomes of which plasmids are a typical embodiment. Generally such vectors further includes signal sequence, origin of replication, one or more marker genes, an enhancer element, a promoter and transcription termination sequences operably linked to the light and/or heavy chain polynucleotide so as to facilitate expression. Polynucleotides encoding the light and heavy chains may be inserted into separate vectors and transfected into the same host cell or, if desired both the heavy chain and light chain can be inserted into the same vector for transfection into the host cell. Both chains can, for example, be arranged, under the control of a dicistronic operon and expressed to result in the functional and correctly folded antibody molecule as described in Skerra, A. (1994) Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli, Gene 151, 131-135, or Skerra, A. (1994) A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments, Gene 141,79-8. Thus according to one aspect of the present invention there is provided a process of constructing a vector encoding the light and/or heavy chains of an antibody or antigen binding fragment thereof of the invention, which method includes inserting into a vector, a polynucleotide encoding either a light chain and/or heavy chain of an antibody molecule of the invention.

[0079] When using recombinant techniques, the antibody molecule can be produced intracellularly, in the periplasmic space, or directly secreted into the medium (cf. also Skerra 1994, supra). If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10: 163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of E coli. The antibody can also be produced in any oxidizing environment. Such an oxidizing environment may be provided by the periplasm of Gram-negative bacteria such as E. coli, in the extracellular milieu of Gram-positive bacteria or in the lumen of the endoplasmatic reticulum of eukaryotic cells (including animal cells such as insect or mammalian cells) and usually favors the formation of structural disulfide bonds. It is, however, also possible to produce an antibody molecule of the invention in the cytosol of a host cell such as E. coli. In this case, the polypeptide can either be directly obtained in a soluble and folded state or recovered in form of inclusion bodies, followed by renaturation in vitro. A further option is the use of specific host strains having an oxidizing intracellular milieu, which may thus allow the formation of disulfide bonds in the cytosol (Venturi M, Seifert C, Hunte C. (2002) "High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm." J. Mol. Biol. 315, 1-8).

[0080] The antibody molecule produced by the cells can be purified using any conventional purification technology, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being one preferred purification technique. Antibody molecules may be purified via affinity purification with proteins/ligands that specifically and reversibly bind constant domains such as the CH1 or the CL domains. Examples of such proteins are immunoglobulin-binding bacterial proteins such as Protein A, Protein G, Protein A/G or Protein L, wherein Protein L binding is restricted to antibody molecules that contain kappa light chains. An alternative method for purification of antibodies with κ-light chains is the use of bead coupled anti kappa antibodies (KappaSelect). The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies (Lindmark et al., J. Immunol. Meth. 62: 1-13 (1983)). Protein G is recommended for all mouse isotypes and for human gamma3 (Guss et al., EMBO J. 5: 15671575 (1986)). The choice of the purification method that is used for a particular antibody molecule of the invention is within the knowledge of the person of average skill in the art.

[0081] It is also possible to equip one of the chains of the antibody molecule of the invention with an affinity tag. Affinity tags such as the Strep-tag® or Strep-tag@ II (Schmidt, T.G.M. et al. (1996) J. Mol. Biol. 255, 753-766), the myc-tag, the FLAG™-tag, the His6-tag or the HA-tag allow easy detection and also simple purification of the recombinant antibody molecule.

[0082] The terms "mutated", "mutant" and "mutation" in reference to a nucleic acid or a polypeptide refers to the exchange, deletion, or insertion of one or more nucleotides or amino acids, respectively, compared to the naturally occurring nucleic acid or polypeptide, i.e. to a reference sequence that can be taken to define the wild-type.

[0083] It is understood in this regard that the term "position", when used in accordance with the present invention, means the position of an amino acid within an amino acid sequence depicted herein. This position may be indicated relative to a resembling native sequence, e.g. a sequence of a naturally occurring IgG domain or chain. The term "corresponding" as used herein also includes that a position is not necessarily, or not only, determined by the number of the preceding nucleotides/amino acids. Thus, the position of a given amino acid in accordance with the present invention which may be substituted may vary due to deletion or addition of amino acids elsewhere in the antibody chain.

[0084] Thus, under a "corresponding position" in accordance with the present disclosure it is to be understood that amino acids may differ in the indicated number but may still have similar neighbouring amino acids. Said amino acids which may be exchanged, deleted or added are also encompassed by the term "corresponding position". In order to determine whether an amino acid residue in a given amino acid sequence corresponds to a certain position in the amino acid sequence of a naturally occurring immunoglobuline domain or chain, the skilled person can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as BLAST2.0, which stands for Basic Local Alignment Search Tool or ClustalW or any other suitable program which is suitable to generate sequence alignments.

[0085] In some embodiments a substitution (or replacement) is a conservative substitution. Conservative substitutions are generally the following substitutions, listed according to the amino acid to be mutated, each followed by one or more replacement(s) that can be taken to be conservative: Ala Gly, Ser, Val; Arg Lys; Asn Gin, His; Asp Glu; Cys

Ser; Gin Asn; Glu Asp; Gly Ala; His Arg, Asn, Gin; lie Leu, Val; Leu lie, Val; Lys Arg, Gin, Glu; Met Leu, Tyr, lie; Phe Met, Leu, Tyr; Ser Thr; Thr Ser; Trp Tyr; Tyr Trp, Phe; Val lie, Leu. Other substitutions are also permissible and can be determined empirically or in accord with other known conservative or nonconservative substitutions. As a further orientation, the following eight groups each contain amino acids that can typically be taken to define conservative substitutions for one another: 1) Alanine (Ala), Glycine (Gly); 2) Aspartic acid (Asp), Glutamic acid (Glu); 3) Asparagine (Asn), Glutamine (Gin); 4) Arginine (Arg), Lysine (Lys); 5) Isoleucine (lie), Leucine (Leu), Methionine (Met), Valine (Val); 6) Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp); 7) Serine (Ser), Threonine (Thr); and 8) Cysteine (Cys), Methionine (Met) [0086] If such substitutions result in a change in biological activity, then more substantial changes, such as the following, or as further described below in reference to amino acid classes, may be introduced and the products screened for a desired characteristic. Examples of such more substantial changes are: Ala -» Leu, lie; Arg ->· Gin; Asn -» Asp, Lys, Arg, His; Asp Asn; Cys Ala; Gin Glu; Glu Gin; His Lys; lie Met, Ala, Phe; Leu Ala, Met, Norleucine;

Lys Asn; Met Phe; Phe Val, lie, Ala; Trp Phe; Tyr Thr, Ser; Val Met, Phe, Ala.

[0087] In some embodiments an antibody molecule according to the invention includes one or more amino acid residues, including two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen or eighteen amino acid residues, that are mutated to prevent dimerization via cystein residues or to modulate Fc-function. In some of these embodiments one or more amino acid residue(s) of the CH2 domain and/or of the hinge region that is able to mediate binding to Fc receptors are mutated. If present, the one or more amino acid residue(s) able to mediate binding to Fc receptors may be an amino acid residue that is able to activate antibody dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CDC). In some embodiments a respective amino acid residue capable of mediating binding to Fc receptors is substituted by another amino acid, generally when comparing the sequence to the sequence of a corresponding naturally occurring domain in an immunoglobulin, such as an IgG. In some embodiments such an amino acid residue capable of mediating binding to Fc receptors is deleted, generally relative to the sequence of a corresponding naturally occurring domain in an immunoglobulin, such as an IgG. However, in other embodiments of the invention that relate to a bispecific antibody molecule consisting of a Fab fragment, a single chain Fv fragment and an immunoglobulin CH2 domain, it is within the scope of the invention to introduce mutations in the CH2 domain of human γ1, for example, that optimize antibody dependent cytotoxicity (ADCC). Such mutations are described in the international patent applications WO2011/076922 and WO2011/089211, for example.

[0088] In some embodiments the one or more mutated, e.g. substituted or deleted, amino acid residues is/are an amino acid located at one of the positions 226, 228, 229, 230, 231,232, 233, 234, 235, 236, 237, 238, 265, 297, 327, and 330. Again, the numbering of amino acids used corresponds to the sequence positions according to the Kabat numbering [EU-index], A corresponding deletion of an amino acid may for example be a deletion of amino acid 228, generally a proline in IgG, a deletion of amino acid 229, generally a cysteine in IgG, a deletion of amino acid 230, generally a proline in IgG, a deletion of amino acid 231, generally an alanine in IgG, a deletion of amino acid 232, generally a proline in IgG, a deletion of amino acid 233, generally a glutamic acid in IgG, a deletion of amino acid 234, generally a leucine in IgG, a deletion of amino acid 235, generally a leucine in IgG, a deletion of amino acid 236, generally a glycine in IgG, a deletion of amino acid 237, generally a glycine in IgG, a deletion of amino acid 238, generally a proline in IgG and a deletion of amino acid 265, generally an aspartic acid in IgG. A corresponding substitution of an amino acid may for example be a substitution of amino acid 226, generally a cysteine in IgG, a substitution of amino acid 228, generally a proline in IgG, a substitution of amino acid 229, generally a cysteine in IgG, a substitution of amino acid 230, generally a proline in IgG, a substitution of amino acid 231, generally an alanine in IgG, a substitution of amino acid 232, generally a proline in IgG, a substitution of amino acid 233, generally a glutamic acid in IgG, a substitution of amino acid 234, generally a leucine in IgG, a substitution of amino acid 235, generally a leucine in IgG, a substitution of amino acid 265, generally an aspartic acid in IgG, a substitution of amino acid 297, generally an asparagine in IgG, a substitution of amino acid 327, generally an alanine in IgG, and a substitution of amino acid 330, generally an alanine in IgG. A respective substitution may be one of substitution Cys226-»Ser, substitution Cys229->Ser, substitution Glu233->Pro, substitution Leu234-»Val, substitution Leu235-»Ala, substitution Asp265-»Gly, substitution Asn297->Gln, substitution Ala327->Gln, substitution Ala327->Gly, and substitution Ala330-»Ser. As can be taken from the above, in some embodiments one or two of the cysteine residues at positions 226 and 229 in the hinge region are being substituted for another amino acid, for instance substituted for a serine residue. Thereby the formation of a disulphide bond with another main chain can be prevented. Further, and as also explained below, deleting and/or substituting (mutating) selected amino acid residues in the CH2 domain that is able to mediate binding to Fc-receptors can cause an antibody molecule of the invention to have less or no activity in terms of antibody-dependent cell-mediated cytotoxicity and fixation of complement.

[0089] Another type of amino acid variant of an antibody alters the original glycosylation pattern (if any) of the antibody molecule. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

[0090] In the context of the present invention in some embodiments the portion of the main chain of the antibody molecule of the invention, which represents the Fc region of an immunoglobulin, is typically inert, or at least essentially of low influence, with regard to binding to Fc receptors. As said, this is achieved by deleting and/or substituting (mutating) at least one of selected amino acid residues in the CFI2 domain that are able to mediate binding to an Fc-receptor. Such molecules are also referred to herein as "Fc-attenuated" antibody molecules or "Fcko" antibody molecules. The portion of an antibody chain according to the invention that can be taken to represent a portion of an Fc fragment, i.e. the CFI2 domain, thus might define a "scaffold" without providing a particular biological function such as an effector function, for example. Flowever, it has been found in the present invention, that this scaffold may provide significant advantages in terms of purification, production efficiency and/or stability of the antibody molecules of the invention compared to known antibody molecules (cf. the Examples).

[0091] In some embodiments the recognition, and accordingly binding, of this Fc-corresponding portion to a given Fc receptor is of about 2-fold, about 5-fold, about 8-fold, about 10-fold, about 12-fold, about 15-fold, about 20-fold or lower than the Fc region of a naturally occurring immunoglobulin. In some embodiments this Fc-corresponding portion is entirely void of its ability of binding to Fc receptors. The binding of an antibody to Fc receptors, including determining a dissociation constant, can easily be determined by the skilled artisan using standard techniques such as surface plasmon resonance, e.g. using a Biacore™ measurement. Any other method of measuring biomolecular binding may likewise be used, which may for instance rely on spectroscopical, photochemical, photometric or radiological means. Examples for the corresponding detection methods are fluorescence correlation spectroscopy, photochemical cross-linking and the use of photoactive or radioactive labels respectively. Some of these methods may include additional separation techniques such as electrophoresis or FIPLC.

[0092] Where required, a substitution or deletion of amino acid residues, as explained above, may be carried out to this effect. Suitable mutations can be taken from Armour et al. (Eur. J. Immunol. [1999] 29, 2613-2624), for example. Further suitable positions for mutations to a sequence of an antibody chain can be taken from the crystal structure data published on the complex between FcyRIII and the human IgG 1 Fc fragment (Sondermann et al., Nature [2000] 406, 267-273). In addition to measuring the binding affinity as described above in order to assess the level of "Fc attenuation" or loss of binding affinity, it is also possible to functionally assess the (lack of the) ability to mediate binding to an Fc-receptor. In the case of antibody molecules which bind CD3 as one target, it is for example possible to assess the binding through the mitogenity of such CD3 binding antibody molecules on cells. The mitogenity is mediated by binding of CD3 antibodies to the Fc-receptors on accessory cells, such as monocytes. If an antibody molecule of the invention that has one binding site for CD3 does not show any mitogenic effect whereas the parent monoclonal anti-CD3 antibody that has a functional Fc part induces strong mitosis in T cells, it is clear that, due to the lack of mitosis, the antibody molecule of the invention lacks the ability for Fc binding and can thus be considered as a "Fc knock-out" molecule. Illustrative examples of a method of assessing anti-CD3 mediated mitogenity have been described by Davis, Vida &amp; Lipsky (J.Immunol (1986) 137, 3758), and by Ceuppens, JL, &amp; van Vaeck, F, (see J.Immunol. (1987) 139, 4067, or Cell. Immunol. (1989) 118, 136). Further illustrative suitable examples of an assay for assessing mitogenity of an antibody have been described by Rosenthal-Allieri et al. (Rosenthal-Allieri MA, Ticcioni M, Deckert M, Breittmeyer JP, Rochet N, Rouleaux M, and Senik A, Bernerd A, Cell Immunol. 1995 163(1):88-95) and Grosse-Hovest et al. (Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee H-G, and Jung G, Eur J Immunol. [2003] May;33(5):1334-1340). In addition, the lack of Fc binding can be assessed by the ability of an antibody molecule of the invention to mediate one or more of the well-known effector functions of the Fc part.

[0093] As noted above, substitutions or deletions of cysteine residues may be carried out in order to introduce or to remove one or more disulphide bonds, including introducing or removing a potential ora previously existing disulphide bond. Thereby linkage between a main chain and a chain of lower weight/shorter length of an antibody molecule according to the invention may be controlled including established, strengthened or abolished. By introducing or removing one or more cysteine residues a disulphide bridge may be introduced or removed. As an illustrative example, a tetrameric antibody molecule according to the disclosure generally has one or more disulphide bonds that link two dimeric antibody molecules. One such disulphide bond is typically defined by a cysteine in the main chain of a first dimeric antibody molecule and a cysteine in the hinge region of a second dimeric antibody molecule. In this regard, in some embodiments an antibody according to the invention may include an amino acid substitution of a native cysteine residue at positions 226 and/or 229, relative to the sequence of a human IgG immunoglobulin according to the Kabat numbering [EU-Index], by another amino acid residue.

[0094] Substitutions or deletions of amino acid residues such as arginine, asparagine, serine, threonine or tyrosine residues may also be carried out to modify the glycosylation pattern of an antibody. As an illustrative example, an IgG molecule has a single N-linked biantennary carbohydrate at Asn297 of the CFI2 domain. For IgG from either serum or produced ex vivo in hybridomas or engineered cells, the IgG are heterogeneous with respect to the Asn297 linked carbohydrate. For human IgG, the core oligosaccharide typically consists of GlcNAc2Man3GlcNAc, with differing numbers of outer residues.

[0095] As indicated, besides binding of antigens/epitopes, an immunoglobulin is known to have further "effector functions", biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an immunoglobulin, and vary with the immunoglobulin isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptors); and B cell activation. Exerting effector functions of an antibody generally involves recruiting effector cells. Several immunoglobulin effector functions are mediated by Fc receptors (FcRs), which bind the Fc region of an antibody. FcRs are defined by their specificity for immunoglobulin isotypes; Fc receptors for IgG antibodies are referred to as FcyR, for IgE as FcsR, for IgA as FcaR and so on. Any of these effector functions (or the loss of such effector functions) such a CDC or ADCC can be used in order to evaluate whether an antibody molecule of the invention lacks the ability of Fc binding.

[0096] In this context, it is noted that the term "Fc receptor" or "FcR" defines a receptor, generally a protein that is capable of binding to the Fc region of an antibody. Fc receptors are found on the surface of certain cells of the immune system of an organism, for example natural killer cells, macrophages, neutrophils, and mast cells. In vivo Fc receptors bind to immunoglobulins that are immobilized on infected cells or present on invading pathogens. Their activity stimulates phagocytic or cytotoxic cells to destroy microbes, or infected cells by antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity. Some viruses such as flaviviruses use Fc receptors to help them infect cells, by a mechanism known as antibody-dependent enhancement of infection. FcRs have been reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-92 (1991); Capel et al., Immunomethods 4: 25-34 (1994); and de Flaas et al., J. Lab. Clin. Med. 126: 330-41 (1995).

[0097] "Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1997) may be performed.

[0098] The term "complement system" is used in the art to refer a number of small proteins - called complement factors -found in blood, generally circulating as inactive precursors (pro-proteins). The term refers to the ability of this inalterable and not adaptable system to "complement" the capability of antibodies and phagocytic cells to clear pathogens such as bacteria, as well as antigen-antibody complexes, from an organism. An example of complement factors is the complex C1, which includes C1q and two serine protases, C1r and C1s. The complex C1 is a component of the CDC pathway. C1 q is a hexavalent molecule with a molecular weight of approximately 460,000 and a structure likened to a bouquet of tulips in which six collagenous "stalks" are connected to six globular head regions. To activate the complement cascade, C1 q has to bind to at least two molecules of lgG1, lgG2 or lgG3.

[0099] "Antibody-dependent cell-mediated cytotoxicity" or ADCC refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells - such as natural killer (NK) cells, neutrophils and macrophages - enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are required for killing of the target cell by this mechanism. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express FcyRI, FcyRII and FcyRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as described in US Patent Nos. 5,500,362 or 5,821,337 may be carried out. Useful effector cells for such assays include, but are not limited to, peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. In some embodiments ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as disclosed in Clynes et al., PNAS USA 95: 652-656 (1998).

[0100] Several antibody effector functions are mediated by Fc receptors (FcRs), which bind the Fc region of an antibody. FcRs are defined by their specificity for immunoglobulin isotypes; Fc receptors for IgG antibodies are referred to as FcyR, for IgE as FcsR, for IgA as FcaR and so on. Three subclasses of FcyR have been identified: FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD16).

[0101] Turning now to nucleic acids of the invention, a nucleic acid molecule encoding one or more chains of an antibody according to the invention may be any nucleic acid in any possible configuration, such as single stranded, double stranded or a combination thereof. Nucleic acids include for instance DNA molecules, RNA molecules, analogues of the DNA or RNA generated using nucleotide analogues or using nucleic acid chemistry, locked nucleic acid molecules (LNA), and protein nucleic acids molecules (PNA). DNA or RNA may be of genomic or synthetic origin and may be single or double stranded. Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc. A respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label.

[0102] In some embodiments a nucleic acid sequence encoding a chain, such as a main chain and/or a smaller chain of an antibody according to the invention is included in a vector such as a plasmid. Where a substitution or deletion is to be included in an antibody chain, when compared to a naturally occurring domain or region of an antibody, the coding sequence of the respective native domain/region, e.g. included in the sequence of an immunoglobulin, can be used as a starting point for the mutagenesis. For the mutagenesis of selected amino acid positions, the person skilled in the art has at his disposal the various established standard methods for site-directed mutagenesis. A commonly used technique is the introduction of mutations by means of PCR (polymerase chain reaction) using mixtures of synthetic oligonucleotides, which bear a degenerate base composition at the desired sequence positions. For example, use of the codon NNK or NNS (wherein N = adenine, guanine or cytosine or thymine; K = guanine or thymine; S = adenine or cytosine) allows incorporation of all 20 amino acids plus the amber stop codon during mutagenesis, whereas the codon WS limits the number of possibly incorporated amino acids to 12, since it excludes the amino acids Cys, lie, Leu, Met, Phe, Trp, Tyr, Val from being incorporated into the selected position of the polypeptide sequence; use of the codon NMS (wherein M = adenine or cytosine), for example, restricts the number of possible amino acids to 11 at a selected sequence position since it excludes the amino acids Arg, Cys, Gly, lie, Leu, Met, Phe, Trp, Val from being incorporated at a selected sequence position. In this respect it is noted that codons for other amino acids (than the regular 20 naturally occurring amino acids) such as selenocystein or pyrrolysine can also be incorporated into a nucleic acid of a antibody molecule. It is also possible, as described by Wang, L., et al. (2001) Science 292, 498-500, or Wang, L., and Schultz, P.G. (2002) Chem. Comm. 1, 1-11, to use "artificial" codons such as UAG which are usually recognized as stop codons in order to insert other unusual amino acids, for example o-methyl-L-tyrosine or p-aminophenylalanine.

[0103] The use of nucleotide building blocks with reduced base pair specificity, as for example inosine, 8-oxo-2’de-oxyguanosine or 6(2-deoxy-p-D-ribofuranosyl)-3,4-dihydro-8H-pyrimin-do-1,2-oxazine-7-one (Zaccolo et al. (1996) J. Mol. Biol. 255, 589-603), is another option for the introduction of mutations into a chosen sequence segment. A further possibility is the so-called triplet-mutagenesis. This method uses mixtures of different nucleotide triplets, each of which codes for one amino acid, for incorporation into the coding sequence (Virnekas B, et al., 1994 Nucleic Acids Res 22, 5600-5607).

[0104] A nucleic acid molecule encoding a chain, such as a main chain and/or a smaller chain of an antibody according to the invention can be expressed using any suitable expression system, for example in a suitable host cell or in a cell-free system. The obtained antibody molecule is enriched by means of selection and/ or isolation.

[0105] As explained above, an antibody molecule according to the invention may be directed against any desired target epitopes/antigens. Depending on the selected epitopes/antigens the antibody may be suitable in the treatment or prevention of disease. Accordingly, in some embodiments an antibody according to the invention may be used in a method of treating and/or preventing a medical condition such as a disorder or disease. In embodiments where one of the antibodies incorporated in a bispecific molecule is capable of activating immune cells in an FcR-dependent manner it may be particularly useful to select an antibody molecule that has an Fc-corresponding portion that shows reduced binding to Fc-receptors. By this means an undesired immune activation mediated by FcR binding is prevented. In some embodiments a disease to be treated or prevented may be a proliferatory disease. Examples of a proliferative disease include, but are not limited to, hemopoetic malignancies, such as acute and chronic myeloic and lymphatic leukemias, as well as lymphomas, or solid tumors. Examples of solid tumors include, but are not limited to, tumors of the gastrointestinal tract, bone, lung, kidney, prostate, breast, brain, ovary, uterus, testis, mesenchymal tumors and skin, such as melanoma.

[0106] The invention also provides a pharmaceutical composition that includes an antibody molecule of the invention and, optionally a pharmaceutically acceptable excipient.

[0107] The antibody molecule according to the invention can be administered via any parenteral or non-parenteral (enteral) route that is therapeutically effective for proteinaceous drugs. Parenteral application methods include, for example, intracutaneous, subcutaneous, intramuscular, intratracheal, intranasal, intravitreal or intravenous injection and infusion techniques, e.g. in the form of injection solutions, infusion solutions or tinctures, as well as aerosol installation and inhalation, e.g. in the form of aerosol mixtures, sprays or powders. An overview about pulmonary drug delivery, i.e. either via inhalation of aerosols (which can also be used in intranasal administration) or intracheal instillation is given by J.S. Patton et al. The lungs as a portal of entry for systemic drug delivery. Proc. Amer. Thoracic Soc. 2004 Vol. 1 pages 338-344, for example). Non-parenteral delivery modes are, for instance, orally, e.g. in the form of pills, tablets, capsules, solutions or suspensions, or rectally, e.g. in the form of suppositories. Antibody molecules of the invention can be administered systemically or topically in formulations containing conventional non-toxic pharmaceutically acceptable excipients or carriers, additives and vehicles as desired.

[0108] In one embodiment of the present invention the pharmaceutical is administered parenterally to a mammal, and in particularto humans. Corresponding administration methods include, but are not limited to, for example, intracutaneous, subcutaneous, intramuscular, intratracheal or intravenous injection and infusion techniques, e.g. in the form of injection solutions, infusion solutions or tinctures as well as aerosol installation and inhalation, e.g. in the form of aerosol mixtures, sprays or powders. A combination of intravenous and subcutaneous infusion and /or injection might be most convenient in case of compounds with a relatively short serum half life. The pharmaceutical composition may be an aqueous solution, an oil-in water emulsion or a water-in-oil emulsion.

[0109] In this regard it is noted that transdermal delivery technologies, e.g. iontophoresis, sonophoresis or microneedle-enhanced delivery, as described in Meidan VM and Michniak BB 2004 Am. J. Ther. 11 (4): 312-316, can also be used for transdermal delivery of an antibody molecule described herein. Non-parenteral delivery modes are, for instance, oral, e.g. in the form of pills, tablets, capsules, solutions or suspensions, or rectal administration, e.g. in the form of suppositories. The antibody molecules of the invention can be administered systemically or topically in formulations containing a variety of conventional non-toxic pharmaceutically acceptable excipients or carriers, additives, and vehicles.

[0110] The dosage of the antibody molecule applied may vary within wide limits to achieve the desired preventive effect or therapeutic response. It will, for instance, depend on the affinity of the antibody molecule for a chosen target as well as on the half-life of the complex between the antibody molecule and the ligand in vivo. Further, the optimal dosage will depend on the biodistribution of the antibody molecule or a conjugate thereof, the mode of administration, the severity of the disease/disorder being treated as well as the medical condition of the patient. For example, when used in an ointment for topical applications, a high concentration of the antibody molecule can be used. However, if wanted, the antibody molecule may also be given in a sustained release formulation, for example liposomal dispersions or hydrogel-based polymer microspheres, like PolyActiveTM or OctoDEXTM (cf. Bos et al., Business Briefing: Phar-matech 2003: 1-6). Other sustained release formulations available are for example PLGA based polymers (PR pharmaceuticals), PLA-PEG based hydrogels (Medincell) and PEA based polymers (Medivas).

[0111] Accordingly, the antibody molecules of the present invention can be formulated into compositions using pharmaceutically acceptable ingredients as well as established methods of preparation (Gennaro, A.L. and Gennaro, A.R. (2000) Remington: The Science and Practice of Pharmacy, 20th Ed., Lippincott Williams &amp; Wilkins, Philadelphia, PA). To prepare the pharmaceutical compositions, pharmaceutically inert inorganic or organic excipients can be used. To prepare e.g. pills, powders, gelatine capsules or suppositories, for example, lactose, talc, stearic acid and its salts, fats, waxes, solid or liquid polyols, natural and hardened oils can be used. Suitable excipients for the production of solutions, suspensions, emulsions, aerosol mixtures or powders for reconstitution into solutions or aerosol mixtures prior to use include water, alcohols, glycerol, polyols, and suitable mixtures thereof as well as vegetable oils.

[0112] The pharmaceutical composition may also contain additives, such as, for example, fillers, binders, wetting agents, glidants, stabilizers, preservatives, emulsifiers, and furthermore solvents or solubilizers or agents for achieving a depot effect. The latter is that fusion proteins may be incorporated into slow or sustained release or targeted delivery systems, such as liposomes and microcapsules.

[0113] The formulations can be sterilized by numerous means, including filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile medium just prior to use.

[0114] Numerous possible applications for the inventive antibody molecule exist in medicine. In addition to their use in in vitro diagnostics or drug delivery, an antibody molecule of the invention, which binds, for example, tissue-or tumor-specific cellular surface molecules can be generated.

[0115] The invention is further illustrated by the following non-limiting Examples.

EXAMPLE I

[0116] A bispecific Fc-attenuated bivalent molecule, also designated to be of the bsFcko-1/2-format, with tumour X CD3 specificity, as schematically depicted in Fig. 1E, was generated. Modifications of amino acids of the hinge region and of the CH2 domain were introduced as shown in Fig. 10. Bispecific Fc-attenuated tetravalent molecules, also designated to be of the bsFcko-1-format, with tumour X CD3 specificity, as schematically depicted in Fig. 1G, were generated. Modifications of amino acids of the hinge region and of the CH2 domain were introduced as shown in Fig. 1P.

[0117] Cloning and amplification of plasmids was carried out using Escherichia coli DH5a (Invitrogen, Karlsruhe, Germany). The build-up of the respective vectors is depicted in Fig. 2.

[0118] Cotransfection of expression vectors encoding main and smaller chains, which can also be referred to as heavy and light chains, of indicated specificities was done in Sp2/0 plasmocytoma cells, obtained from the American Type Culture Collection (ATCC, Manassas, VA). For the build-up of the respective vectors reference is made to Fig. 2 (see also Example II below). Cells were cultured in IMDM media, supplemented with 10% fetal calf serum (PAN-Biotech, Aidenbach, Germany), 1 % penicillin and streptomycin (Lonza, Basel, Switzerland). Stable transfectants were selected by adding 1 mg/ml G418 (Invitrogen, Karlsruhe, Germany).

[0119] Bispecific antibodies were purified from supernatants of cultures of stably transfected cells via affinity chromatography using protein A for the Fcko-1 format and KappaSelect for the bsFcko-1/2 format (both chromatography media were obtained from GE Healthcare, Munich, Germany).

EXAMPLE II

[0120] Immunoglobulin V regions were combined with the desired constant C regions in an expression vector. The cloning procedure indicated here allows the introduction of complete Ig V regions and their expression in lymphoid cells without any alterations of their amino acid sequence. To this end, the nucleotide sequence of a VDJ and VJ fragment of a monospecific antibody was used to design primer pairs (C C’; D D’; Table 1). The reamplified DNA fragments of the V segments were digested (VJ directly and VDJ after reamplification with primer pair E E’ Table 1) with appropriate restriction nucleases (summarized in Table 1) and then ligated into the expression vectors. Alternatively, the V domains were synthezised as DNA fragments at GeneArt, Regensburg, Germany. This method was used for genes coding for the V regions of the antibody directed to EGFR (clone C225). The vectors (Figure 2) contain human heavy and human light constant region genes. Thus, insertion of the amplified and digested V segments reconstitutes the original genomic organisation of the Ig genes in the vectors without altering any amino acid of the V regions.

[0121] The original vector for the heavy chain contains the human γ1 isotype Ig heavy chain (Fig. 2A). Restriction sites were introduced at the required positions in introns in order to exchange the Aatll-Clal fragment with the VDJ fragment of the heavy chain of monoclonal antibodies 4G8 (anti-Flt3), BV10 (anti-FLT3), 4G7 (anti-CD19), C225 (anti-EGFR) and 9.2.27 (anti-CSPG4) or any other monoclonal antibody. The region relevant for cloning the VDJ fragment is shown enlarged in Figure 2B. The fragment to be exchanged contains parts of the first intron with an Aatll restriction site, the second exon of the leader sequence, the VDJ region and part of the heavy chain intron with the restriction site Clal. For the substitution of all exons of the constant region of the human γ1 heavy chain restriction sites were introduced at the required position in the heavy chain intron (Mlul) and in the 5’-UTR heavy chain polyA-region (pA-region; Spel), as shown in Figure 2A and 2C.

[0122] Furthermore, with the expression vectors constructed, it is possible to exchange the entire constant region of the human Igy1 isotype (Mlul-Spel fragment; see Figure 2A) either against constant regions of all other antibody isotypes or against Fc parts with optimized or reduced effector function. In the case of antibodies optimized for triggering ADCC amino acid substitutions were introduced in the CH2 domain of human γ1 constant region as shown in International patent applications WO2011/076922 and WO2011/089211. In order to generate bispecific antibodies as depicted in Figs. 1A-N Mlul and Spel flanked DNA fragments containing either exons coding for wildtype or modified constant domains of the Ig heavy chain can be inserted. The Mlul-Spel fragment to be exchanged is shown enlarged in Figure 2C. Adding the second antigen specificity of a bispecific antibody, scFv-fragments either in VFI-VL or VL-VH orientation can be included via the restriction enzyme sites BspEI and Spel, as also shown in Figure 2A. The region relevant for cloning of a scFv fragment in VL-VH orientation is shown enlarged in Figure 2C. ScFv fragments with the specifity for CD3 (clone humanized UCHT1; VL-VH orientation), CD28 (clone 9.3; VL-VH orientation), TCRa/β (clone BMA031; VH-VL orientation) were generated by PCR with oligonucleotides F and F’ listed in Table 2. Alternatively, they were synthesized as DNA-fragments at GeneArt, Regensburg, Germany. This method was used for genes coding for the antibodies directed to CD16 (clone 3G8; VL-VH orientation). The DNA fragment of the scFv segments in VH-VL and VL-VH orientation, respectively, was digested with the appropriate restriction nucleases (summerized in Table 2) and was then ligated into the expression vector.

[0123] The original vector for the light chain contains the VJ region of the light chain and the C region of human κ gene (Figure 2D). Restriction sites were introduced at the required locations (Xhol and Spel) in order to substitute the light chain Xhol-Spel fragment with the appropriate VJ fragment of the light chain of monoclonal antibodies 4G8 (anti-FLT3), BV10 (anti-FLT3), 4G7 (anti-CD19), C225 (anti-EGFR) or 9.2.27 (anti-CSPG4) or any other monoclonal antibody. The region adjacent to the fragment to be exchanged is shown in Figure 2E. This region contains parts of the second exon of the leader sequence, a suitable restriction site (Xhol) for in frame fusion, the VJ region and parts of the kappa chain intron with restriction site Spel. In order to replace the constant domain of the light chain (CL) restriction sites were introduced at the required locations (Pmll and BsmBI). The region adjacent to the fragment to be exchanged is shown enlarged in Figure 2F. This region contains parts of the kappa chain intron, a suitable restriction site (Pmll), the CL region and parts of the 3’-UTR region kappa chain polyA-region (pA-region) with restriction site (BsmBI).

Table 1: Oligonucleotides used for amplification of VDJ and VJ segments for the insertion into expression vectors

(continued)

Restriction sites are shown in bold and indicated by letters in parentheses.

Table 2: Oligonucleotides used for amplification of scFv segments for the insertion into expression vectors

Restriction sites are shown in bold and indicated by letters in parentheses.

[0124] Thus, bispecific antibody molecules with FLT3xCD3 (4G8xUCHT1, BV10xllCHT1), FLT3xTCRa/p (4G8xBMA031, BV10xBMA031), FLT3xCD28 (4G8x9.3, BV10x9.3), FLT3xCD16 (4G8x3G8, BV10x3G8), CD19xCD3 (4G7xUCHT1), CD19xTCRa/p (4G7xBMA031), CD19xCD28 (4G7x9.3), CD19xCD16 (4G7x3G8), CSPG4xCD3 (9.2.27xUCHT1), CSPG4xTCRa/p (9.2.27xBMA031), CSPG4xCD28 (9.2.27x9.3), CSPG4xCD16 (9.2.27x3G8), EGFRxCD3 (C225xUCHT1), EGFRxTCRa/β (C225xBMA031), EGFRxCD28 (C225x9.3), EGFRxCD16 (C225x3G8) as tetravalent bsFc"K0-1 and bivalent bsFc_KO-1/2 were obtained. Sequences of the corresponding chains are depicted as SEQ ID NO: 1 to SEQ ID NO: 26 and in Fig. 6.

[0125] Cotransfection of the expression vectors encoding the chimeric heavy and light chain (lgGI/κ) or modified heavy chains into the non-lg-producing myeloma cell line Sp2/0 yielded stable transfectomas secreting bispecific monoclonal antibodies which are able to bind specifically to the desired antigen. The functional characterisation of these antibody molecules is illustrated in the following experiments using FLT3xCD3, CD19xTCRa/p and CSPGxCD3 bispecific antibody molecules.

EXAMPLE III

[0126] T cell activation by the two antibody formats of Example I, the bsFcko-1/2-format and the bsFcko-1-format, with and without FLT3/CD19 positive REH cells was determined. Data are shown in Fig. 3. The bispecific antibody molecules used had the FLT3 binding site (first binding site) of clone 4G8 and a CD3 binding site (second binding site) of clone UCHT1. The "bsFcko-1/2-format" molecule was comprised of the chains of SEQ ID NO: 1 and SEQ ID NO: 6) and the "bsFcko-1-format" molecule was comprised of the chains of SEQ ID NO: 1 and SEQ ID NO: 26. The bispecific antibody molecule that binds CSPG4 and CD3 was in the "bsFcko-1/2 format" and was comprised of the chains of SEQ ID NO: 3 and SEQ ID NO: 18. In addition a bispecific antibody molecule in the "bsFck0-1/2 format" binding CD19 and TCRa/β comprised of the chains of SEQ ID NO: 4 and SEQ ID NO: 15 was used. A) Human mononuclear cells (PBMCs) were obtained from peripheral blood of healthy donors and isolated using density gradient centrifugation. PBMCs were transferred to 96 well plates (100,000/well). Subsequently, either irradiated FLT3/CD19 positive REH cells (50,000/well) or medium were added, and finally antibodies were added at concentrations as indicated (Fig. 3A). After 24 hours cells were incubated with 3H tymidine (0.5 μΟίΛ/νβΙΙ). After a further 24 hours cells were applied onto glass fiber filters using a cell harvester. Radioactivity was subsequently detected by means of a scintillation counter. B) Heparinized whole blood (50 μΙ/well) was incubated in 96 well plates with and without FLT3/CD19 positive REH cells (50,000/well) and with antibodies at the concentrations indicated in Fig. 3B. After 24 hours the concentration of TNF in the supernatant was determined by ELISA.

[0127] REH cells (Deutsche Sammlung fur Mikroorganismen und Zellkulturen, DSMZ, Braunschweig, Germany) and PBMCs were cultured in RPMI 1640 medium, supplemented with 10% fetal calf serum (PAN-Biotech, Aidenbach, Germany), 1% penicillin and streptomycin (Lonza, Basel, Switzerland).

EXAMPLE IV

[0128] The lysis of FLT3/CD19 expressing REH cells (Fig. 4A) and CSPG expressing SKMel63 cells (Fig. 4B) by bispecific antibodies and activated CD8+T killer cells was determined.

[0129] Human mononuclear cells (PBMCs) were stimulated using the monospecific CD3 antibody UCHT1 (10ng/ml) for three days. Subsequently activated CD8+T cells were isolated by positive selection using magnetic cell sorting. The cells were added to 51Cr labelled FLT3/CD19 positive REH cells (Fig. 4A) or CSPG4-positive SKMel63 cells (Fig. 4B), and incubated with antibodies at the concentrations as indicated. After 4 hours cell supernatants were harvested onto scintillation plates and radioactivity was determined in a scintillation counter.

[0130] Specific lysis in percent was analysed under defined experimental conditions as follows: cpm(exp)-cpm(bg) / cpm(100)-cpm(bg), wherein cpm(bg) corresponds to the chromium release without antibody and effector cells, and cpm(100) corresponds to the chromium release after incubation of target cells with a detergent.

[0131] SKMel63 cells were obtained from Dr. B. Giickel, Klinik fur Gynakologie, University of Tiibingen, Germany.

EXAMPLE V

[0132] Aggregation and production rate of FLT3 X CD3 antibodies (FLT binding site: clone 4G8, CD3 binding site: clone UCHT1) having identical specificity was compared between three different formats: bispecific single-chain format (bs-scFv), bsFcko-1/2-Format, bsFcko-1-Format. The antibody molecule of the "bsFcko-1/2-format" was comprised of the chains of SEQ ID NO: 1 and SEQ ID NO: 6 and the antibody molecule of the "bsFcko-1-format" was comprised of the chains of SEQ ID NO: 1 and SEQ ID NO: 26.

[0133] Bispecific single chain molecules were purified by affinity chromatography using protein L.

[0134] Gelfiltration was performed using a superdex 200 PC3.2/30 column and a SMARTSystem (GE-Healthcare, Munich, Germany). Standard proteins used were katalase (232 kDa, from bovine liver), aldolase (158 kDa; from rabbit muscle), albumin (67 kDa; from bovine serum) and ribonuclease A (13.7 kDa; from bovine pancreas). Results are shown in Fig. 5A. It is evident from Fig. 5A that formation of aggregates is considerably more pronounced if the antibody is expressed as bs-scFv (43 % aggregation rate) rather than bsFcko-1/2 (no aggregation detected) or bsFcko-1 (2 % aggregration rate), i.e. the bispecific antibody molecules of the present invention remain monomeric molecules with essentially no aggregation tendency.

[0135] For comparison of production rates the genes encoding for bispecific molecules containing the 4G8 (anti-FLT3) and the UCHT1 (anti-CD3) -specificity in the depicted formats were introduced into Sp2/0 cells and antibodies were purified using affinity chromatography. The amount of antibody purified from the supernatants of clones selected for maximal production is depicted in Fig. 5B. Antibody concentrations were determined by optical spectroscopy assuming an optical density at 280nm of 1.4 for an antibody concentration of 1 mg/ml. The production rates for the bsFcko-1/2 and bsFcko-1 antibody molecules were significantly higher than those for the respective bs-scFv molecule.

[0136] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The compositions, methods, procedures, treatments, molecules and specific compounds described herein are presently representative of certain embodiments are exemplary and are not intended as limitations on the scope of the invention. The listing or discussion of a previously published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[0137] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including," containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

[0138] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[0139] Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

Reference List [0140] 1 Davis, L., Vida, R. and Lipsky.P.E. Regulation of human T lymphocyte mitogenesis by antibodies to CD3, J. Immunol., 137: 3758-3767, 1986. 2 Jung,G., Ledbetter, J .A. and Muller-Eberhard,H.J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates, Proc.Natl.Acad.Sci.U.S.A, 84: 4611-4615, 1987. 3 Jung,G. and Eberhard.H.J. An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immu-nol.Today, 9: 257-260, 1988. 4 Staerz.U.D., Kanagawa.O. and Bevan.M.J. Hybrid antibodies can target sites for attack by T cells, Nature, 314: 628-631, 1985. 5 Perez,P., Hoffman,R.W., Shaw.S., Bluestone.J.A. and Segal,D.M. Specific targeting of cytotoxic T cells by anti-13 linked to anti-target cell antibody, Nature, 316: 354-356, 1985. 6 Jung,G., Honsik.C.J., Reisfeld.R.A. and Muller-Eberhard,H.J. Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates, Proc.Natl.Acad.Sci.U.S.A, 83: 4479-4483, 1986. 7 Jung,G. and Eberhard.H.J. An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immu-nol.Today, 9: 257-260, 1988. 8 Jung.G., Freimann.U., Von.M.Z., Reisfeld.R.A. and Wilmanns.W. Target cell-induced T cell activation with bi- and trispecific antibody fragments, Eur.J.Immunol., 21: 2431-2435, 1991. 9 Rosenberg,S.A., Lotze.M.T., Yang.J.C., Aebersold.P.M., Linehan.W.M., Seipp.C.A. and White,D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann.Surg., 210: 474-484, 1989. 10 Tibben.J.G., Boerman.O.C., Massuger.L.F., Schijf.C.P., Claessens.R.A. and Corstens.F.H. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab’)2 in ovarian carcinoma patients, Int.J.Cancer, 66: 477-483, 1996. 11 Kroesen.B.J., Buter.J., Sleijfer.D.T., Janssen,R.A., van derGraaf.W.T., The.T.H., de.L.L. and Mulder,N.H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2, Br.J.Cancer, 70: 652-661, 1994. 12 Jung.G. and Eberhard.H.J. An in-vitro model for tumor immunotherapy with antibody heteroconjugates, Immu-nol.Today, 9: 257-260, 1988. 13 Jung.G., Freimann.U., Von.M.Z., Reisfeld.R.A. and Wilmanns.W. Target cell-induced T cell activation with bland trispecific antibody fragments, Eur.J.Immunol., 21: 2431-2435, 1991. 14 Bargou.R., Leo,E., Zugmaier.G., Klinger,M., Goebeler.M., Knop.S., Noppeney.R., Viardot.A., Hess.G., Schuler,M., Einsele.H., Brandi,C., Wolf,A., Kirchinger.P., Klappers.P., Schmidt,M., Riethmuller.G., Reinhardt,C., Baeuer-le.P.A. and Kufer.P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, 321: 974-977,2008. 15 Topp.M.S., Kufer.P., Gokbuget.N., Goebeler.M., Klinger,M., Neumann,S., Horst,H.A., Raff.T., Viardot.A., Schmid,M., Stelljes.M., Schaich.M., Degenhard.E., Kohne-Volland,R., Bruggemann.M., Ottmann.O., Pfeifer,H., Bur-meister.T., Nagorsen.D., Schmidt,M., Lutterbuese.R., Reinhardt,C., Baeuerle.P.A., Kneba.M., Einsele.H., Riethmuller.G., Hoelzer.D., Zugmaier.G. and Bargou.R.C. Targeted therapy with the T-cell-engaging antibody blinatu-momab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J.Clin.Oncol., 29: 2493-2498, 2011. 16 Brischwein.K., Parr,L., Pflanz.S., Volkland.J., Lumsden.J., Klinger,M., Locher.M., Hammond,S.A., Kiener.P., Kufer.P., Schlereth.B. and Baeuerle.P.A. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class, J.lmmunother., 30: 798-807, 2007. 17 Bargou.R., Leo,E., Zugmaier.G., Klinger,M., Goebeler.M., Knop,S., Noppeney.R., Viardot.A., Hess,G., Schuler,M., Einsele.H., Brandi,C., Wolf,A., Kirchinger.P., Klappers.P., Schmidt,M., Riethmuller.G., Reinhardt,C., Baeuer-le,P.A. and Kufer.P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, 321: 974-977, 2008. 18 Topp.M.S., Kufer.P., Gokbuget.N., Goebeler.M., Klinger,M., Neumann,S., Horst,H.A., Raff.T., Viardot.A., Schmid,M., Stelljes.M., Schaich.M., Degenhard.E., Kohne-Volland,R., Bruggemann.M., Ottmann.O., Pfeifer,H., Bur-meister.T., Nagorsen.D., Schmidt,M., Lutterbuese.R., Reinhardt,C., Baeuerle.P.A., Kneba.M., Einsele.H., Rieth-muller.G., Hoelzer.D., Zugmaier.G. and Bargou.R.C. Targeted therapy with the T-cell-engaging antibody blinatu-momab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J.Clin.Oncol., 29: 2493-2498, 2011. 19 Grosse-Hovest.L., Hartlapp,!., Marwan.W., Brem.G., Rammensee.H.G. and Jung.G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing, Eur.J.Immunol., 33: 1334-1340, 2003. 20 Grosse-Hovest.L., Muller,S., Minoia.R., Wolf.E., Zakhartchenko.V., Wenigerkind.H., Lassnig.C., Besenfelder.U., Muller,M., Lytton.S.D., Jung.G. and Brem.G. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing, Proc.Natl.Acad.Sci.U.S.A, 101: 6858-6863,2004. 21 Marvin,J.S. and Zhu,Z. Recombinant approaches to IgG-like bispecific antibodies, Acta Pharmacol.Sin., 26: 649-658, 2005. 22 Mabry,R., Lewis,K.E., Moore,M., McKernan.P.A., Bukowski.T.R., Bontadelli.K., Brender.T., Okada.S., Lum,K., West.J., Kuijper.J.L., Ardourel.D., Franke.S., Lockwood,L., Vu,T., Frank,A., Appleby,M.W., Wolf,A., Reardon,B., Hamacher.N.B., Stevens,B., Lewis,P., Lewis,K.B., Gilbertson,D.G., Lantry.M., Julien.S.H., Ostrander,C., Chan.C., Byrnes-Blake.K., Brody,J., Presnell.S., Meengs.B., Levin,S.D. and Snavely.M. Engineering of stable bispecific antibodies targeting IL-17A and IL-23, Protein Eng Des Sel, 23: 115-127, 2010. 23 Marvin,J.S. and Zhu,Z. Recombinant approaches to IgG-like bispecific antibodies, Acta Pharmacol.Sin., 26: 649-658, 2005. 24 Mabry,R., Lewis,K.E., Moore,M., McKernan.P.A., Bukowski.T.R., Bontadelli.K., Brender.T., Okada.S., Lum.K., West.J., Kuijper.J.L., Ardourel.D., Franke.S., Lockwood,L., Vu,T., Frank,A., Appleby,M.W., Wolf,A., Reardon,B., Hamacher.N.B., Stevens,B., Lewis,P., Lewis,K.B., Gilbertson,D.G., Lantry.M., Julien.S.H., Ostrander,C., Chan.C., Byrnes-Blake.K., Brody,J., Presnell.S., Meengs.B., Levin,S.D. and Snavely.M. Engineering of stable bispecific antibodies targeting IL-17A and IL-23, Protein Eng Des Sel, 23: 115-127, 2010. 25 Dall’Aqua et al. "Contribution of domain interface residues to the stability of antibody CH3 domain homodimers" Biochemistry (1998) Volume: 37, Issue: 26, Pages: 9266-9273. 26 S.Miller Protein-Protein Recognition and the Association of Immunoglobulin Constant Domains. J .Mol.Biol. (1990) Volume 216 pp 965-973 27 J. Deisenhofer, Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry (1981) Volume 20 pp 2361-2370 28 Roopenian &amp; Akilesh; FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology (2007) Volume 7 pp:715-725. 29 Reiter Y., Brinkmann U., Kreitman R.J., Jung S-H., Lee B and Pastan I., Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions, Biochemistry 1994, 33, 6551-5459. 30 International Patent Application WO2011/076922

31 International Patent Application WO2011/089211 SEQUENCE LISTING

[0141]

<110> Synimmune GbmH <120> Bispecific Antibody Molecule

<130> SYN14309PCT <150> US 61/577,327 <151 > 2011-12-19 <160> 50 <170> Patentln version 3.5

<210> 1 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> light chain sequence, anti-FLT3 chimeric light chain (clone 4G8) <400> 1

Asp lie Val Leu Thr Gin Ser Pro Ala Thr Leu Ser Val Thr Pro 15 10 15

Gly Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gin Ser lie Ser 20 25 30

Asn Asn Leu His Trp Tyr Gin Gin Lys Ser His Glu Ser Pro Arg 35 40 45

Leu Leu lie Lys Tyr Ala Ser Gin Ser lie Ser Gly lie Pro Ser 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser lie 65 70 75

Asn Ser Val Glu Thr Glu Asp Phe Gly Val Tyr Phe Cys Gin Gin 80 85 90

Ser Asn Thr Trp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu 95 100 105 lie Lys Arg Thr Val Ala Ala Pro Ser Val Phe lie Phe Pro Pro 110 115 120

Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val 140 145 150

Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu Ser Val Thr Glu 155 160 165

Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180

Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 185 190 195

Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210

Arg Gly Glu Cys

<210>2 <211> 220 <212> PRT <213> Artificial Sequence <220> <223> light chain sequence, anti- FLT3 chimeric light chain (clone BV10) <400> 2

Asp lie Val Met Thr Gin Ser Pro Ser Ser Leu Ser Val Ser Ala 15 10 15

Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gin Ser Leu Leu 20 25 30

Asn Ser Gly Asn Gin Lys Asn Tyr Met Ala Trp Tyr Gin Gin Lys 35 40 45

Pro Gly Gin Pro Pro Lys Leu Leu lie Tyr Gly Ala Ser Thr Arg 50 55 60

Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr 65 70 75

Asp Phe Thr Leu Thr lie Ser Ser Val Gin Ala Glu Asp Leu Ala 80 85 90

Val Tyr Tyr Cys Gin Asn Asp His Ser Tyr Pro Leu Thr Phe Gly 95 100 105

Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala Pro Ser 110 115 120

Val Phe lie Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 125 130 135

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 140 145 150

Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 155 160 165

Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser 170 175 180

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 185 190 195

Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro 200 205 210

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 215 220

<210> 3 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> light chain sequence, anti-CSPG4 chimeric light chain (clone 9.2.27) <400> 3

Asp lie Glu Leu Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu 15 10 15

Gly Gin Arg Ala Thr lie Ser Cys Arg Ala Ser Glu Ser Val Asp 20 25 30

Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gin Gin Lys Pro Gly 35 40 45

Gin Pro Pro Lys Leu Leu lie Tyr Leu Ala Ser Asn Leu Glu Ser 50 55 60

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe 65 70 75

Thr Leu Thr lie Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr 80 85 90

Tyr Cys Gin Gin Asn Asn Glu Asp Pro Leu Thr Phe Gly Gly Gly 95 100 105

Thr Lys Leu Glu lie Lys Arg Thr Val Ala Ala Pro Ser Val Phe 110 115 120 lie Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser 125 130 135

Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val 140 145 150

Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu 155 160 165

Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 170 175 180

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 185 190 195

Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr 200 205 210

Lys Ser Phe Asn Arg Gly Glu Cys 215

<210>4 <211 > 219 <212> PRT <213> Artificial Sequence <220> <223> light chain sequence, anti-CD19 chimeric light chain (clone 4G7) <400>4

Asp lie Val Met Thr Gin Ala Ala Pro Ser lie Pro Val Thr Pro Gly 15 10 15

Glu Ser Val Ser lie Ser Cys Arg Ser Ser Lys Ser Leu Leu Asn Ser 20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gin Arg Pro Gly Gin Ser 35 40 45

Pro Gin Leu Leu lie Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg lie 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gin His 85 90 95

Leu Glu Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe lie Phe Pro Pro Ser Asp Glu 115 120 125

Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin 145 150 155 160

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215

<210>5 <211 > 214 <212> PRT <213> Artificial Sequence <220> <223> light chain sequence, anti- EGFR chimeric light chain (clone C225) <400>5

Asp lie Leu Leu Thr Gin Ser Pro Val lie Leu Ser Val Ser Pro 15 10 15

Gly Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gin Ser lie Gly 20 25 30

Thr Asn lie His Trp Tyr Gin Gin Arg Thr Asn Gly Ser Pro Arg 35 40 45

Leu Leu lie Lys Tyr Ala Ser Glu Ser lie Ser Gly lie Pro Ser 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser lie 65 70 75

Asn Ser Val Glu Ser Glu Asp lie Ala Asp Tyr Tyr Cys Gin Gin 80 85 90

Asn Asn Asn Trp Pro Thr Thr Phe Gly Ala Gly Thr Lys Leu Glu 95 100 105

Leu Lys Arg Thr Val Ala Ala Pro Ser Val Phe lie Phe Pro Pro 110 115 120

Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val 140 145 150

Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu Ser Val Thr Glu 155 160 165

Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180

Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 185 190 195

Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210

Arg Gly Glu Cys

<210>6 <211> 589 <212> PRT <213> Artificial Sequence <220> <223> heavy chain/main chain sequence, FLT3 x CD3; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD3 single-chain (clone UCHT1, VL-VH)] chain of a glycan-ko-variant-halfmolecule <400> 6

Gin Val Gin Leu Gin Gin Pro Gly Ala Glu Leu Val Lys Pro Gly 15 10 15

Ala Ser Leu Lys Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr 20 25 30

Ser Tyr Trp Met His Trp Val Arg Gin Arg Pro Gly His Gly Leu 35 40 45

Glu Trp lie Gly Glu lie Asp Pro Ser Asp Ser Tyr Lys Asp Tyr 50 55 60

Asn Gin Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser 65 70 75

Ser Asn Thr Ala Tyr Met His Leu Ser Ser Leu Thr Ser Asp Asp 80 85 90

Ser Ala Val Tyr Tyr Cys Ala Arg Ala lie Thr Thr Thr Pro Phe 95 100 105

Asp Phe Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser 110 115 120

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser 125 130 135

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 140 145 150

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 155 160 165

Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu 170 175 180

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 185 190 195

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr 200 205 210

Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His 215 220 225

Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser Val 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp 260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser 320 325 330

Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly 335 340 345

Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 350 355 360

Gly Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Asp lie Arg 365 370 375

Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 380 385 390

Leu Leu lie Tyr Tyr Thr Ser Arg Leu Glu Ser Gly Val Pro Ser 395 400 405

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr lie 410 415 420

Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 425 430 435

Gly Asn Thr Leu Pro Trp Thr Phe Gly Gin Gly Thr Lys Val Glu 440 445 450 lie Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 455 460 465

Gly Ser Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin 470 475 480

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser 485 490 495

Phe Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly Lys 500 505 510

Gly Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly Val Ser 515 520 525

Thr Tyr Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val Asp 530 535 540

Lys Ser Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala 545 550 555

Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly 560 565 570

Asp Ser Asp Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val 575 580 585

Thr Val Ser Ser

<210> 7 <211> 594 <212> PRT <213> Artificial Sequence <220> <223> FLT3x CD3; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD3 singlechain (clone UCHT1, VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 7

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Leu His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe lie 50 55 60

Ser Arg Leu Ser lie Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ala Asp Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Lys Gly Gly lie Tyr Tyr Ala Asn His Tyr Tyr Ala Met Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val 225 230 235 240

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro 325 330 335 lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie 340 345 350

Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 355 360 365

Val Thr lie Thr Cys Arg Ala Ser Gin Asp lie Arg Asn Tyr Leu Asn 370 375 380

Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Tyr 385 390 395 400

Thr Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly 405 410 415

Ser Gly Thr Asp Tyr Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp 420 425 430

Phe Ala Thr Tyr Tyr Cys Gin Gin Gly Asn Thr Leu Pro Trp Thr Phe 435 440 445

Gly Gin Gly Thr Lys Val Glu lie Lys Gly Gly Gly Gly Ser Gly Gly 450 455 460

Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gin Leu Val Glu Ser Gly 465 470 475 480

Gly Gly Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala 485 490 495

Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala 500 505 510

Pro Gly Lys Gly Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly 515 520 525

Val Ser Thr Tyr Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val 530 535 540

Asp Lys Ser Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala 545 550 555 560

Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp 565 570 575

Ser Asp Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val 580 585 590

Ser Ser

<210>8 <211> 585 <212> PRT <213> Artificial Sequence <220 <223> FLT3 x TCR alpha/beta; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal TCR alpha/beta single-chain (clone BMA031; VH-VL)], chain of a glycan-ko-variant-halfmolecule <400 8

Gin Val Gin Leu Gin Gin Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Leu Lys Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Trp Met His Trp Val Arg Gin Arg Pro Gly His Gly Leu Glu Trp lie 35 40 45

Gly Glu lie Asp Pro Ser Asp Ser Tyr Lys Asp Tyr Asn Gin Lys Phe 50 55 60

Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Asn Thr Ala Tyr 65 70 75 80

Met His Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Ala lie Thr Thr Thr Pro Phe Asp Phe Trp Gly Gin Gly Thr 100 105 110

Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser Val 225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr 245 250 255

Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu 260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285

Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val Ser 290 295 300

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320

Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr lie 325 330 335

Ser Lys Ala Lys Gly Gin Pro Ser Gly Glu Val Gin Leu Gin Gin Ser 340 345 350

Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys 355 360 365

Ala Ser Gly Tyr Lys Phe Thr Ser Tyr Val Met His Trp Val Lys Gin 370 375 380

Lys Pro Gly Gin Gly Leu Glu Trp lie Gly Tyr lie Asn Pro Tyr Asn 385 390 395 400

Asp Val Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr 405 410 415

Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr 420 425 430

Ser Glu Asp Ser Ala Val His Tyr Cys Ala Arg Gly Ser Tyr Tyr Asp 435 440 445

Tyr Asp Gly Phe Val Tyr Gly Gin Gly Thr Leu Val Thr Val Ser Ser 450 455 460

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin 465 470 475 480 lie Val Leu Thr Gin Ser Pro Ala lie Met Ser Ala Ser Pro Gly Glu 485 490 495

Lys Val Thr Met Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Met His 500 505 510

Trp Tyr Gin Gin Lys Ser Gly Thr Ser Pro Lys Arg Trp lie Tyr Asp 515 520 525

Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly 530 535 540

Ser Gly Thr Ser Tyr Ser Leu Thr lie Ser Ser Met Glu Ala Glu Asp 545 550 555 560

Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser Asn Pro Leu Thr Phe 565 570 575

Gly Ala Gly Thr Lys Leu Glu Leu Lys 580 585

<210> 9 <211> 590 <212> PRT <213> Artificial Sequence <220> <223> FLT3xTCRalpha/beta; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal TCR alpha/beta single-chain (clone BMA031; VH-VL)], chain of a glycan-ko-variant-halfmolecule <400> 9

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Leu His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe lie 50 55 60

Ser Arg Leu Ser lie Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ala Asp Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Lys Gly Gly lie Tyr Tyr Ala Asn His Tyr Tyr Ala Met Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val 225 230 235 240

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro 325 330 335 lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Glu Val 340 345 350

Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val 355 360 365

Lys Met Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr Val Met 370 375 380

His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie Gly Tyr 385 390 395 400 lie Asn Pro Tyr Asn Asp Val Thr Lys Tyr Asn Glu Lys Phe Lys Gly 405 410 415

Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu 420 425 430

Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val His Tyr Cys Ala Arg 435 440 445

Gly Ser Tyr Tyr Asp Tyr Asp Gly Phe Val Tyr Gly Gin Gly Thr Leu 450 455 460

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 465 470 475 480

Gly Gly Gly Ser Gin lie Val Leu Thr Gin Ser Pro Ala lie Met Ser 485 490 495

Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Thr Ser Ser 500 505 510

Val Ser Tyr Met His Trp Tyr Gin Gin Lys Ser Gly Thr Ser Pro Lys 515 520 525

Arg Trp lie Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg 530 535 540

Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr lie Ser Ser 545 550 555 560

Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser 565 570 575

Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 580 585 590

<210> 10 <211> 592 <212> PRT <213> Artificial Sequence <220> <223> FLT3 x CD28; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD28 single-chain (clone 9.3; VL-VFI)], being a chain of a glycan-ko-variant-halfmolecule <400> 10

Gin Val Gin Leu Gin Gin Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Leu Lys Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Trp Met His Trp Val Arg Gin Arg Pro Gly His Gly Leu Glu Trp lie 35 40 45

Gly Glu lie Asp Pro Ser Asp Ser Tyr Lys Asp Tyr Asn Gin Lys Phe 50 55 60

Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Asn Thr Ala Tyr 65 70 75 80

Met His Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Ala lie Thr Thr Thr Pro Phe Asp Phe Trp Gly Gin Gly Thr 100 105 110

Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser Val 225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr 245 250 255

Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu 260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285

Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val Ser 290 295 300

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320

Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr lie 325 330 335

Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Glu Leu Thr Gin Ser 340 345 350

Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr lie Ser Cys 355 360 365

Arg Ala Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gin Trp 370 375 380

Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie Phe Ala Ala 385 390 395 400

Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser 405 410 415

Gly Thr Asn Phe Ser Leu Asn lie His Pro Val Asp Glu Asp Asp Val 420 425 430

Ala Met Tyr Phe Cys Gin Gin Ser Arg Lys Val Pro Tyr Thr Phe Gly 435 440 445

Gly Gly Thr Lys Leu Glu lie Lys Arg Gly Gly Gly Gly Ser Gly Gly 450 455 460

Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Lys Leu Gin Gin Ser Gly 465 470 475 480

Pro Gly Leu Val Thr Pro Ser Gin Ser Leu Ser lie Thr Cys Thr Val 485 490 495

Ser Gly Phe Ser Leu Ser Asp Tyr Gly Val His Trp Val Arg Gin Ser 500 505 510

Pro Gly Gin Gly Leu Glu Trp Leu Gly Val lie Trp Ala Gly Gly Gly 515 520 525

Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Lys Ser lie Ser Lys Asp 530 535 540

Asn Ser Lys Ser Gin Val Phe Leu Lys Met Asn Ser Leu Gin Ala Asp 545 550 555 560

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Gly Tyr Ser Tyr Tyr 565 570 575

Tyr Ser Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 580 585 590

<210> 11 <211> 597 <212> PRT <213> Artificial Sequence <220 <223> FLT3 x CD28; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD28 single-chain (clone 9.3, VL-VFI)], chain of a glycan-ko-variant-halfmolecule <400 11

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Leu His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe lie 50 55 60

Ser Arg Leu Ser lie Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ala Asp Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Lys Gly Gly lie Tyr Tyr Ala Asn His Tyr Tyr Ala Met Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val 225 230 235 240

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro 325 330 335 lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie 340 345 350

Glu Leu Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg 355 360 365

Ala Thr lie Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Val Thr 370 375 380

Ser Leu Met Gin Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu 385 390 395 400

Leu lie Phe Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe 405 410 415

Ser Gly Ser Gly Ser Gly Thr Asn Phe Ser Leu Asn lie His Pro Val 420 425 430

Asp Glu Asp Asp Val Ala Met Tyr Phe Cys Gin Gin Ser Arg Lys Val 435 440 445

Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Arg Gly Gly 450 455 460

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Lys 465 470 475 480

Leu Gin Gin Ser Gly Pro Gly Leu Val Thr Pro Ser Gin Ser Leu Ser 485 490 495 lie Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asp Tyr Gly Val His 500 505 510

Trp Val Arg Gin Ser Pro Gly Gin Gly Leu Glu Trp Leu Gly Val lie 515 520 525

Trp Ala Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Lys 530 535 540

Ser lie Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Leu Lys Met Asn 545 550 555 560

Ser Leu Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys 565 570 575

Gly Tyr Ser Tyr Tyr Tyr Ser Met Asp Tyr Trp Gly Gin Gly Thr Thr 580 585 590

Val Thr Val Ser Ser 595

<210> 12 <211> 589 <212> PRT <213> Artificial Sequence <220 <223> FLT3 x CD16; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD16 single-chain (clone 3G8; VL-VH)], being a chain of a glycan-ko-variant-halfmolecule <400 12

Gin Val Gin Leu Gin Gin Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Leu Lys Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Trp Met His Trp Val Arg Gin Arg Pro Gly His Gly Leu Glu Trp lie 35 40 45

Gly Glu lie Asp Pro Ser Asp Ser Tyr Lys Asp Tyr Asn Gin Lys Phe 50 55 60

Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Asn Thr Ala Tyr 65 70 75 80

Met His Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Ala lie Thr Thr Thr Pro Phe Asp Phe Trp Gly Gin Gly Thr 100 105 110

Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 165 170 175

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190

Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser 195 200 205

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220

His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser Val 225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met He Ser Arg Thr 245 250 255

Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu 260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285

Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val Ser 290 295 300

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320

Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr lie 325 330 335

Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Val Leu Thr Gin Ser 340 345 350

Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr He Ser Cys 355 360 365

Lys Ala Ser Gin Ser Val Asp Phe Asp Gly Asp Ser Phe Met Asn Trp 370 375 380

Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie Tyr Thr Thr 385 390 395 400

Ser Asn Leu Glu Ser Gly He Pro Ala Arg Phe Ser Ala Ser Gly Ser 405 410 415

Gly Thr Asp Phe Thr Leu Asn lie His Pro Val Glu Glu Glu Asp Thr 420 425 430

Ala Thr Tyr Tyr Cys Gin Gin Ser Asn Glu Asp Pro Tyr Thr Phe Gly 435 440 445

Gly Gly Thr Lys Leu Glu He Lys Gly Gly Gly Gly Ser Gly Gly Gly 450 455 460

Gly Ser Gly Gly Gly Gly Ser Gin Val Thr Leu Lys Glu Ser Gly Pro 465 470 475 480

Gly He Leu Gin Pro Ser Gin Thr Leu Ser Leu Thr Cys Ser Phe Ser 485 490 495

Gly Phe Ser Leu Arg Thr Ser Gly Met Gly Val Gly Trp He Arg Gin 500 505 510

Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His He Trp Trp Asp Asp 515 520 525

Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr He Ser Lys 530 535 540

Asp Thr Ser Ser Asn Gin Val Phe Leu Lys He Ala Ser Val Asp Thr 545 550 555 560

Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gin He Asn Pro Ala Trp Phe 565 570 575

Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585

<210> 13 <211> 594 <212> PRT <213> Artificial Sequence <220> <223> FLT3 x CD16; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD16 single-chain (clone 3G8; VL-VH)], being a chain of a glycan-ko-variant-halfmolecule <400> 13

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Leu His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe lie 50 55 60

Ser Arg Leu Ser lie Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ala Asp Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Lys Gly Gly lie Tyr Tyr Ala Asn His Tyr Tyr Ala Met Asp Tyr 100 105 110

Trp Gly Gin Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175

Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val 195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220

Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val 225 230 235 240

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255

Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro 325 330 335 lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie 340 345 350

Val Leu Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg 355 360 365

Ala Thr lie Ser Cys Lys Ala Ser Gin Ser Val Asp Phe Asp Gly Asp 370 375 380

Ser Phe Met Asn Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu 385 390 395 400

Leu lie Tyr Thr Thr Ser Asn Leu Glu Ser Gly lie Pro Ala Arg Phe 405 410 415

Ser Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn lie His Pro Val 420 425 430

Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gin Gin Ser Asn Glu Asp 435 440 445

Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Gly Gly Gly 450 455 460

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Thr Leu 465 470 475 480

Lys Glu Ser Gly Pro Gly He Leu Gin Pro Ser Gin Thr Leu Ser Leu 485 490 495

Thr Cys Ser Phe Ser Gly Phe Ser Leu Arg Thr Ser Gly Met Gly Val 500 505 510

Gly Trp He Arg Gin Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His 515 520 525 lie Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg 530 535 540

Leu Thr He Ser Lys Asp Thr Ser Ser Asn Gin Val Phe Leu Lys He 545 550 555 560

Ala Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gin He 565 570 575

Asn Pro Ala Trp Phe Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val 580 585 590

Ser Ser

<210> 14 <211> 592 <212> PRT <213> Artificial Sequence <220> <223> CD19 x CD3, bsFcko-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal anti-CD3 single-chain (clone UCHT1; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 14

Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu He Lys Pro Gly Ala 15 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp He 35 40 45

Gly Tyr lie Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Arg Val Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Gin Met 340 345 350

Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 355 360 365 lie Thr Cys Arg Ala Ser Gin Asp lie Arg Asn Tyr Leu Asn Trp Tyr 370 375 380

Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Tyr Thr Ser 385 390 395 400

Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 405 410 415

Thr Asp Tyr Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp Phe Ala 420 425 430

Thr Tyr Tyr Cys Gin Gin Gly Asn Thr Leu Pro Trp Thr Phe Gly Gin 435 440 445

Gly Thr Lys Val Glu lie Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 450 455 460

Ser Gly Gly Gly Gly Ser Glu Val Gin Leu Val Glu Ser Gly Gly Gly 465 470 475 480

Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 485 490 495

Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly 500 505 510

Lys Gly Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly Val Ser 515 520 525

Thr Tyr Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val Asp Lys 530 535 540

Ser Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 545 550 555 560

Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp 565 570 575

Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 15 <211> 588 <212> PRT <213> Artificial Sequence <220> <223> CD19 x TCR alpha/beta, bsFcko-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal anti- TCR alpha/beta single-chain (clone BMA031; VH-VL)]: being a chain of a glycan-ko-variant-halfmolecule <400> 15

Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu lie Lys Pro Gly Ala 15 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Tyr lie Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Arg Val Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Glu Val Gin Leu 340 345 350

Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met 355 360 365

Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr Val Met His Trp 370 375 380

Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie Gly Tyr lie Asn 385 390 395 400

Pro Tyr Asn Asp Val Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala 405 410 415

Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser 420 425 430

Ser Leu Thr Ser Glu Asp Ser Ala Val His Tyr Cys Ala Arg Gly Ser 435 440 445

Tyr Tyr Asp Tyr Asp Gly Phe Val Tyr Gly Gin Gly Thr Leu Val Thr 450 455 460

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 465 470 475 480

Gly Ser Gin lie Val Leu Thr Gin Ser Pro Ala lie Met Ser Ala Ser 485 490 495

Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Thr Ser Ser Val Ser 500 505 510

Tyr Met His Trp Tyr Gin Gin Lys Ser Gly Thr Ser Pro Lys Arg Trp 515 520 525 lie Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 530 535 540

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr lie Ser Ser Met Glu 545 550 555 560

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser Asn Pro 565 570 575

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 580 585

<210> 16 <211> 595 <212> PRT <213> Artificial Sequence <220> <223> CD19 x CD28; bsFcko-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal CD28 single-chain (clone 9.3; VL-VH)],chain of a glycan-ko-variant-halfmolecule <400> 16

Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu lie Lys Pro Gly Ala 15 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Tyr lie Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Arg Val Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Glu Leu 340 345 350

Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr 355 360 365 lie Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu 370 375 380

Met Gin Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie 385 390 395 400

Phe Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly 405 410 415

Ser Gly Ser Gly Thr Asn Phe Ser Leu Asn lie His Pro Val Asp Glu 420 425 430

Asp Asp Val Ala Met Tyr Phe Cys Gin Gin Ser Arg Lys Val Pro Tyr 435 440 445

Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Arg Gly Gly Gly Gly 450 455 460

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Lys Leu Gin 465 470 475 480

Gin Ser Gly Pro Gly Leu Val Thr Pro Ser Gin Ser Leu Ser lie Thr 485 490 495

Cys Thr Val Ser Gly Phe Ser Leu Ser Asp Tyr Gly Val His Trp Val 500 505 510

Arg Gin Ser Pro Gly Gin Gly Leu Glu Trp Leu Gly Val lie Trp Ala 515 520 525

Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Lys Ser lie 530 535 540

Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Leu Lys Met Asn Ser Leu 545 550 555 560

Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Gly Tyr 565 570 575

Ser Tyr Tyr Tyr Ser Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr 580 585 590

Val Ser Ser 595

<210> 17 <211> 592 <212> PRT <213> Artificial Sequence <220> <223> CD19 x CD16; bsFcko-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal CD16 single-chain (clone 3G8; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 17

Glu Val Gin Leu Gin Gin Ser Gly Pro Glu Leu lie Lys Pro Gly Ala 15 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30

Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Tyr lie Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Arg Val Phe Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Val Leu 340 345 350

Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr 355 360 365 lie Ser Cys Lys Ala Ser Gin Ser Val Asp Phe Asp Gly Asp Ser Phe 370 375 380

Met Asn Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie 385 390 395 400

Tyr Thr Thr Ser Asn Leu Glu Ser Gly lie Pro Ala Arg Phe Ser Ala 405 410 415

Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn lie His Pro Val Glu Glu 420 425 430

Glu Asp Thr Ala Thr Tyr Tyr Cys Gin Gin Ser Asn Glu Asp Pro Tyr 435 440 445

Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Gly Gly Gly Gly Ser 450 455 460

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Thr Leu Lys Glu 465 470 475 480

Ser Gly Pro Gly lie Leu Gin Pro Ser Gin Thr Leu Ser Leu Thr Cys 485 490 495

Ser Phe Ser Gly Phe Ser Leu Arg Thr Ser Gly Met Gly Val Gly Trp 500 505 510 lie Arg Gin Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His lie Trp 515 520 525

Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr 530 535 540 lie Ser Lys Asp Thr Ser Ser Asn Gin Val Phe Leu Lys lie Ala Ser 545 550 555 560

Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gin lie Asn Pro 565 570 575

Ala Trp Phe Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 18 <211> 592 <212> PRT <213> Artificial Sequence <220> <223> CSPG4 x CD3, bsFcko-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal anti-CD3 single-chain (clone UCHT1; VL-VH)], a chain of a glycan-ko-variant-halfmolecule <400> 18

Gin Val Lys Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Val Lys lie Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser 20 25 30

Trp Met Asn Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Arg lie Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Gin Val Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95

Ala Arg Gly Asn Thr Val Val Val Pro Tyr Thr Met Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Gin Met 340 345 350

Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 355 360 365 lie Thr Cys Arg Ala Ser Gin Asp lie Arg Asn Tyr Leu Asn Trp Tyr 370 375 380

Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Tyr Thr Ser 385 390 395 400

Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly 405 410 415

Thr Asp Tyr Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp Phe Ala 420 425 430

Thr Tyr Tyr Cys Gin Gin Gly Asn Thr Leu Pro Trp Thr Phe Gly Gin 435 440 445

Gly Thr Lys Val Glu lie Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 450 455 460

Ser Gly Gly Gly Gly Ser Glu Val Gin Leu Val Glu Ser Gly Gly Gly 465 470 475 480

Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 485 490 495

Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly 500 505 510

Lys Gly Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly Val Ser 515 520 525

Thr Tyr Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val Asp Lys 530 535 540

Ser Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp 545 550 555 560

Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp 565 570 575

Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 19 <211> 588 <212> PRT <213> Artificial Sequence <220> <223> CSPG4 x TCR alpha/beta, bsFcko-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal anti-TCR alpha/beta single-chain (clone BMA031; VH-VL)], chain of a glycan-ko-variant-halfmolecule <400 19

Gin Val Lys Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Val Lys lie Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser 20 25 30

Trp Met Asn Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp He 35 40 45

Gly Arg lie Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Gin Val Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95

Ala Arg Gly Asn Thr Val Val Val Pro Tyr Thr Met Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Glu Val Gin Leu 340 345 350

Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met 355 360 365

Ser Cys Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr Val Met His Trp 370 375 380

Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp lie Gly Tyr lie Asn 385 390 395 400

Pro Tyr Asn Asp Val Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala 405 410 415

Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser 420 425 430

Ser Leu Thr Ser Glu Asp Ser Ala Val His Tyr Cys Ala Arg Gly Ser 435 440 445

Tyr Tyr Asp Tyr Asp Gly Phe Val Tyr Gly Gin Gly Thr Leu Val Thr 450 455 460

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 465 470 475 480

Gly Ser Gin lie Val Leu Thr Gin Ser Pro Ala lie Met Ser Ala Ser 485 490 495

Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Thr Ser Ser Val Ser 500 505 510

Tyr Met His Trp Tyr Gin Gin Lys Ser Gly Thr Ser Pro Lys Arg Trp 515 520 525 lie Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 530 535 540

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr lie Ser Ser Met Glu 545 550 555 560

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser Asn Pro 565 570 575

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 580 585

<210> 20 <211> 595 <212> PRT <213> Artificial Sequence <220> <223> CSPG4 x CD28; bsFcko-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal CD28 single-chain (clone 9.3; VL-VH)], being a chain of a glycan-ko-variant-halfmolecule <400 20

Gin Val Lys Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Val Lys lie Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser 20 25 30

Trp Met Asn Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Arg lie Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Gin Val Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95

Ala Arg Gly Asn Thr Val Val Val Pro Tyr Thr Met Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Glu Leu 340 345 350

Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr 355 360 365 lie Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu 370 375 380

Met Gin Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie 385 390 395 400

Phe Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly 405 410 415

Ser Gly Ser Gly Thr Asn Phe Ser Leu Asn lie His Pro Val Asp Glu 420 425 430

Asp Asp Val Ala Met Tyr Phe Cys Gin Gin Ser Arg Lys Val Pro Tyr 435 440 445

Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Arg Gly Gly Gly Gly 450 455 460

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Lys Leu Gin 465 470 475 480

Gin Ser Gly Pro Gly Leu Val Thr Pro Ser Gin Ser Leu Ser lie Thr 485 490 495

Cys Thr Val Ser Gly Phe Ser Leu Ser Asp Tyr Gly Val His Trp Val 500 505 510

Arg Gin Ser Pro Gly Gin Gly Leu Glu Trp Leu Gly Val lie Trp Ala 515 520 525

Gly Gly Gly Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Lys Ser lie 530 535 540

Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Leu Lys Met Asn Ser Leu 545 550 555 560

Gin Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Gly Tyr 565 570 575

Ser Tyr Tyr Tyr Ser Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr 580 585 590

Val Ser Ser 595

<210> 21 <211> 592 <212> PRT <213> Artificial Sequence <220> <223> CSPG4 x CD16; bsFcko-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal CD16 single-chain (clone 3G8; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 21

Gin Val Lys Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 15 10 15

Ser Val Lys lie Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser 20 25 30

Trp Met Asn Trp Val Lys Gin Arg Pro Gly Gin Gly Leu Glu Trp lie 35 40 45

Gly Arg lie Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80

Met Gin Val Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95

Ala Arg Gly Asn Thr Val Val Val Pro Tyr Thr Met Asp Tyr Trp Gly 100 105 110

Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175

Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220

Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu 325 330 335

Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Val Leu 340 345 350

Thr Gin Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr 355 360 365 lie Ser Cys Lys Ala Ser Gin Ser Val Asp Phe Asp Gly Asp Ser Phe 370 375 380

Met Asn Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie 385 390 395 400

Tyr Thr Thr Ser Asn Leu Glu Ser Gly lie Pro Ala Arg Phe Ser Ala 405 410 415

Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn lie His Pro Val Glu Glu 420 425 430

Glu Asp Thr Ala Thr Tyr Tyr Cys Gin Gin Ser Asn Glu Asp Pro Tyr 435 440 445

Thr Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Gly Gly Gly Gly Ser 450 455 460

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Thr Leu Lys Glu 465 470 475 480

Ser Gly Pro Gly lie Leu Gin Pro Ser Gin Thr Leu Ser Leu Thr Cys 485 490 495

Ser Phe Ser Gly Phe Ser Leu Arg Thr Ser Gly Met Gly Val Gly Trp 500 505 510 lie Arg Gin Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His lie Trp 515 520 525

Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr 530 535 540 lie Ser Lys Asp Thr Ser Ser Asn Gin Val Phe Leu Lys lie Ala Ser 545 550 555 560

Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gin lie Asn Pro 565 570 575

Ala Trp Phe Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 22 <211> 590 <212> PRT <213> Artificial Sequence <220> <223> EGFR x CD3; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD3 single-chain (clone UCHT1; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 22

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Val His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60

Ser Arg Leu Ser lie Asn Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ser Asn Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gin Gly 100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr 325 330 335 lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Gin Met Thr Gin 340 345 350

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr lie Thr 355 360 365

Cys Arg Ala Ser Gin Asp lie Arg Asn Tyr Leu Asn Trp Tyr Gin Gin 370 375 380

Lys Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Tyr Thr Ser Arg Leu 385 390 395 400

Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 405 410 415

Tyr Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr 420 425 430

Tyr Cys Gin Gin Gly Asn Thr Leu Pro Trp Thr Phe Gly Gin Gly Thr 435 440 445

Lys Val Glu lie Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 450 455 460

Gly Gly Gly Ser Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val 465 470 475 480

Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser 485 490 495

Phe Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly 500 505 510

Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly Val Ser Thr Tyr 515 520 525

Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val Asp Lys Ser Lys 530 535 540

Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 545 550 555 560

Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr 565 570 575

Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 23 <211> 586 <212> PRT <213> Artificial Sequence <220> <223> EGFR x TCR alpha/beta; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal TCR alpha/beta single-chain (clone BMA031; VH-VL)], chain of a glycan-ko-variant-halfmolecule <400> 23

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Val His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60

Ser Arg Leu Ser lie Asn Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ser Asn Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gin Gly 100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr 325 330 335 lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Glu Val Gin Leu Gin Gin 340 345 350

Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys 355 360 365

Lys Ala Ser Gly Tyr Lys Phe Thr Ser Tyr Val Met His Trp Val Lys 370 375 380

Gin Lys Pro Gly Gin Gly Leu Glu Trp lie Gly Tyr lie Asn Pro Tyr 385 390 395 400

Asn Asp Val Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu 405 410 415

Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu 420 425 430

Thr Ser Glu Asp Ser Ala Val His Tyr Cys Ala Arg Gly Ser Tyr Tyr 435 440 445

Asp Tyr Asp Gly Phe Val Tyr Gly Gin Gly Thr Leu Val Thr Val Ser 450 455 460

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 465 470 475 480

Gin lie Val Leu Thr Gin Ser Pro Ala lie Met Ser Ala Ser Pro Gly 485 490 495

Glu Lys Val Thr Met Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Met 500 505 510

His Trp Tyr Gin Gin Lys Ser Gly Thr Ser Pro Lys Arg Trp lie Tyr 515 520 525

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 530 535 540

Gly Ser Gly Thr Ser Tyr Ser Leu Thr lie Ser Ser Met Glu Ala Glu 545 550 555 560

Asp Ala Ala Thr Tyr Tyr Cys Gin Gin Trp Ser Ser Asn Pro Leu Thr 565 570 575

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 580 585

<210> 24 <211> 593 <212> PRT <213> Artificial Sequence <220> <223> EGFR x CD28; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD28 single-chain (clone 9.3; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 24

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Val His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60

Ser Arg Leu Ser lie Asn Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ser Asn Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gin Gly 100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr 325 330 335 lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Glu Leu Thr Gin 340 345 350

Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr lie Ser 355 360 365

Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gin 370 375 380

Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie Phe Ala 385 390 395 400

Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly 405 410 415

Ser Gly Thr Asn Phe Ser Leu Asn lie His Pro Val Asp Glu Asp Asp 420 425 430

Val Ala Met Tyr Phe Cys Gin Gin Ser Arg Lys Val Pro Tyr Thr Phe 435 440 445

Gly Gly Gly Thr Lys Leu Glu lie Lys Arg Gly Gly Gly Gly Ser Gly 450 455 460

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Lys Leu Gin Gin Ser 465 470 475 480

Gly Pro Gly Leu Val Thr Pro Ser Gin Ser Leu Ser lie Thr Cys Thr 485 490 495

Val Ser Gly Phe Ser Leu Ser Asp Tyr Gly Val His Trp Val Arg Gin 500 505 510

Ser Pro Gly Gin Gly Leu Glu Trp Leu Gly Val lie Trp Ala Gly Gly 515 520 525

Gly Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Lys Ser lie Ser Lys 530 535 540

Asp Asn Ser Lys Ser Gin Val Phe Leu Lys Met Asn Ser Leu Gin Ala 545 550 555 560

Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Gly Tyr Ser Tyr 565 570 575

Tyr Tyr Ser Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr Val Ser 580 585 590

Ser

<210> 25 <211> 590 <212> PRT <213> Artificial Sequence <220> <223> EGFRx CD16; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD16 single-chain (clone 3G8; VL-VH)], chain of a glycan-ko-variant-halfmolecule <400> 25

Gin Val Gin Leu Lys Gin Ser Gly Pro Gly Leu Val Gin Pro Ser Gin 15 10 15

Ser Leu Ser lie Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30

Gly Val His Trp Val Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45

Gly Val lie Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60

Ser Arg Leu Ser lie Asn Lys Asp Asn Ser Lys Ser Gin Val Phe Phe 65 70 75 80

Lys Met Asn Ser Leu Gin Ser Asn Asp Thr Ala lie Tyr Tyr Cys Ala 85 90 95

Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gin Gly 100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175

Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190

Ser Ser Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro 195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220

Thr His Thr Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro Ser 225 230 235 240

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro 260 265 270

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Gin Ser Thr Tyr Arg Val Val 290 295 300

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320

Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser Pro lie Glu Lys Thr 325 330 335 lie Ser Lys Ala Lys Gly Gin Pro Ser Gly Asp lie Val Leu Thr Gin 340 345 350

Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gin Arg Ala Thr lie Ser 355 360 365

Cys Lys Ala Ser Gin Ser Val Asp Phe Asp Gly Asp Ser Phe Met Asn 370 375 380

Trp Tyr Gin Gin Lys Pro Gly Gin Pro Pro Lys Leu Leu lie Tyr Thr 385 390 395 400

Thr Ser Asn Leu Glu Ser Gly lie Pro Ala Arg Phe Ser Ala Ser Gly 405 410 415

Ser Gly Thr Asp Phe Thr Leu Asn lie His Pro Val Glu Glu Glu Asp 420 425 430

Thr Ala Thr Tyr Tyr Cys Gin Gin Ser Asn Glu Asp Pro Tyr Thr Phe 435 440 445

Gly Gly Gly Thr Lys Leu Glu lie Lys Gly Gly Gly Gly Ser Gly Gly 450 455 460

Gly Gly Ser Gly Gly Gly Gly Ser Gin Val Thr Leu Lys Glu Ser Gly 465 470 475 480

Pro Gly lie Leu Gin Pro Ser Gin Thr Leu Ser Leu Thr Cys Ser Phe 485 490 495

Ser Gly Phe Ser Leu Arg Thr Ser Gly Met Gly Val Gly Trp lie Arg 500 505 510

Gin Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His lie Trp Trp Asp 515 520 525

Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr lie Ser 530 535 540

Lys Asp Thr Ser Ser Asn Gin Val Phe Leu Lys lie Ala Ser Val Asp 545 550 555 560

Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gin lie Asn Pro Ala Trp 565 570 575

Phe Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 580 585 590

<210> 26 <211> 693 <212> PRT <213> Artificial Sequence <220> <223> heavy chain/main chain sequence, FLT3 x CD3; bsFcko-1 [N-terminal anti-FLT3 chimeric heavy chain and C- terminal CD3 single-chain (clone UCHT1; VL-VH)]: being a chain of a ko-variant-(full) molecule that includes a CH3 domain, not a glycomutant <400> 26

Gin Val Gin Leu Gin Gin Pro Gly Ala Glu Leu Val Lys Pro Gly 15 10 15

Ala Ser Leu Lys Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr 20 25 30

Ser Tyr Trp Met His Trp Val Arg Gin Arg Pro Gly His Gly Leu 35 40 45

Glu Trp lie Gly Glu lie Asp Pro Ser Asp Ser Tyr Lys Asp Tyr 50 55 60

Asn Gin Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser 65 70 75

Ser Asn Thr Ala Tyr Met His Leu Ser Ser Leu Thr Ser Asp Asp 80 85 90

Ser Ala Val Tyr Tyr Cys Ala Arg Ala lie Thr Thr Thr Pro Phe 95 100 105

Asp Phe Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser Ala Ser 110 115 120

Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser 125 130 135

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 140 145 150

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 155 160 165

Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu 170 175 180

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 185 190 195

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr 200 205 210

Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His 215 220 225

Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 245 250 255

Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp 260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 305 310 315

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gin Leu Pro Ser 320 325 330

Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu 335 340 345

Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 350 355 360

Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 365 370 375

Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 380 385 390

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 395 400 405

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 410 415 420

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 425 430 435

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Gly Asp 440 445 450 lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 455 460 465

Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Asp lie Arg Asn 470 475 480

Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu 485 490 495

Leu lie Tyr Tyr Thr Ser Arg Leu Glu Ser Gly Val Pro Ser Arg 500 505 510

Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr lie Ser 515 520 525

Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Gly 530 535 540

Asn Thr Leu Pro Trp Thr Phe Gly Gin Gly Thr Lys Val Glu lie 545 550 555

Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 560 565 570

Ser Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro 575 580 585

Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe 590 595 600

Thr Gly Tyr Thr Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly 605 610 615

Leu Glu Trp Val Ala Leu lie Asn Pro Tyr Lys Gly Val Ser Thr 620 625 630

Tyr Asn Gin Lys Phe Lys Asp Arg Phe Thr lie Ser Val Asp Lys 635 640 645

Ser Lys Asn Thr Ala Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu 650 655 660

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp 665 670 675

Ser Asp Trp Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val Thr 680 685 690

Val Ser Ser

<210> 27 <211> 49 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 27 ctcttcacag gtgtcctctc tgaggtccag ctgcagcagt ctggacctg 49 <210> 28

<211> 59 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400 28 gggagaaggt aggactcacc tgaggagact gtgagagtgg tgccttggcc ccagtagtc 59

<210> 29 <211> 51 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 29 tcttcacagg tgtcctctcc caggtgaagc tgcagcaatc tggacctgag c 51

<210> 30 <211> 51 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 30 aatgggagaa ggtaggactc acctgaggag acggtgaccg tggtcccttg g 51

<210> 31 <211> 53 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 31 tctcttcaca ggtgtcctct ctcaggtcca actgcagcag cctggggctg age 53

<210> 32 <211> 52 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 32 gagaaggtag gactcacctg aggagactgt gagagtggtg ccttggcccc ag 52

<210> 33 <211> 60 <212> DNA <213> Artificial Sequence <220 <223> oligonucleotide for he VDJ segment <400 33 agacgtccac tctgtctttc tcttcacagg tgtcctctcc caggtgcagc tgaagcagtc 60

<210> 34 <211> 49 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 34 gagaaggtag gactcacctg aggagaeggt gactgaggtt ccttgaccc 49

<210> 35 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 35 agacgtccac tctgtctttc tcttcacagg tgtcctctcc 40

<210> 36 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for he VDJ segment <400> 36 agacgtccac tctgtctttc tcttcacagg tgtcctctcc 40

<210> 37 <211> 43 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 37 actcgaggag atattgtgat gactcaggct gcaccctcta tac 43

<210> 38 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400 38 aactagtact tacgtttcag ctccagcttg gtcccagcac cgaacgtg 48

<210> 39 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 39 tctcgaggag acatcgagct cactcagtct ccagcttctt tg 42

<210> 40 <211> 46 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 40 aactagtact tacgtttgat ctccagcttg gtgccccctc caaagg 46

<210> 41 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 41 actcgaggag atattgtgct aactcagtct ccagccaccc tg 42

<210> 42 <211> 41 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 42 tactagtact tacgttttat ttccagcttg gtcccccctc c 41

<210> 43 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for Ic VJ segment <400> 43 actcgaggag acattgtgat gacacagtct ccatcctccc 40

<210> 44 <211> 47 <212> DNA <213> Artificial Sequence <220 <223> oligonucleotide for Ic VJ segment <400 44 actagtactt acgtttcagc tccagcttgg tcccagcacc gaacgtg 47

<210> 45 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for scFv segment <400> 45 atccggagat atccagatga cccagtcccc gagctccctg 40

<210> 46 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for scFv segment <400> 46 tactagttat cacgaggaga cggtgaccag ggttccttga cccca 45

<210> 47 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for scFv segment <400> 47 atccggagaa gtgcagctgc agcagtccgg ccctgagct 39

<210> 48 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for scFv segment <400> 48 tactagttat cacttcagtt ccagcttggt gccagcgccg aaggt 45

<210> 49 <211> 41 <212> DNA <213> Artificial Sequence <220 <223> oligonucleotide for scFv segment <400 49 atccggagac attgtgctga cccagtcccc tgcctccctg g 41

<210 50 <211 >45 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide for scFv segment <400> 50 tactagttat caagagctca cagtcactgt ggtgccctgg cccca 45 Claims 1. A recombinant bispecific antibody molecule consisting of a Fab fragment comprising a first binding site for a first antigen, a single chain Fv fragment comprising a second binding site for a second antigen and an immunoglobulin CH2 domain, wherein the Fab fragment further comprises the hinge region, wherein the Fab fragment and the single chain Fv fragment are linked via the CH2 domain, wherein at least one amino acid residue of the CH2 domain that is able to mediate binding to Fc receptors is lacking or mutated, and wherein further the amino acid residues of sequence positions 226 and 229 (numbering of sequence positions according to the EU-index), are lacking or mutated, wherein the at least one amino acid residue of the hinge region or the CH2 domain that is able to mediate binding to Fc receptors is lacking or mutated, is selected from the group consisting of sequence position 228, 230, 231,232, 233, 234, 235, 236, 237, 238, 265, 297, 327, and 330 (numbering of sequence positions according to the EU-index). 2. The antibody molecule of claim 1, a) wherein either the first binding site or the second binding site binds a tumor associated antigen; wherein (i) the tumor associated antigen is preferably located on the vasculature of a tumor; and/or (ii) the tumor associated antigen is preferably a surface antigen or an antigen of the extracellular matrix; and/or (iii) the tumor associated antigen is preferably selected from the group consisting of CD10, CD19, CD20, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CDw52, Fms-like tyrosine kinase 3 (FLT-3, CD135), c-Kit(CD117), CSF1 R, (CD115), CD133, PDGFR-a(CD140a), PDGFR-β (CD140b), chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), Muc-1, EGFR, de2-7-EGFR, EGFRvlll, Folate binding protein, Her2neu, Her3, PSMA, PSCA, PSA, TAG-72, HLA-DR, IGFR, CD133, IL3R, fibroblast activating protein (FAP), Carboanhydrase IX(MN/CA IX), Carcinoembryonic antigen (CEA), EpCAM, CDCP1, Derlinl, Tenascin, frizzled 1-10, the vascular antigens VEGFR2 (KDR/FLK1), VEGFR3 (FLT4, CD309), Endoglin, CLEC14, Tem1-8, and Tie2; and/or b) wherein either the first binding site or the second binding site preferably binds a T-cell- or NK (natural killer) cell specific receptor molecule, wherein the T-cell- or NK cell specific receptor molecule is preferably one of CD3, the T cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1 BB, CD2, CD5 and CD95, wherein the TCR is preferably TCR (alpha/beta) or TCR (gamma/delta). 3. The antibody molecule of claim 1 or 2, wherein (i) the Fab fragment is linked to the CH2 domain via the heavy chain CH1 and VH domains of the Fab fragment or via the CL and VL light chain domains of the Fab fragment, wherein the heavy chain domains of the Fab fragment or the light chain domains of the Fab fragment are preferably arranged at the N-terminus of the polypeptide chain, wherein the CH2 domain is preferably linked to the scFv fragment via the variable domain of the light chain (VL domain) of the scFv fragment that comprises the second binding site or via the variable domain of the heavy chain (VFI domain) of the scFv fragment that comprises the second binding site; or (ii) the Fab fragment that comprises the first binding site for the first antigen preferably consists of the VL domain fused to the CH1 domain and the VFI domain fused to the CL domain, wherein the CH1 domain of the Fab fragment is preferably fused to the CFI2 domain, and/or wherein the VL-CFI1 chain of the Fab fragment is preferably arranged at the N-terminus of the polypeptide chain. 4. The antibody molecule of any one of the preceding claims, wherein the Fab fragment is linked to the CFI2 domain via the heavy chain CH 1 and VFI domains of the Fab fragment. 5. The antibody molecule of claim 4, wherein the heavy chain domains of the Fab fragment are arranged at the N-terminus of the polypeptide chain. 6. The antibody molecule of claim 5, wherein the CFI2 domain is linked to the scFv fragment via the variable domain of the light chain (VL domain) of the scFv fragment that comprises the second binding site. 7. The antibody molecule of claim 5, wherein the CFI2 domain is linked to the scFv fragment via the variable domain of the heavy chain (VFI domain) of the scFv fragment that comprises the second binding site. 8. The antibody molecule of any one of the preceding claims, a) wherein the Fab fragment comprises a hinge region; and/or b) wherein the first binding site binds a tumor associated surface antigen and the second binding site binds one of CD3, the T cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1 BB, CD2, CD5 and CD95. 9. The antibody molecule of claim 1, wherein a cysteine at one or both of positions 226 and 229 that are lacking or mutated is replaced by a different amino acid (numbering of sequence positions according to the EU-index). 10. The antibody molecule of any one of the preceding claims, comprising at least one mutation selected from the group consisting of a deletion of amino acid 228, a deletion of amino acid 229, a deletion of amino acid 230, a deletion of amino acid 231, a deletion of amino acid 232, a deletion of amino acid 233, a substitution Glu233->Pro, a substitution Leu234-»Val, a deletion of amino acid 234, a substitution Leu235->Ala, a deletion of amino acid 235, a deletion of amino acid 236, a deletion of amino acid 237, a deletion of amino acid 238, a substitution Asp265->Gly, a substitution Asn297-»Gln, a substitution Ala327->Gln, and a substitution Ala330->Ser (numbering of sequence positions according to the EU-index). 11. The antibody molecule of any one of the preceding claims, wherein the Fab fragment is linked to the CFI2 domain via a heavy chain domain of the Fab fragment or via a light chain domain of the Fab fragment, wherein the heavy chain domains of the Fab fragment are preferably arranged at the N-terminus of the polypeptide chain. 12. A pharmaceutical composition comprising an antibody molecule as defined in any one of the preceding claims. 13. An antibody molecule as defined in any one of claims 1 to 11 for use in the treatment of a disease, where the disease is preferably a proliferatory disease, wherein the proliferatory disease is preferably selected from the group consisting of hemopoetic malignancies, such as acute and chronic myeloic and lymphatic leukemias, as well as lymphomas, solid tumors such as tumors of the gastrointestinal tract, lung, kidney, prostate, breast, brain, ovary, uterus, mesenchymal tumors and melanoma. 14. A nucleic acid molecule encoding an antibody molecule as defined in any one of claims 1 to 11, or a vector com prising said nucleic acid molecule, or a host cell comprising said nucleic acid molecule or said vector. 15. A method of producing an antibody molecule of any one of claims 1 to 11, comprising expressing a nucleic acid encoding the antibody molecule under conditions allowing expression of the nucleic acid, wherein the antibody molecule is preferably expressed in a host cell or a cell-free system.

Patentansprüche 1. Rekombinantes, bispezifisches Antikörpermolekül, bestehend aus einem Fab-Fragment, umfassend eine erste Bindungsstelle für ein erstes Antigen, ein single-chain Fv-Fragment, umfassend eine zweite Bindungsstelle für ein zweites Antigen, und eine CH2-lmmunglobulin-domäne, wobei das Fab-Fragment weiterhin die Gelenkregion umfasst, wobei das Fab-Fragment und das single-chain Fv-Fragment über die CH2-Domäne verknüpft sind, wobei mindestens ein Aminosäurerest der CH2-Domäne, der die Bindung an Fc-Rezeptoren vermitteln kann, fehlt oder mutiert ist, und wobei weiterhin die Aminosäurereste der Sequenzpositionen 226 und 229 (Nummerierung der Sequenzpositionen nach EU-lndex) fehlen oder mutiert sind, wobei der mindestens eine Aminosäurerest der Gelenkregion oder der CH2-Domäne, der die Bindung an Fc-Rezeptoren vermitteln kann, fehlt oder mutiert ist, aus der Gruppe ausgewählt ist, bestehend aus den Sequenzpositionen 228,230,231,232,233,234,235,236,237,238,265,297,327 und 330 (Nummerierung der Sequenzpositionen nach EU-lndex). 2. Antikörpermolekül nach Anspruch 1, a) wobei entwederdie erste Bindungsstelle oderdie zweite Bindungsstelle ein tumorassoziiertes Antigen bindet, wobei i) sich das tumorassoziierte Antigen vorzugsweise an der Tumorvaskulatur befindet; und/oder ii) das tumorassoziierte Antigen vorzugsweise ein Oberflächenantigen oder ein Antigen der extrazellulären Matrix ist; und/oder iii) das tumorassoziierte Antigen vorzugsweise aus der Gruppe ausgewählt ist, bestehend aus CD10, CD19, CD20, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CDw52, Fms-ähnlicher Tyrosinkinase 3 (FLT-3, CD135), c-Kit (CD117), CSF1 R (CD115), CD133, PDGFR-a (CD140a), PDGFR-ß (CD140b), Chondroitinsulfat-Proteoglykan 4 (CSPG4, melanom-assoziiertes Chondroitinsulfat-Proteoglykan), Muc-1 , EGFR, de2-7-EGFR, EGFRvlll, Folatbindungsprotein, Her2neu, Her3, PSMA, PSCA, PSA, TAG-72, FILA-DR, IGFR, CD133, IL3R, Fibroblasten-aktivierendem Protein (FAP), Carboanhydrase IX (MN/CA IX), carcinoembryonalem Antigen (CEA), EpCAM, CDCP1 , Derlinl, Tenascin, Frizzled 1 -10, den vaskulären Antigenen VEGFR2 (KDR/FLK1), VEGFR3 (FLT4, CD309), Endoglin, CLEC14, Tem1-8 und Tie2; und/oder b) wobei entweder die erste Bindungsstelle oder die zweite Bindungsstelle vorzugsweise ein T-Zellen- oder NK (natürliche Killer)-Zellen-spezifisches Rezeptormolekül bindet, wobei das T-Zellen- oder NK-Zellen-spezifische Rezeptormolekül vorzugsweise eines von CD3, dem T-Zellen Rezeptor (TCR), CD28, CD16, NKG2D,Ox40, 4-1 BB, CD2, CD5 und CD95 ist, wobei der TCR vorzugsweise TRC (alpha/ beta) oder TCR (gamma/delta) ist. 3. Antikörpermolekül nach Anspruch 1 oder 2, wobei (i) das Fab-Fragment mit der CH2-Domäne über die CH1- und VFI-Domänen der schweren Kette des Fab-Fragments oder über die CL- und VL-Domänen der leichten Kette des Fab-Fragments verknüpft sind, wobei die Domänen der schweren Kette des Fab-Fragments oderdie Domänen der leichten Kette des Fab-Fragments vorzugsweise an dem N-Terminus der Polypeptidkette angeordnet sind, wobei die CH2-Domäne vorzugsweise mit dem scFv-Fragment über die variable Domäne der leichten Kette (VL-Domäne) des scFv-Fragmentes verknüpft ist, das die zweite Bindungsstelle umfasst, oder über die variable Domäne der schweren Kette (VH-Domäne) des scFv-Fragmentes, das die zweite Bindungsstelle umfasst; oder (ii) das Fab-Fragment, das die erste Bindungsstelle für das erste Antigen umfasst, vorzugsweise aus der VL-Domäne, fusioniert mit der CH 1-Domäne, und der VH-Domäne, fusioniert mit der CL-Domäne, besteht, wobei die CH 1-Domäne des Fab-Fragmentes vorzugsweise mit der CH2-Domäne fusioniert ist, und/ oder wobei die VL-CH1-Kette des Fab-Fragments vorzugsweise an dem N-Terminus der Polypeptidkette angeordnet ist. 4. Antikörpermolekül nach einem der vorhergehenden Ansprüche, wobei das Fab-Fragment mit der CH2-Domäne über die CH1- und VH-Domänen der schweren Kette des Fab-Fragments verknüpft sind. 5. Antikörpermolekül nach Anspruch 4, wobei die Domänen der schweren Kette des Fab-Fragments an dem N-Ter-minus der Polypeptidkette angeordnet sind. 6. Antikörpermolekül nach Anspruch 5, wobei die CH2-Domäne mit dem scFv-Fragment über die variable Domäne der leichten Kette (VL-Domäne) des scFv-Fragments verknüpft ist, das die zweite Bindungsstelle umfasst. 7. Antikörpermolekül nach Anspruch 5, wobei die CH2-Domäne mit dem scFv-Fragment über die variable Domäne der schweren Kette (VH-Domäne) des scFv-Fragments verknüpft ist, das die zweite Bindungsstelle umfasst. 8. Antikörpermolekül nach einem der vorhergehenden Ansprüche, a) wobei das Fab-Fragment eine Gelenkregion umfasst; und/oder b) wobei die erste Bindungsstelle ein tumorassoziiertes Oberflächenantigen bindet und die zweite Bindungsstelle eines von CD3, dem T-Zellen-Rezeptor (TCR), CD28, CD16, NKG2D, 0x40,4-1 BB, CD2, CD5 und CD95 bindet. 9. Antikörpermolekül nach Anspruch 1, wobei ein Cystein an einer oder beiden Positionen 226 und 229, die fehlen oder mutiert sind, durch eine andere Aminosäure ersetzt ist (Nummerierung der Sequenzpositionen nach EU-lndex). 10. Antikörpermolekül nach einem der vorhergehenden Ansprüche, umfassend mindestens eine Mutation, ausgewählt aus der Gruppe, bestehend aus einer Deletion der Aminosäure 228, einer Deletion der Aminosäure 229, einer Deletion der Am inosäure 230, einer Deletion der Aminosäure 231, einer Deletion der Aminosäure 232, einer Deletion der Aminosäure 233, einer Substitution GI233—»Pro, einer Substitution Leu234—»Val, einer Deletion der Aminosäure 234, einer Substitution Leu235—»Ala, einer Deletion der Aminosäure 235, einer Deletion der Aminosäure 236, einer Deletion der Aminosäure 237, einer Deletion der Aminosäure 238, einer Substitution Asp265—»G ly, einer Substitution Asn297-»Gln, einer Substitution Ala327-»Gln und einer Substitution Ala330-»Ser (Nummerierung der Sequenzpositionen nach EU-lndex). 11. Antikörpermolekül nach einem der vorhergehenden Ansprüche, wobei das Fab-Fragment mit der CH2-Domäne über eine Domäne der schweren Kette des Fab-Fragments oder über eine Domäne der leichten Kette des Fab-Fragments verknüpft ist, wobei die Domänen der schweren Kette des Fab-Fragments vorzugsweise an dem N-Terminus der Polypeptidkette angeordnet sind. 12. Pharmazeutische Zusammensetzung, umfassend ein Antikörpermolekül, wie in einem der vorhergehenden Ansprüche definiert. 13. Antikörpermolekül, wie in einem der Ansprüche 1 bis 11 definiert, zur Verwendung bei der Behandlung einer Erkrankung, wobei die Erkrankung vorzugsweise eine proliferatorische Erkrankung ist, wobei die proliferatorische Erkrankung vorzugsweise aus der Gruppe ausgewählt ist, bestehend aus hämatopoetischen Malignomen, wie z.B. akute und chronische myeloische und lymphatische Leukämien, sowie Lymphome, solide Tumore, wie z.B. Tumore des Magen-Darm-Trakts, der Lunge, der Nieren, der Prostata, der Brust, des Gehirns, der Eierstöcke, des Uterus, mesenchymale Tumore und Melanome. 14. Nukleinsäuremolekül, das ein Antikörpermolekül kodiert, wie nach einem der Ansprüche 1 bis 11 definiert, oder ein Vektor, umfassend das Nukleinsäuremolekül, oder eine Wirtszelle, umfassend das Nukleinsäuremolekül oder den Vektor. 15. Verfahren zur Herstellung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 11, umfassend das Exprim ieren einer Nukleinsäure, die das Antikörpermolekül unter Bedingungen kodiert, die die Expression der Nukleinsäure erlauben, wobei das Antikörpermolekül vorzugsweise in einer Wirtszelle oder in einem zellfreien System exprimiert ist.

Revendications 1. Molécule d’anticorps bispécifique recombinant comportant un fragment Fab comprenant un premier site de liaison pour un premier antigène, un fragment Fv à chaîne simple comprenant un second site de liaison pour un second antigène et un domaine CH2 d’immunoglobuline, le fragment Fab comprenant en outre la région charnière, le fragment Fab et le fragment Fv à chaîne simple étant lié via le domaine CH2, au moins un résidu d’acide aminé du domaine CH2, qui est capable de médier la liaison à des récepteurs Fc, étant manquant ou muté, et en outre les résidus d’acides aminés des positions de séquence 226 et 229 (la numérotation des positions de séquence selon index UE) étant manquant ou muté, l’au moins un résidu d’acide aminé de la région charnière ou du domaine CH2, qui est capable de médier la liaison à des récepteurs Fc, qui manque ou est muté, étant sélectionné du groupe comportant la position de séquence 228, 230, 231,232, 233, 234, 235, 236, 237, 238, 265, 297, 327 et 330 (la numérotation des positions de séquence selon index UE). 2. Molécule d’anticorps selon la revendication 1, a) ou le premier site de liaison ou le second site de liaison se liant à un antigène associé à une tumeur, i) l’antigène associé à une tumeur étant de préférence situé au système vasculaire d’une tumeur; et/ou ii) l’antigène associé à une tumeur étant de préférence un antigène de surface ou un antigène de la matrice extracellulaire; et/ou iii) l’antigène associé à une tumeur étant de préférence sélectionné du groupe comportant CD10, CD19, CD20, CD21 , CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CDw52, de la tyrosine kinase 3 analogue à fms (FLT-3, CD135), le c-kit (CD117), CSF1 R (CD115), CD133, PDGFR-a (CD140a), PDGFR-ß (CD140b), le protéoglycane 4 à base de sulfate de chondroïtine (CSPG4, le protéoglycane 4 à base de sulfate de chondroïtine associé au mélanome, Muc-1 , EGFR, de2-7-EGFR, EGFRvIII, la protéine de liaison au folate, Her2neu, Fler3, PSMA, PSCA, PSA, TAG-72, FILA-DR, IGFR, CD133, IL3R, la protéine activatrice de fibroblaste, (FAP), la carboanhydrase IX (MN/CA IX), l’antigène carcino-embryonnaire (CEA), EpCAM, CDCP1, Derlinl, la tenascine, frizzled 1 -10, les antigènes vasculaires VEGFR2 (KDR/FLK1 ), VEGFR3 (FLT4, CD309), l’endogline, CLEC14, Terni -8 et Tie2; et/ou a) ou le premier site de liaison ou le second site de liaison de préférence se liant à la molécule réceptrice spécifique de la cellule T ou NK (cellule tueuse naturelle), la molécule réceptrice spécifique de la cellule T ou NK étant de préférence l’une parmi CD3, le récepteur de cellule T (TCR), CD28, CD16, NKG2D, 0x40, 4-1 BB, CD2, CD5 et CD95, le TCR étant de préférence TCR (alpha/bêta) ou TCR (gamma/delta). 3. Molécule d’anticorps selon la revendication 1 ou 2, (i) le fragment Fab étant lié au domaine CH2 via les domaines CH1 et VFI de la chaîne lourde du fragment Fab ou via les domaines CL et VL de la chaîne légère du fragment Fab, les domaines de la chaîne lourde du fragment Fab ou les domaines de la chaîne légère du fragment Fab étant de préférence situés au N-terminale de la chaîne polypeptidique, le domaine CH2 étant de préférence lié au fragment scFv via le domaine variable de la chaîne légère (le domaine VL) du fragment scFv qui comprend le second site de liaison ou via le domaine variable de la chaîne lourde (domaine VH) du fragment scFv qui comprend le second site de liaison; ou (ii) le fragment Fab qui comprend le premier site de liaison pour le premier antigène de préférence comportant le domaine VL fusionné au domaine CH1 et le domaine VH fusionné au domaine CL, le domaine CH1 du fragment Fab étant de préférence fusionné au domaine CH2, et/ou la chaîne VL-CH1 du fragment Fab étant de préférence situé au N-terminale de la chaîne polypeptidique. 4. Molécule d’anticorps selon l’une quelconque des revendications précédentes, le fragment Fab étant lié au domaine CH2 via les domaines CH1 et VH de la chaîne lourde du fragment Fab. 5. Molécule d’anticorps selon la revendication 4, les domaines de la chaîne lourde du fragment Fab étant situés au N-terminale de la chaîne polypeptidique. 6. Molécule d’anticorps selon la revendication 5, le domaine CH2 étant lié au fragment scFv via le domaine variable de la chaîne légère (domaine VL) du fragment scFv qui comprend le second site de liaison. 7. Molécule d’anticorps selon la revendication 5, le domaine CH2 étant lié au fragment scFv via le domaine variable de la chaîne lourde (domaine VH) du fragment scFv qui comprend le second site de liaison. 8. Molécule d’anticorps selon l’une quelconque des revendications précédentes, a) le fragment Fab comprenant une région charnière; et/ou b) le premier site de liaison se liant à un antigène de surface associé à une tumeur et le second site de liaison se liant à un parmi le CD3, le récepteur de cellule T (TCR), CD28, CD16, NKG2D, 0x40, 4-1 BB, CD2, CD5 et CD95. 9. Molécule d’anticorps selon la revendication 1, une cystéine sur une ou les deux positions 226 et 229 qui manquent ou sont mutées étant remplacée par un acide aminé différent (la numérotation des positions de séquence selon index UE). 10. Molécule d’anticorps selon l’une quelconque des revendications précédentes, comportant au moins une mutation sélectionnée du groupe comprenant une délétion de l’acide aminé 228, une délétion de l’acide aminé 29, une délétion de l’acide aminé 230, une délétion de l’acide aminé 231, une délétion de l’acide aminé 232, une délétion de l’acide aminé 233, une substitution Glu233->Pro, une substitution Leu234-A/al, une délétion de l’acide aminé 234, une substitution Leu235->Ala, une délétion d’un acide aminé 235, une délétion d’un acide aminé 236, une délétion de l’acide aminé 237, une délétion de l’acide aminé 238, une substitution Asp265->Gly, une substitution Asn297->Gln, une substitution Ala327->Gln et une substitution Ala330->Ser (la numérotation des positions de séquence selon index UE). 11. Molécule d’anticorps selon l’une quelconque des revendications précédentes, le fragment Fab étant lié au domaine CH2 via un domaine de la chaîne lourde du fragment Fab ou via un domaine de la chaîne légère du fragment Fab, les domaines de la chaîne lourde du fragment Fab étant de préférence situés au N-terminale de la chaîne polypeptidique. 12. Composition pharmaceutique comportant une molécule d’anticorps telle que définie selon l’une quelconque des revendications précédentes. 13. Molécule d’anticorps telle que définie selon l’une quelconque des revendications 1 à 11 pour l’utilisation dans le traitement d’une maladie, la maladie étant de préférence une maladie proliferatoire, la maladie prolifératoire étant de préférence sélectionnée du groupe comportant des malignités hématopoïétiques comme des leucémies myé-loiques et lymphatiques aiguës et chroniques ainsi que des lymphomes, des tumeurs solides comme des tumeurs du tractus gastrointestinal, du poumon, du rein, de la prostate, de la poitrine, du cerveau, de l’ovaire, de l’utérus, des tumeurs mésenchymateuses et des mélanomes. 14. Molécule d’acide nucléique codant pour une molécule d’anticorps telle que définie selon l’une quelconque des revendications 1 à 11 ou un vecteur comportant ladite molécule d’acide nucléique ou une cellule hôte comportant ladite molécule d’acide nucléique ou ledit vecteur. 15. Procédé pour la production d’une molécule d’anticorps selon l’une quelconque des revendications 1 à 11 comportant l’expression d’un acide nucléique codant pour le molécule d’anticorps dans des conditions permettant l’expression de l’acide nucléique, la molécule d’anticorps étant de préférence exprimé dans une cellule hôte ou un système sans cellule.

Fig. 6 A) light chain sequences 1) Anti-FLT3 chimeric light chain (clone 4G8): (SEQ ID NO: 1)

DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGS

GSGTDFTLSINSVETEDFGVYFCQQSNTWPYTFGGGTKLEIKP7yAAPSUF/FPPSDEQLKSGrA SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRG EC* 2) Anti-FLT3 chimeric light chain (clone BV10): (SEQ ID NO: 2)

PIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYMAWYQQKPGQPPKLLIYGASTRES

GVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCOyNDHSYPLTFGAGTKLELKPrt/AAPSVF/FPPS

DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC* 3) Anti-CSPG4 chimeric light chain (clone 9.2.27): (SEQ ID NO: 3)

DIELTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPA

RFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPLTFGGGTKLEIKP7VAAPSVF/FPPSPEQE

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC*

Anti-CD19 chimeric light (clone 4G7) (SEQ ID NO: 4) DIVMTQAAPSIPVTPGESVSISCRSSKSLLNSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVP DRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGAGTKLELK RTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC* 5) Anti-EGFR light chain (clone C225) (SEQ ID NO: 5)

DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSG

SGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRrVAAPSt/F/FPPSPEQLKSGTAS

VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC*

Fig. 6 CONT. B) heavy chain/main chain sequences 1) FLT3 X CD3; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD3 single-chain (clone UCHT1; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 6)

QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQ

KFKPKATLTVDRSSNTAYMHLSSLTSDPSAVYYCARAITTTPFDFWGQGTTLTVSSASTKGPSV

FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVP

SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMISR

TPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKE

YKCKVSUKQLPSP\EKT\SKAKGQPSGDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQ

KPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTL TISSLQPEDFA TYYCQQGNTLPWTFGQGT

KVE/KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAP

GKGLEVWALINPYKGVSTYNQKFKPRFTISVPKSKNTAYLQMNSLRAEPTAVYYCARSGYYGP SPWYFPVWGQGTLVTVSS* 2) FLT3 X CD3; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD3 single-chain (clone UCHT1; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 7)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHWVRQSPGKGLEWLGVIWSGGSTDYNAA

FISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMDYWGQGTSVTVSSAST

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS

VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDT

LMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDW

LNGKEYKCK\/SNKQL.PSP\EKT\SKAKGQPSGDIQMTQSPSSLSASVGDRVTITCRASQDIRNYL

NWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPW

7FGQG77<yE/KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTIVIN

WVRQAPGKGLEWVALINPYKGVSTYNQKFKPRFTISVDKSKNTAYLQMNSLRAEPTAVYYCA RSGYYGPSDWYFDVWGQGTLVTVSS*

Fig. 6 CONT. 3) FLT3 X TCRa/ß; bsFcko-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal TCRa/ß single-chain (clone BMA031; VH-VL orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 8)

QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQ

KFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFWGQGTTLTVSSASTKGPSV

FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTV

PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMIS

RTPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGK

EYKCKVSNKQLPSPIEKTISKAKGQPSGEVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMH

WVKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVHYCAR

GSYYDYDGFVYGQGTLVTVSSGGGGSGGGGSGGGGSQ/VL TQSPAIMSASPGEKVTMTCSA T

SSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSL TISSMEAEDAA TYYCQ QWSSNPLTFGAGTKLELK* 4) FLT3 X TCRa/ß; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal TCRa/ß single-chain (clone BMA031; VH-VL orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 9)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHVWRQSPGKGLEWLGVIWSGGSTDYNAA

FISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMDYWGQGTSVTVSSAST

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS

WTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDT

LMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKQLPSPIEKTISKAKGQPSGEVQLQQSGPELVKPGASVKMSCKASGYKFTS

YVMHWVKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVH

YCARGSYYDYDGFVYGQGTLVTVSSGGGGSGGGGSGGGGSQ/VLTQSPA/MSASPGEKVTMT

CSATSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATY YCQQWSSNPLTFGAGTKLELK"

Fig. 6 CONT. 5) FLT3 X CD28; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD28 single-chain (clone 9.3; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 10)

QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQ

KFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFWGQGTTLTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKE YKCKVSNKQLPSPIEKTISKAKGQPSGP/EZ. TQSPASLA VSLGQRA TISCRASESVEYYVTSLMQ WYQQKPGQPPKLLIFAASNVESGVPARFSGSGSGTNFSLNIHPVDEDDVAMYFCQQSRKVPYT FGGG7KLE/KRGGGGSGGGGSGGGGSQVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHW VRQSPGQGLEWLGVIWAGGGTNYNSALMSRKS1SKDNSKSQVFLKMNSLQADDTAVYYCARD KGYSYYYSM DYWGQGTTVTVSS* 6) FLT3 X CD28; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD28 single-chain (clone 9.3; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 11)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHWVRQSPGKGLEWLGVIWSGGSTDYNAA

FISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMDYWGQGTSVTVSSAST

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS

VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDT

LMISRTPEVTCVVVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKQLPSPIEKTISKAKGQPSG

DIELTQSPASLAVSLGQRATISCRASESVEYYVTSLMQWYQQKPGQPPKLLIFAASNVESGVPA

RFSGSGSGTNFSLNIHPVDEDDVAMYFCQQSRKVPYTFGGGTKLEIKRGGGGSGGGGSGGGG

SQVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHWVRQSPGQGLEWLGVIWAGGGTNYNS ALMSRKSISKDNSKSQVFLKMNSLQADDTAVYYCARDKGYSYYYSMDYWGQGTTVTVSS*

Fig. 6 CONT. 7) FLT3 X CD16; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) and C-terminal CD16 single-chain (clone 3G8; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 12)

QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQ

KFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFWGQGTTLTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVP SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMISR TPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKE YKCKVSNKQLPSPIEKTISKAK GOPSGDIVLTQSPASLA VSLGQRA TISCKASQSVDFDGDSFMN WYQQKPGQPPKLLIYTTSNLESGIPARFSASGSG TDFTLNIHPVEEEDTA TYYCQQSNEDPYTF GGGTKLE/KGGGGSGGGGSGGGGSQVTLKESGPGILQPSQTLSLTCSFSGFSLRTSGMGVGW IRQPSGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTATYYCAQINP AWFAYWGQGTLVTVSS* 8) FLT3 X CD16; bsFck0-1/2 [N-terminal anti-FLT3 chimeric heavy chain (clone BV10) and C-terminal CD16 single-chain (clone 3G8; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO. 13)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGLHVWRQSPGKGLEWLGVIWSGGSTDYNAA

FISRLSISKDNSKSQVFFKMNSLQADDTAIYYCARKGGIYYANHYYAMDYWGQGTSVTVSSAST

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS

WTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDT

LMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDW

LNGKEYKCKVSNKQLPSPIEKTISKAKGQPSGP/VL TQSPASLA VSLGQRA TISCKASQSVDFDG

DSFMNWYQQKPGQPPKLLIYTTSNLESGIPARFSASGSGTDFTLNIHPVEEEDTATYYCQQSNE

DPY7FGGG77CLE/KGGGGSGGGGSGGGGSQVTLKESGPGILQPSQTLSLTCSFSGFSLRTSG

MGVGWIRQPSGKGLEWLAH1WWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTATYY CAQINPAWFAYWGQGTLVTVSS*

Fig. 6 CONT. 9) CD19 X CD3, bsFck0-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal anti-CD3 single-chain (clone UCHT1; VL-VH orientation)]: being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 14)

EVQLQQSGPELIKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNE

KFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGTYYYGSRVFDYWGQGTTLTVSSASTK

GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV

VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTL

MISRTPEVTCVVVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWL ΝβΚΕΥΚ0Κ\/5ΝΚ0[-ΡΒΡ\ΕΚΤ\8ΚΑΚβΟΡ3ΰΡ1ΟΜΤΟ8Ρ881.8Α8νβΡΙ*νΤΙΤα*Α8ΟΡΙΠΝΥί.Ν

WYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWT

FGQGrKtÆ/KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNW

VRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARS GYYGDSDWYFDVWGQGTLVTVSS* 10) CD19 X TCRa/ß, bsFck0-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal anti-TCRa/ß single-chain (clone BMA031; VH-VL orientation)]: being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 15)

EVQLQQSGPELIKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNE

KFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGTYYYGSRVFDYWGQGTTLTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTL MISRTPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWL NGKEYKCKVSNKQLPSPIEKTISKAKGQPSGEVQLQQSGPELVKPGASVKMSCKASGYKFTSY VMHVWKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVHY CARGSYYDYDGF\/YGQGTLVT\f SSGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTC SA TSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSL TISSMEAEDAA TYY CQQWSSNPL TFGAGTKLELK*

Fig. 6 CONT. 11) CD19 X CD28; bsFck0-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and exterminai CD28 single-chain (clone 9.3; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 16)

EVQLQQSGPELIKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNE

KFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGTYYYGSRVFDYWGQGTTLTVSSASTK

GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV

VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTL

MISRTPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWL

NGKEYKCKVSNKQLPSPIEKTISKAKGQPSG DIEL TQSPASLA VSLGQRA TISCRASESVEYYVTSLMQWYQQKPGQPPKLUFAASNVESGVPA RFSGSGSGTNFSLNIHPVDEDDVAMYFCQQSRKVPYTFGGGTKLEIKRGGGGSGGGGSGGGG SQVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHWVRQSPGQGLEWLGVIWAGGGTNYNS ALMSRKSISKDNSKSQVFLKMNSLQADDTAVYYCARDKGYSYYYSMDYWGQGTTVTVSS* 12) CD19 X CD16; bsFck0-1/2 [N-terminal anti-CD19 chimeric heavy chain (clone 4G7) and C-terminal CD16 single-chain (clone 3G8; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 17)

EVQLQQSGPELIKPGASVKIVISCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNPGTKYNE

KFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGTYYYGSRVFDYWGQGTTLTVSSASTK

GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV

VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTL

MISRTPEVTCWVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWL

NGKEYKCKVSNKQLPSPIEKTISKAKGQPSGD/VLTQSPASLA VSLGQRATISCKASQSVDFDGD

SFMNWYQQKPGQPPKLLIYTTSNLESGIPARFSASGSGTDFTLNIHPVEEEDTATYYCQQSNED

PYTFGGGrKLE/KGGGGSGGGGSGGGGSQVTLKESGPGILQPSQTLSLTCSFSGFSLRTSGM

GVGWIRQPSGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTATYYC AQINPAWFAYWGQGTLVTVSS*

Fig. 6 CONT. 13) CSPG4 X CD3, bsFck0-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal anti-CD3 single-chain (clone UCHT1; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 18)

QVKLQQSGPELVKPGASVKISCKASGYAFSRSWMNWVKQRPGQGLEWIGRIYPGDGDTNYN G KFKGKATLT AD KSSST AYMQVSSLTSVDS AVYFCARG NTVWPYTM DYWGQGTT VTVSSAS

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS

SWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKD

TLMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQD

WLNGKEYKCK\/SNKQLPSP\EKT\SKAKGQPSGDIQMTQSPSSLSASVGDR\mTCRASQDIRNY

LNWYQQKPGKAPKLUYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLP

W7FGQG7KUE/KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTM

NWVRQAPGKGLEWVALINPYKGVSTYNQKFKPRFTISVDKSKNTAYLQMNSLRAEDTAVYYC ARSGYYGDSDWYFDVWGQGTLVTVSS* 14) CSPG4 X TCRa/ß, bsFck0-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal anti-TCRa/ß single-chain (clone BMA031; VH-VL orientation)]: being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 19)

QVKLQQSGPELVKPGASVKISCKASGYAFSRSWMNWVKQRPGQGLEWIGRIYPGDGDTNYN G KFKG KATLT AD KSSST AYMQVSSLTSVDS AVYFCARG NTWVPYTM DYWGQGTTVTVSSAS

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS

SWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKD

TLMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKQLPSPIEKTISKAKGQPSGEVQLQQSGPELVKPGASVKMSCKASGYKFT

SYVMHWVKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAV

HYCARGSYYDYDGFVYGQGTLVTVSS GGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTM

TCSATSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAAT YYCQQWSSNPLTFGAGTKLELK*

Fig. 6 CONT. 15) CSPG4 X CD28; bsFck0-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal CD28 single-chain (clone 9.3; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 20)

QVKLQQSGPELVKPGASVKISCKASGYAFSRSWMNWVKQRPGQGLEWIGRIYPGDGDTNYN GKFKG KATLT ADKSSST AYMQVSSLTSVDS AVYFC ARG NTVWPYTM DYWGQGTTVTVSSAS

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVN H KPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKD TLMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQD WLNGKEYKCKVSNKQLPSPIEKTISKAKGQPSG

DIELTQSPASLAVSLGQRATISCRASESVEYYVTSLMQWYQQKPGQPPKLLIFAASNVESGVPA

RFSGSGSGTNFSLNIHPVDEDDVAMYFCQQSRKVPYTFGGGTKLEIKRGGGGSGGGGSGGGG

SQVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHWVRQSPGQGLEWLGVIWAGGGTNYNS ALMSRKSISKDNSKSQVFLKMNSLQADDTAVYYCARDKGYSYYYSMDYWGQGTTVTVSS* 16) CSPG4 X CD16; bsFck0-1/2 [N-terminal anti-CSPG4 chimeric heavy chain (clone 9.2.27) and C-terminal CD16 single-chain (clone 3G8; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 21)

QVKLQQSGPELVKPGASVKISCKASGYAFSRSWMNWVKQRPGQGLEWIGRIYPGDGDTNYN GKFKG KATLT ADKSSST AYM QVSSLTSVDS AVYFC ARG NTVWPYTM DYWGQGTTVTVSSAS

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS

SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKD

TLMISRTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKQLPSPIEKTISKAKGQPSGD/VL TQSPASLA VSLGQRA TISCKASQSVDFD

GDSFMNWYQQKPGQPPKLUYTTSNLESGIPARFSASGSGTDFTLNIHPVEEEDTATYYCQQSN

EDPY7FGGG7KLE/KGGGGSGGGGSGGGGSQVTLKESGPGILQPSQTLSLTCSFSGFSLRTSG

MGVGWIRQPSGKGLEWLAHIWWPDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTATYY CAQINPAWFAYWGQGTLVTVSS*

Fig. 6 CONT. 17) EGFR X CD3; bsFck0-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD3 single-chain (clone UCHT1; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 22)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTP

FTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPS

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMIS

RTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGK

EYKCMSNKQLPSP\EKT\SKAKGQPSGDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQ

QKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQ

G7KVE/KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQ

APGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYY GDSDWYFDVWGQGTLVTVSS* 18) EGFR X TCRa/ß; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal TCRa/ß single-chain (clone BMA031; VH-VL orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 23)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTP

FTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPS

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMIS

RTPEVTCVVVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGK

EYKCKVSNKQLPSPIEKTISKAKGQPSGEVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMH

WVKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVHYCAR

GSYYDYDGFVYGQGTLVTVSSGGGGSGGGGSGGGGSQ/VL TQSPAIMSASPGEKVTMTCSA T

SSVSYMHWYGGKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCG QWSSNPLTFGAGTKLELK*

Fig. 6 CONT. 19) EGFR X CD28; bsFcko-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD28 single-chain (clone 9.3; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 24)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTP

FTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPS

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTV

PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMIS

RTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGK

EYKCKVSNKQLPSPIEKTISKAKGQPSG

DIELTQSPASLAVSLGQRATISCRASESVEYYVTSLMQWYQQKPGQPPKLUFAASNVESGVPA

RFSGSGSGTNFSLNIHPVDEDDVAMYFCGOSRKVPYTFGGGTKLEIKRGGGGSGGGGSGGGG

SQVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHWVRQSPGQGLEWLGVIWAGGGTNYNS ALMSRKSISKDNSKSQVFLKMNSLQADDTAVYYCARDKGYSYYYSMDYWGQGTTVTVSS* 20) EGFR X CD16; bsFck0-1/2 [N-terminal anti-EGFR chimeric heavy chain (clone C225) and C-terminal CD16 single-chain (clone 3G8; VL-VH orientation)], being a chain of a glycan-ko-variant-halfmolecule (SEQ ID NO: 25)

QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTP

FTSRLSINKDNSKSQVFFKMNSLQSNPTAIYYCARALTYYDYEFAYWGQGTLVTVSSASTKGPS

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPSPAPPVAGPSVFLFPPKPKDTLMIS

RTPEVTCVWGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGK

EYKCKVSNKQLPSPIEKTISKAKGQPSGP/W.rQSPASf.A VSLGQRA TISCKASQSVDFDGDSFM

NWYQQKPGGPPKLUYTTSNLESGIPARFSASGSGTDFTLNIHPVEEEDTATYYCQQSNEDPYT

FGGGrKf-E/KGGGGSGGGGSGGGGSQVTLKESGPGILQPSQTLSLTCSFSGFSLRTSGMGVG

WIRQPSGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKIASVDTADTATYYCAQIN PAWFAYWGQGTLVTVSS*

Fig. 6 CONT. 21) FLT3 X CD3; bsFck0-1 [N-terminal anti-FLT3 chimeric heavy chain (clone 4G8) und C-terminal CD3 single-chain (clone UCHT1; VL-VH orientation)]: being a chain of a ko-variant-(full) molecule that includes a CH3 domain, not a glycomutant (SEQ ID NO: 26)

QVQLQQPGAELVKPGASLKLSCKSSGYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQ

KFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDFWGQGTTLTVSSASTKGPSV

FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVP

SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISR

TPEVTCVVVGVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE

YKCKVSNKQLPSPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

KSGDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLUYYTSRLESGVPSR

FSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSE

VQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQ KFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS*

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • WO 2011047180 A [0009] · WO 9948523 A [0075] • WO 2009018386 A [0009] · WO 2011076922 A [0087] [0122] [0140] • WO 2007109254 A [0009] · WO 2011089211 A [0087] [0122] [0140] • WO 2011025964 A [0009] · US 5500362 A [0099] • WO 2006031994 A [0009] · US 5821337 A [0099] • WO 0202773 A [0061] · US 61577327 B [0141]

Non-patent literature cited in the description • DAVIS, L.; VIDA, R.; LIPSKY, P.E. Regulation of · JUNG, G.; EBERHARD, H.J. An in-vitro model for human T lymphocyte mitogenesis by antibodies to tumor immunotherapy with antibody heteroconju- CD3. J. Immunol., 1986, vol. 137, 3758-3767 [0002] gates. Immunol.Today, 1988, vol. 9, 257-260 [0003] • JUNG.G. ; LEDBETTER,J.A.; MULLER-EBER- · JUNG.G.; FREIMANN.U.; VON MARSHALL,Z.; HARD,H.J. Induction of cytotoxicity in resting human REISFELD.R.A.; WILMANNS.W. Target cell-in- T lymphocytes bound to tumor cells by antibody het- ducedT cell activation with bi-and trispecific antibody eroconjugates. Proc.Nati.Acad.Sci.U.S.A, 1987, vol. fragments. Eur.J.Immunol., 1991, vol. 21,2431-2435 84, 4611-4615 [0003] [0140] [0003] • JUNG.G. ; EBERHARD,H.J. An in-vitro modelfortu- · ROSENBERG, S.A.; LOTZE, M.T.; YANG,J.C.; mor immunotherapy with antibody heteroconjugates. AEBERSOLD.P.M.; LINEHAN.W.M.;

Immunol. Today, 1988, vol. 9,257-260 [0003] [0140] SEIPP.C.A.; WHITE,D.E. Experience with the use • JUNG.G.; BRANDL.M.; EISNER,W.; of high-dose interleukin-2 in the treatment of652 can- FRAUNBERGER.P.; REIFENBERGER.G.; cer patients. Ann.Surg., 1989, vol. 210, 474-484 SCHLEGEL.U. ; WIESTLER.O.D.; REULEN.H.J.; [0003] WILMANNS.W. Local immunotherapy of glioma pa- * TIBBEN.J.G.; BOERMAN.O.C.; tients with a combination of 2 bispecific antibody frag- MASSUGER.L.F.; SCHIJF.C.P.; ments and resting autologous lymphocytes: evidence CLAESSENS.R.A.; CORSTENS.F.H. Pharmacoki- for in situ T-cell activation and therapeutic efficacy. netics, biodistribution and biological effects of intra-

IntJ Cancer., 2001, vol. 91, 225-30 [0003] venously administered bispecific monoclonal anti- • STAERZ.U.D.; KANAGAWA.O.; BEVAN.M.J. Hy- body OC/TR F(ab’)2 in ovarian carcinoma patients, brid antibodies can target sites for attack by T cells. Int.J. Cancer, 1996, vol. 66, 477-483 [0003] [0140]

Nature, 1985, vol. 314, 628-631 [0003] [0140] · KROESEN.B.J.; BUTER.J.; SLEIJFER.D.T.; • PEREZ,P.; HOFFMAN,R.W.; SHAW.S.; JANSSEN,R.A.; VAN DER GRAAF.W.T.; BLUESTONE.J.A.; SEGAL,D.M. Specific targeting ΤΗΕ,Τ.Η.; DE, L.L.; MULDER,N.H. Phase I study of cytotoxic T cells by anti-T3 linked to anti-target cell of intravenously applied bispecific antibody in renal antibody. Nature, 1985, vol. 316, 354-356 [0003] cell cancer patients receiving subcutaneous inter- 10140] leukin 2. Br.J.Cancer, 1994, vol. 70, 652-661 [0003] • JUNG.G.; HONSIK.C.J.; REISFELD.R.A.; MULL- · JUNG.G.; EBERHARD,H.J. An in-vitro model fortu- ER-EBERHARD.H.J. Activation of human peripheral mor immunotherapy with antibody heteroconjugates, blood mononuclear cells by anti-T3: killing of tumor Immunol. Today, 1988, vol. 9, 257-260 [0003] target cells coated with anti-target-anti-T3 conju- · JUNG.G.; FREIMANN.U.; VON MARSHALL,Z.; gates. Proc.Nati.Acad.Sci.U.S.A, 1986, vol. 83, REISFELD.R.A.; WILMANNS, W. Target cell-in- 4479-4483 [0003] [0140] ducedT cell activation with bi-and trispecific antibody • GROSSE-HOVEST.L.; HARTLAPP.I.; fragments. Eur. J. Immunol., 1991, vol. 21, MARWAN.W.; BREM.G.; RAMMENSEE.H.G.; 2431-2435 [0003] JUNG.G. A recombinant bispecific single-chain anti- · BARGOU, R. et al. Tumor regression in cancer pa- body induces targeted, supra-agonistic CD28-stimu- tients byvery low doses of a T cell-engaging antibody, lation and tumor cell killing. Eur.J.Immunol., 2003, Science, 2008, vol. 321,974-977 [0005] vol. 33, 1334-1340 [0003] [0008] [0140] • TOPP, M.S. et al. Targeted therapy with the · KABAT et al. Sequences of Proteins of Immunolog- T-cell-engaging antibody blinatumomab of chemo- ical Interest. United States Public Health Service, Na- therapy-refractory minimal residual disease in B-lin- tional Institutes of Health, 1991 [0064] eage acute lymphoblastic leukemia patients results · JONES etal. Nature, 1986, vol. 321,522-525 [0075] in high response rate and prolonged leukemia-free · VERHOEYEN M et al. Science, 1988, vol. 239, survival. J.Clin.Oncol., 2011, vol. 29, 2493-2498 1534-1536 [0075] [0005] [0007] · QUEEN C et al. PNAS, 1989, vol. 86, 10, , 029-10, • BRISCHWEIN.K. etal. Strictly target cell-dependent 033 [0075] activation of T cells by bispecific single-chain anti- · CO, M et al. Nature, 1991, vol. 351,501-502 [0075] body constructs of the BiTE class. J.immunother., · PADLAN E. A. etal. Mol. Immunol., 1991, vol. 28, 2007, vol. 30, 798-807 [0006] 489-498 [0076] • BARGOU.R. et al. Tumor regression in cancer pa- · PEDERSEN J. T. et al. J. Mol. Biol., 1994, vol. 235, tientsbyvery lowdosesofaT cell-engaging antibody. 959-973 [0076]

Science, 2008, vol. 321,974-977 [0007] · The pharmacology of monoclonal Antibodies. MARK • GROSSE-HOVEST.L. etal. Cloned transgenic farm G. E. et al. Handbook of Experimental Pharmacolo- animals produce a bispecific antibody for T cell-me- gy. Springer-Verlag, 1994, vol. 113, 105-134 [0076] diated tumor cell killing. Proc.Natl.Acad.Sci.U.S.A, · SKERRA, A. Use of the tetracycline promoter for the 2004, vol. 101,6858-6863 [0008] tightlyregulatedproductionofamurineantibodyfrag- • LU et al. Journal of Immunological Methods, 2002, ment in Escherichia coli. Gene, 1994, vol. 151, vol. 267 (2), 213-226 [0009] 131-135 [0078] • DALL’AQUA et al. Contribution of domain interface · SKERRA, A. A general vector, pASK84, for cloning, residues to the stability of antibody CH3 domain ho- bacterial production, and single-step purification of modimers. Biochemistry, 1998, vol. 37 (26), antibody Fab fragments. Gene, 1994, vol. 141, 79-8 9266-9273 [0022] [0140] [0078] • S.MILLER. Protein-Protein Recognition and the As- · CARTER et al. Biol Technology, 1992, vol. 10, sociation of Immunoglobulin Constant Domains. 163-167 [0079] J.Mol.Biol., 1990, vol. 216, 965-973 [0022] [0140] · VENTURI M ; SEIFERTC ;HUNTEC. High level pro- • J. DEISENHOFER. Crystallographic refinement and duction of functional antibody Fab fragments in an atomic models of a human Fc fragment and its com- oxidizing bacterial cytoplasm. J. Mol. Biol., 2002, vol. plex with fragment B of protein A from Staphylococ- 315, 1-8 [0079] cusaureusat2.9-and2.8-Aresolution. Biochemistry, · LINDMARK et al. J. Immunol. Meth., 1983, vol. 62, 1981, vol. 20, 2361-2370 [0022] [0140] 1-13 [0080] • ROOPENIAN ; AKILESH. FcRn: the neonatal Fere- · GUSSetal. EMBOJ., 1986, vol. 5,15671575 [0080] ceptor comes of age. Nature Reviews Immunology, · SCHMIDT, T.G.M. etal. J. Mol. Biol., 1996, vol. 255, 2007, vol. 7, 715-725 [0022] [0140] 753-766 [0081] • HOLT LJ etal. TrendsBiotechnol., 2003, vol. 21 (11), · ARMOUR et al. Eur. J. Immunol., 1999, vol. 29, 484-490 [0025] 2613-2624 [0092] • SELA, M. Sc/ence, 1969, vol. 166,1365-1374 [0036] · SONDERMANN et al. Nature, 2000, vol. 406, • LAVER, W.G. et al. Cell, 1990, vol. 61, 553-556 267-273 [0092] [0036] · DAVIS ; VIDA ; LIPSKY. J.Immunol, 1986, vol. 137, • Antibodies: A Laboratory Manual. Cold Spring Harbor 3758 [0092]

Laboratory, 1988 [0046] · CEUPPENS.JL ; VAN VAECK, F.J.Immunol., 1987, • Sequences of Proteins of immunological Interest. US vol. 139, 4067 [0092]

Department of Health and Human Services, 1991 · Cell. Immunol., 1989, vol. 118, 136 [0092] [0046] · ROSENTHAL-ALLIERI MA ; TICCIONI M ; DECK- • CHOTHIAetal. J. Mol. Biol., 1992, vol. 227, 799-817 ERT M; BREITTMEYER JP ; ROCHET N; [0046] ROULEAUX M ; SENIK A ; BERNERD A. Cell Im- • TOMLINSON et al. EMBO J., 1995, vol. 14, munol., 1995, vol. 163 (1), 88-95 [0092]

4628-4638 [0046] · GROSSE-HOVEST L ; HARTLAPP I ; MARWAN

• Protein Sequence and Structure Analysis of Antibody W ; BREM G ; RAMMENSEE H-G ; JUNG G. Eur J

Variable Domains. In: Antibody Engineering Lab Immunol., 2003, vol. 33 (5), 1334-1340 [0092]

Manual. Springer-Verlag [0046] · RAVETCH ; KINET.Annu. Rev. Immunol., 1991, vol. • REITER et al. Stabilization of the Fv fragments in 9, 457-92 [0096] [0099] recombinant immunotoxins by disulfide bonds engi- · CAPEL et al. Immunomethods, 1994, vol. 4, 25-34 neered into conserved framework regions. Biochem- [0096] istry, 1994, vol. 33, 6551-5459 [0049] · DE HAAS et al. J. Lab. Clin. Med., 1995, vol. 126, 330-41 [0096] • GAZZANO-SANTORO et al. J. Immunol. Methods, · BARGOU.R. ; LEO,E. ; ZUGMAIER.G.; 1997, vol. 202, 163 [0097] KLINGER,M.; GOEBELER.M. ; KNOP.S.; • CLYNES et al. PNAS USA, 1998, vol. 95, 652-656 NOPPENEY.R. ; VIARDOT.A.; HESS.G. ; SCHUL- [0099] ER,M. Tumor regression in cancer patients by very • WANG, L. et al. Science, 2001, vol. 292, 498-500 low doses of a T cell-engaging antibody. Science, [0102] 2008, vol. 321,974-977 [0140] • WANG, L.; SCHULTZ, P.G. Chem. Comm., 2002, · TOPP.M.S.; KUFER.P. ; GOKBUGET.N.; vol. 1,1-11 [0102] GOEBELER.M. ; KLINGER,M. ; NEUMANN,S.; • ZACCOLOetal.J. Mol. Biol., 1996, vol. 255,589-603 HORST,H.A.; RAFF.T. ; VIARDOT.A.; [0103] SCHMID,M. Targeted therapy with the T-cell-engag- • VIRNEKAS Betal. Nucleic Acids Res, 1994, vol. 22, ing antibody blinatumomab of chemotherapy-refrac- 5600-5607 [0103] tory minimal residual disease in B-lineage acute lym- • J.S. PATTON et al. The lungs as a portal of entry for phoblastic leukemia patients results in high response systemic drug delivery. Proc. Amer. Thoracic Soc., rate and prolonged leukemia-free survival. J. Clin.On- 2004, vol. 1,338-344 [0107] col., 2011, vol. 29, 2493-2498 [0140] • MEIDAN VM ; MICHNIAK BB. Am. J. Ther., 2004, · BRISCHWEIN.K. ; PARR.L. ; PFLANZ.S.; vol. 11 (4), 312-316 [0109] VOLKLAND.J. ; LUMSDEN.J.; KLINGER,M.; • BOS etal. Business Briefing: Pharmatech, 2003,1-6 LOCHER.M. ; HAMMOND,S.A.; KIENER.P.; [0110] KUFER.P. Strictly target cell-dependent activation of • GENNARO, A.L.; GENNARO, A.R. Remington: The T cells by bispecific single-chain antibody constructs

Science and Practice of Pharmacy. Lippincott Wil- of the BiTE class. J.lmmunother., 2007, vol. 30,

Hams &amp; Wilkins, 2000 [0111] 798-807 [0140] • DAVIS,L.; VIDA.R. ; LIPSKY.P.E. Regulation of hu- · GROSSE-HOVEST.L.; MULLER,S.; MINOIA.R.; man T lymphocyte mitogenesis by antibodies to CD3. WOLF.E.; ZAKHARTCHENKO.V.; J.Immunol., 1986, vol. 137, 3758-3767 [0140] WENIGERKIND.H.; LASSNIG.C.; • JUNG.G. ; FREIMANN.U. ; VON.M.Z. ; BESENFELDER.U. ; MULLER,M. ; LYTTON.S.D. REISFELD.R.A. ; WILMANNS.W. Target cell-in- Cloned transgenic farm animals produce a bispecific ducedT cell activation with bi-and trispecific antibody antibody for T cell-mediated tumor cell killing, fragments. Eur.J.lmmunol., 1991, vol. 21,2431-2435 Proc.Natl.Acad.Sci.U.S.A, 2004, vol. 101,6858-6863 [0140] [0140] • ROSENBERG,S.A.; LOTZE.M.T.; YANG.J.C.; · MARVIN,J.S.; ZHU,Z. Recombinant approaches to AEBERSOLD.P.M.; LINEHAN.W.M.; IgG-like bispecific antibodies. Acta Pharmacol.Sin., SEIPP.C.A.; WHITE,D.E. Experience with the use 2005, vol. 26, 649-658 [0140] of high-dose interleukin-2 in the treatment of 652 can- · MABRY,R.; LEWIS,K.E.; MOORE,M.; cer patients. Ann.Surg., 1989, vol. 210, 474-484 MCKERNAN,P.A.; BUKOWSKI.T.R.; [0140] BONTADELLI.K.; BRENDER.T.; OKADA.S.; • KROESEN.B.J.; BUTER.J.; SLEIJFER.D.T.; LUM,K.; WEST.J. Engineering of stable bispecific JANSSEN,R.A.; VAN DER GRAAF.W.T.; antibodies targeting IL-17A and IL-23. Protein Eng ΤΗΕ,Τ.Η.; DE.L.L.; MULDER,N.H. Phase I study of Des Set, 2010, vol. 23, 115-127 [0140] intravenously applied bispecific antibody in renal cell · REITER Y.; BRINKMANN U.; KREITMAN R.J.; cancer patients receiving subcutaneous interleukin JUNG S-H.; LEE B ; PASTAN I. Stabilization of the 2. Br.J.Cancer, 1994, vol. 70, 652-661 [0140] Fv fragments in recombinant immunotoxins by di sulfide bonds engineered into conserved framework regions. Biochemistry, 1994, vol. 33, 6551-5459 [0140]

Claims (6)

1. Bispecltlkus ellenanyag molekula ΒΧΛΙΑΡΑΙ,ΜΙ IGÉNYPONTOK 1. hépeeiikus elpányag mölókiia, amely1 tártaimat: egy IM> i'agrsiéosp amely tarttlÍSiI-,i%y':SliSÍ· &amp;$Aélp$ %$0 eleó árpigéhhéz, egy egyfccu Fv tragmenst, amely teák mz egy öaaaoilkKiMlMislyal agy inásodik antigénhez, őkegy Immunglohcl n('HC dosrem almiig 1¾ Éepnerm tanatinazza: a csukló régsót, alól a Fab íragsoetts át az egyláncn Fv tVagmens Jomlnen kéréséi! kagesolödlc. ahol a Cl© dőmlanefc legalább agy amtímsava,, amely k^ea köayétk [mit az Fc receptorhoz való kötődést, hiányzik, vagy dmutált, és ahol emellett &amp; 226~os és 22{>-es szekvencia pozícióban levő arninosav csoportok (a szekvencia pozíciókat az Eli'•index szeme szá-mózzok} llaoyoznák vagy elmeialtak, alól a 02 dómén rsek légaflbb egy ammosavák amely képes közveÉtem az Fo reoeptorhoz való kötődést, és hiányzik, vagy elmutilt, akövetező Szekvencia. pozl-siókban levő csopoBok kő^l választék M: 221, 230, 231. 232. 233, 234, 235, 23íx 237, 23R 26$, 293, 327, és 13Ö la §zeÉwcfe;|p0^lelétó:;áz.EIJ4toáex szerlm számoz^tl:), 3; Az L lgénypom szetfai-iélléaaiipgMolékalai,:. a) amely bei) vagy az első kötőhely, vagy a pjásödlkÉÖtőkely iégy tumorhoz kapcsolódó ami-· gént köt meg; ahol (i) a tumorhoz kapcsolódó antigén előnyösen égy tumor érrendszerén helyezkedik el;, és/vsgy fi) a tumorhoz Ikapbaolődő antigén előnyöse?* egy téliden antigén vagy az exfracellulásls mátrix: egy asiigétje, ésTyagy rdi) a tumorhoz kapcsolódó auugcnt el-'-esősen a kosos ke-.' c-vmosdv! salas/Uantdk M:; CD 10. CD 19, C02f CD21, CD22, CD25. CD30, CD33. C'034. C03?, CD44vö:i CD45, CDsv!2, Tntsvszerl Irozm klnáz 3 .(FŰM* CDI 3$), c-Kit (CD 117), CSF1 R, CCDII5), CD 133, piWOa), PDGFR-β (CDI40h), kcmdrohinszulfát proteoghkán 4 (CSPG4, mélmtémátipz kapcsolódó kóndroitinszulfaí proteoglikán), MusoF 1 {}! R de? ' KÓR FOFflvlll, folatkoto téhmse, nm2sseu PoG PSMA PSC \ PS \ TAG-72, HLA-PR, 1GFR, €0133, H..3R, fibroblaszt-aktlvákV tekerje (TÁP), Karboanhidraz IX (MN/CA FX), Ens^inoeiobriottálls: antigln (CEA), EpCAM, CPCP1, ΡοΕΙηΙ,ρΤβηρδΟΒι, kuakorodö 1-10, a VEGEIK (KDR/FlJvl}, VBGFX3 (FLT4, CD309) vaszkuláfisasifeöttek, Endogün,CLFCI4 Térni~8, és Tie2; és/vagy Is) ahol vagy az elsői kötőhely, vagy a második kötőhely előnyösen kötődik egy IVseithez, vagy egy őiE (tefmesaetes ölő) al>«eji «agy MIC seil-specifskus receptor nmleMa előnyösen a CDY a T~seit receptor (TŰR), CD2S, CD 16, MEÖ2P, OndCh 4-1 BB, CP2,: CDS és ODRI közűt m. egyik, ahol a TC1 előnyösen TCRiaiiWbéta) vagy TCH:{gattimisMdta> 3„ Az :l, vagy 2. igénypont szériái ellenanyag molnkul-a* amelyben ||) iFÉ Ragmens a CDf doménhez a Fab íragmeos €HI és VH doménlC nehéz láncán fe> resztül kapcsolódik, vagy a Fab tagmens CL: és ¥1, könnyű lánc öcmiérseken keresztül, ahol a Fab Ragmena nehéz lánc domenjek vagy a Fafoítögtnens könnyű lánc domenjei előnyösen a poiipeptid lánc NnemúMIMn helyezkednek el, ahol a 032 donién előnyösen az seFv íragrnens könnyű lánca (VI donién) variábilis doménjén keresetni kapcsolódik az scFv Ragnienshez, amely dómén tartalmazza a második kötőhelyet, vagy az scFv tragmens nehéz lánc variábilis doménjén kérésziül, amely tartalmazza a második kötőhelyet; vagy (n) az első antigénhez való első kötőhelyet tartalmazó Fah Ragnrens tartalmazza a YL domém a CDi doménhez mzionáltatva, és a VB domént a CL doménhez Aszionáhaiva, ahol a Fab fíngmens CDI doméiije előnyösen a 03:2 doménhez van imonáfiatva, éCvagy ahol a Fab Bagmens VL~€BI doménje előnyösen a poiipeptid lánc Cdernhnáisán taláihatő.
2. 4. Az; előző igénypontok: bármelyike szerinti ellenanyag molekula, abol a Fah tragmens a 032 doménhez a Fab Iragmens nehéz lánc 031 és VB doménjA kérésztől kapcsolódik, 5, A 4. igénypont szerinti ellenanyag molekula, ahol a Fab tragmens nehéz lánc doménék a poiipeptid lánc Ndeffiünslisán találhatók, ő. Az A igénypont szerinti ellenanyag molekula, amelyben a. CB2 dómén az sekv tíágmenshez az scFv tragmens könnyű lánc variábilis doménjén (VL dómét) keresztül fcapesötődik, amely tartalmazza a második kötőhelyei ?. Az S. Igénypont szerimi ellenanyag molekula, amelyben a 032 dómén az scFv tragmenshez az scFv frapaens nehéz; iné variábilis doménjén (VH dómén) keresztül: kapcsolódik, amely tartáirnázza a második kötőhelyet.

   1, Az előző igénypontok bármelyike szerinti ellenanyag molekula, a) amelyben a Fab Iragmens tartalmaz egy csukló régiót; és/vagy b) abol: az: első kötőhely kötődik egy nnnorhoz kapcsolódó felületi antigénhez, és a második kotöheh m alábbiak közül az egyikhez kötődik; 033, a T sejt receptor (TCR), C';P28, CDié, NKG2Í), 0x40, 4-1BB, CD2, CDs ésCD9S,
3. 9, Az: 1. igénypont szerinti amelyben egy ciszíeim, amely a 226"OS #s/lif»es pozíciók közül az egyikken vagy tHWkeítoken hlányztfe vagy ni vm annniaav yiyettestt (a szekvencia pozíciók: számozása az. Eü~mdex szerint).
4. 10, Az előző igénypontok bármelyike szerinti el&amp;l&amp;anpg· 'ía§ifkö^. 'áü^iy 1%¾¾¾¾ .^y olyan mutációt tsAalmaz, amelyet a köv^kezÖ csoportéi vélasztkatypfe ki: a Jlfkaa aatmosav Mé* öiéja, a 220-es aminésáv deléöllja, a itöras aminosav ielééipfm a 2nives atstnösav es aminosav déiéöiőjá., a 233-as ami no w déjéeiöja,.: a Clu2P -> Ékj helyettesítés, a :Len234 A* he·' lyétfesiiés, a 234-és antinosav deléeioja, a Lao235 2^AlaJbélyettetsteSj: a 23$*ös zniinossv deiecióp, a 230-ós atuÉtósav delsolipy a 23?~es aminosan deléel^á, a 2M*m amlnósav deleei^ápaz AspdiS ->ély helyettesítés. az M&amp;7 ·>01ο helyettesítés, azAia.32? ~>Gín helyettesítés, és az Ala.330 ->Ser helyettesítés (a szekvenela pozieiokat az Ei;Mnfe mmm számozzuk); t i, Az előző igénypontok bármelyike szerinti: ellenanyag molektáa, amelyben a kari iragmens á Cl© domenhez: a kab iiagíiíens nehéz iáné dó mégién keresztüls vagy a Fáb Eagmgns könnyű lánc dóménjén keresztül kötődik, shölaJrab Irapsens nehez lánc domégjei előnyösen: a. pöli-pepiid lánc bbtennínáiisáu találhatok. 12, #ybpészati készítmény, amely m: előző jgéppomek bármelyike szerinti ellenanyag mölekülátítartálmaz,
5. 13, Az I II. igénypontok bármelyike szerinti ellenanyag molekula egy betegség kezelésében történő alkalmazásra, ahol a betegség előnyösen egy pmlíiiraetős betegség, ahök a prolíeryiős betegséget előnyösem :* következő csoportból választhatjuk ki: hematopoietikus maiigmitások, azaz például akut és krónikás mieloid és litnlatikns leukémia, valamint iimt&amp;raák, sziárd turaonálg azaz például á psztéámesriináiís tmktu% a tüdő. a vese; apmszíats, az emllyaz agy; a petefészek á mtéh tumoravmesmiéhypmlia tumorok és: melanonta, 14: Huklemsav molekula, amely az l-ll. igénypontok btóöelfiké:«riuíkéfiiá«yhyág;:mő» lekulát kódol, vagy egy vektor, amely a szóban fbtgo sukleinsav molekulát tartasmázzé, vagy egy gazdasefi, amély a szóban ibrgo m.sklehiay moiéfmlát: vagy a szóban Argó vektort taAálmazza,
6. 15. Eljárás az 141. igéüypoíítpk bármelyike szerinti: ellenanyag ranlektda előálíitásám, azzal jellemezve, hogy az ellenanyag molekulát kódoló nukíemsavat expresszállatjuk olyan körűimé" nyék között, amelyek lehetővé tesA a .Í#M^yy^pr«i^|Jhö! az eteányág molekula előnyé" sen egy gazdaseltben vagy sgysettmeíttes::®^